Table of Contents

1 Dossier Analysis

	8
Ē.	Boehr
	ā.
	÷.
	=
 .	
2	E.
—	<u> </u>
	inger
	P
0	
	_
••	
54	
	Ingelh
	0
	Ë.
	5
	ā
	lein
	8
١Ă	P
12	
	BI Trial No.: x1218.pec

Ο

Page

1

ppendix **,** Table of Contents

—
Pa
ω

1.1 Safety Analysis - TG1 2 1.1.1 Adverse events 3 1, Table 1.1.1 Frequencies and proportions of patients with any adverse events overall and by subgroup up to week 26 - TS 4 (TG1) Frequencies and proportions of patients with serious adverse events overall and by subgroup up to week 26 - TS 7 1, Table 1.1.2 (TG1) 1, Table 1.1.3 Frequencies and proportions of patients with adverse events with severe maximum intensity overall and by 8 subgroup up to week 26 - TS (TG1) 1, Table 1.1.4 Frequencies and proportions of patients with adverse events leading to treatment discontinuation overall and 9 by subgroup up to week 26 - TS (TG1) 1.1.2 Adverse events excluding disease-specific adverse events 10 1, Table 1.2.1 Frequencies and proportions of patients with any adverse events excluding disease-specific adverse events 11 overall and by subgroup up to week 26 - TS (TG1) Frequencies and proportions of patients with serious adverse events excluding disease-specific adverse events 14 1, Table 1.2.2 overall and by subgroup up to week 26 - TS (TG1) 1, Table 1.2.3 Frequencies and proportions of patients with adverse events with severe maximum intensity excluding 15 disease-specific adverse events overall and by subgroup up to week 26 - TS (TG1) 16 1.1.3 Adverse events of special interest 1, Table 1.3.1 Frequencies and proportions of patients with adverse events of special interest overall and by subgroup up to 17 week 26 - TS (TG1) 1, Table 1.3.2 Frequencies and proportions of patients with serious adverse events of special interest overall and by 25 subgroup up to week 26- TS (TG1) 1, Table 1.3.3 Frequencies and proportions of patients with adverse events of special interest with severe maximum intensity 33 overall and by subgroup up to week 26 - TS (TG1) 1, Listing 1.3.4 Listing of preferred terms that define adverse events of special interest 41 57 1.1.4 Specific adverse events 58 1, Table 1.4.1 Frequencies and proportions of patients with specific adverse events overall and by subgroup up to week 26 - TS (TG1) 1, Table 1.4.2 Frequencies and proportions of patients with serious specific adverse events overall and by subgroup up to 68 week 26 - TS (TG1) Frequencies and proportions of patients with specific adverse events with severe maximum intensity overall and 77 1, Table 1.4.3 by subgroup up to week 26 - TS (TG1) 1, Listing 1.4.4 Listing of preferred terms that define specific adverse events 86 1.1.5 Adverse events on SOC level 98 1, Table 1.5.1 Frequencies and proportions of patients with adverse events with >=10% occurrence in at least one treatment 99 arm on SOC level overall and by subgroup up to week 26 - TS (TG1) Frequencies and proportions of patients with serious adverse events with >=5% occurrence in at least one 106 1, Table 1.5.2 treatment arm on SOC level overall and by subgroup up to week 26 - TS (TG1) 107

1, Table 1.5.3 Frequencies and proportions of patients with adverse events with severe maximum intensity with >=5% occurrence

Boehringer Ingelheim BI Trial No.: x1218.ped01

Appendix 1, Table of Contents

Table of Contents

		Page
	in at least one	
	treatment arm on SOC level overall and by subgroup up to week 26 - TS (TG1)	
1, Table 1.5.4	Frequencies and proportions of patients with adverse events leading to treatment discontinuation on SOC level up to week 26 - TS (TG1)	108
1.1.6 Adverse events o		111
1, Table 1.6.1	Frequencies and proportions of patients with adverse events with >=10% occurrence in at least one treatment arm on PT level overall	112
1 m-h]- 1 C 0	and by subgroup up to week 26 - TS (TG1)	114
1, Table 1.6.2	Frequencies and proportions of patients with serious adverse events with >=5% occurrence in at least one treatment arm on PT level	114
1 m-hl-1 ()	overall and by subgroup up to week 26 - TS (TG1)	115
1, Table 1.6.3	Frequencies and proportions of patients with adverse events with severe maximum intensity with >=5% occurrence in at least one	115
1	treatment arm on PT level overall and by subgroup up to week 26 - TS (TG1)	110
·	Frequencies and proportions of patients with adverse events leading to treatment discontinuation on PT level up to week 26 - TS (TG1)	116
1.1.7 Other adverse Ev		119
1, Table 1.7.1	Frequencies and proportions of patients with reported non-severe hypoglycaemia with symptoms and plasma glucose <54 mg/dl	120
	overall and by subgroup up to week 26 - TS (TG1)	
1, Table 1.7.2	Frequencies and proportions of patients with reported non-severe hypoglycaemia with symptoms and plasma glucose <=70 mg/dl	121
	overall and by subgroup up to week 26 - TS (TG1)	100
1, Table 1.7.3	Frequencies and proportions of patients with reported severe hypoglycaemia (requiring the assistance of another person)	122
	overall and by subgroup up to week 26 - TS (TG1)	
1.2 Efficacy Analysis - TG1		123
1.2.1 Responder Analys	ses set and the set of	124
1, Table 2.1.1	Responder analysis for HbAlc [%] <6.5% at week 26 overall and by subgroup - mITT (TG1) (NCF)	125
	Responder analysis for HbA1c [%] <7% at week 26 overall and by subgroup - mITT (TG1) (NCF)	127
1, Table 2.1.3	Responder analysis of patients who initiate glycaemic rescue therapy up to 26 weeks, overall and by subgroup - mITT (TG1) (OR)	130
1.2.2 Analyses of cont	inuous variables	132
1, Table 2.2.1	HbAlc [%] change from baseline MMRM results over time up to week 26 overall and by subgroup - mITT (TG1) (OC-AD)	133
1, Figure 2.2.2	Adjusted means (SE) for HbAlc [%] change from baseline MMRM results over time up to week 26 - mITT (TG1) (OC-AD)	148
1, Table 2.2.3	FPG [mq/dL] change from baseline ANCOVA results at week 26 overall and by subgroup - mITT (TG1) (OC-AD-BOCF)	149
1, Table 2.2.4	Body weight [kg] change from baseline MMRM results over time up to week 26 overall and by subgroup - mITT (TG1) (OC-AD)	157

Page =: 1 Dossier Analysis

Appendix 1

1.1 Safety Analysis - TG1

Boehringer Ingelheim BI Trial No.: x1218.ped01 1.1.1 Adverse events

Appendix 1, 1.1

											l vs Placebo			
Subgroup Category	N	_Place n		<u>—</u> E	l pool n	ed	p-value *	Risk ratio	(exact 95% CI) (asymp 95% CI)	Odds ratio	(95% CI)	Risk diff.	(95% CI)	p-value **
Overall	53	34	64.2	52	40	76.9	0.2036	1.20	(0.93,1.60) (0.93,1.54)	1.86	(0.79, 4.47)	0.13	(-0.05,0.30)	
Sex Male	19	15	78.9		14		0.8107	0.93	(0.60,1.43) (0.65,1.33)	0.75			(-0.33,0.23)	0.1035
Female	34	19	55.9	33	26	78.8	0.0519	1.41	(0.99,2.12) (1.00,2.00)	2.93	(0.99, 8.94)	0.23	(0.00,0.44)	
Age <15	26	16	61.5	25	18	72.0	0.5454	1.17	(0.76,1.85) (0.79,1.73)	1.61	(0.48, 5.43)	0.10	(-0.16,0.36)	0.8656
>=15 to <18	27	18	66.7	27	22	81.5	0.2355	1.22	(0.79,1.73) (0.87,1.83) (0.89,1.69)	2.20	(0.61, 8.32)	0.15	(-0.10,0.38)	
Region														0.8040
ŬS	33	22	66.7	36	28	77.8	0.4933	1.17	(0.86,1.66) (0.87,1.57)	1.75	(0.59, 5.26)	0.11	(-0.11,0.33)	
Non-US	20	12	60.0	16	12	75.0	0.4429	1.25	(0.73,2.17) (0.79,1.97)	2.00	(0.46, 9.32)	0.15	(-0.18,0.45)	
BMI [kg/m2] at baseline < median	27	17	63.0	26	18	69.2	0.7213	1.10	(0.71,1.69)	1.32	(0.41, 4.28)	0.06	(-0.20,0.32)	0.5267
>= median	26	17	65.4	26	22	84.6	0.1264	1.29	(0.75,1.62) (0.93,1.93) (0.94,1.79)	2.91	(0.76,12.30)	0.19	(-0.06,0.43)	

Table 1.1.1 Frequencies and proportions of patients with any adverse events overall and by subgroup up to week 26 - TS (TG1)

Only treatment emergent AEs are displayed (onset between first dose until treatment stop +7 days). Subgroups will only be analysed if at least 10 patients are in each subgroup category and at least 10 patients with event in at least one subgroup category (both treatments combined).

A ratio less than one or risk difference less than zero indicates less risk for E pooled.

MedDRA version: 25.0. N: number of patients. n: number of patients with an AE. Risk ratio exact CI estimated by Chan and Zhang, asymptotic CI by Wald. CIs for odds ratios are exact mid-p estimates. Risk diff. exact CI estimated by Chan and Zhang. * 2*one-sided Suissa-Shuster Z-pooled test. ** Q-test for homogeneity (H0) of risk ratios (treatment by subgroup interaction). inf=infinity.

Page ┺

										d vs Placebo_			
Subgroup Category	N	_Place n	eboN	E poo n	led	p-value *		(exact 95% CI) (asymp 95% CI)	Ödds ratio	(95% CI)	Risk diff.	(95% CI)	p-value **
<pre>BMI Z-Score <=2 (Underweight, normal or overweight)</pre>	9	6	66.7 5	5	100.0	0.2005	1.50	(0.67,3.34)	inf	(0.52,inf)	0.33	(-0.23,0.72)	0.4750
>2 to <=3 (Class 1 obesity)	17	10	58.8 21	12	57.1	1.0000	0.97	(0.95,2.38) (0.54,1.89) (0.56,1.67)	0.93	(0.24, 3.52)	-0.02	(-0.33,0.30)	
>3 (Class 2 or 3 obesity)	27	18	66.7 26	23	88.5	0.0664	1.33	(0.98,2.00) (0.98,1.79)	3.83	(0.91,19.32)	0.22	(-0.01,0.44)	
HbAlc [%] at baseline <8.0	29	21	72.4 28	22	78.6	0.7007	1.09	(0.78,1.55) (0.81,1.46)	1.40	(0.40, 4.97)	0.06	(-0.17,0.29)	0.6356
8.0 to 9.0	12	7	58.3 12	10	83.3	0.2283	1.43	(0.78,3.01) (0.83,2.45)	3.57	(0.51,31.46)	0.25	(-0.14,0.59)	
>9.0	12	6	50.0 12	8	66.7	0.5249	1.33	(0.62,3.08) (0.67,2.67)	2.00	(0.36,11.29)	0.17	(-0.25,0.54)	
FPG [mg/dl] at baseline <126	13	9	69.2 19	14	73.7	0.8991	1.06	(0.66,2.07)	1.24	(0.24, 6.24)	0.04	(-0.28,0.38)	0.3967
>=126	39	24	61.5 29	24	82.8	0.0642	1.34	(0.68,1.67) (0.97,1.91) (1.00,1.81)	3.00	(0.94,10.37)	0.21	(-0.01,0.41)	
eGFR (Zappitelli) at baseline <120	24	15	62.5 21	16	76.2	0.4762	1.22	(0.77,1.95)	1.92	(0.51, 7.55)	0.14	(-0.15,0.40)	0.9500
120 to <150	23	15	65.2 19	14	73.7	0.6385	1.13	(0.82,1.80) (0.71,1.78)	1.49	(0.38, 6.08)	0.08	(-0.21,0.37)	
>=150	6	4	66.7 12	10	83.3	0.4982	1.25	(0.76,1.69) (0.69,5.60) (0.67,2.32)	2.50	(0.19,29.87)	0.17	(-0.26,0.64)	

Table 1.1.1 Frequencies and proportions of patients with any adverse events overall and by subgroup up to week 26 - TS (TG1)

Only treatment emergent AEs are displayed (onset between first dose until treatment stop +7 days). Subgroups will only be analysed if at least 10 patients are in each subgroup category and at least 10 patients with event in at least one subgroup category (both treatments combined).

A ratio less than one or risk difference less than zero indicates less risk for E pooled.

MedDRA version: 25.0. N: number of patients. n: number of patients with an AE. Risk ratio exact CI estimated by Chan and Zhang, asymptotic CI by Wald. CIs for odds ratios are exact mid-p estimates. Risk diff. exact CI estimated by Chan and Zhang. * 2*one-sided Suissa-Shuster Z-pooled test. ** Q-test for homogeneity (H0) of risk ratios (treatment by subgroup interaction). inf=infinity.

Appendix 1, Table 1.1.1

Table 1.1.1 Frequencies and proportions of patients with any adverse events overall and by subgroup up to week 26 - TS (TG1)

Subgroup Category	N	_Place n	ebo N	_E poo n	led p-va % *	lue Risk ratic	(exact 959 (asymp 959	<u>} CI</u>)	Ōdds	d vs Placebo_ (95% CI)	Risk diff.	(95% CI)	p-value **
Backg. Antidiabetic Med. at baseline Metformin only	28	20	71.4 26	19	73.1								
Insulin only Metformin and Insulin	28 2 19	20 1 11	50.0 3 57.9 22	19 2 19	66.7 86.4								
None	4	2	50.0 1	0	0								
Time since diagnosis of T2DM <1 year	18	12	66.7 17	13	76.5 0.64	44 1.15	(0.71,1.94 (0.75,1.75		1.63	(0.35, 7.91)	0.10	(-0.21,0.40)	0.8783
1 year – 3 years	24	15	62.5 21	17	81.0 0.19	70 1.30	(0.86,2.0	7)	2.55	(0.64,11.07)	0.18	(-0.09,0.44)	
>3 years	11	7	63.6 14	10	71.4 0.74	40 1.12	(0.60,2.38	3)	1.43	(0.24, 8.39)	0.08	(-0.32,0.46)	

Only treatment emergent AEs are displayed (onset between first dose until treatment stop +7 days). Subgroups will only be analysed if at least 10 patients are in each subgroup category and at least 10 patients with event in at least one subgroup category (both treatments combined).

A ratio less than one or risk difference less than zero indicates less risk for E pooled.

MedDRA version: 25.0. N: number of patients. n: number of patients with an AE. Risk ratio exact CI estimated by Chan and Zhang, asymptotic CI by Wald. CIs for odds ratios are exact mid-p estimates. Risk diff. exact CI estimated by Chan and Zhang. * 2*one-sided Suissa-Shuster Z-pooled test. ** Q-test for homogeneity (H0) of risk ratios (treatment by subgroup interaction). inf=infinity.

Table 1.1.2 Frequencies and proportions of patients with serious adverse events overall and by subgroup up to week 26 - TS (TG1)

Subgroup Category	N	_Place n	ebo	- <u>N</u>	E pool n	Led	p-value *	Risk ratio	E (exact 95% CI) (asymp 95% CI)		d vs Placebo_ (95% CI)	Risk diff.	(95% CI)	p-value **
Overall	53	2	3.8	52	2	3.8	1.0000	1.02	(0.07,15.13) (0.15, 6.97)	1.02	(0.10,10.11)	0.00	(-0.10,0.10)	

Boehringer Ingelheim BI Trial No.: x1218.ped01

Only treatment emergent AEs are displayed (onset between first dose until treatment stop +7 days). Subgroups will only be analysed if at least 10 patients are in each subgroup category and at least 10 patients with event in at least one subgroup category (both treatments combined).

A ratio less than one or risk difference less than zero indicates less risk for E pooled.

MedDRA version: 25.0. N: number of patients. n: number of patients with an AE. Risk ratio exact CI estimated by Chan and Zhang, asymptotic CI by Wald. CIs for odds ratios are exact mid-p estimates. Risk diff. exact CI estimated by Chan and Zhang. * 2*one-sided Suissa-Shuster Z-pooled test. ** Q-test for homogeneity (H0) of risk ratios (treatment by subgroup interaction).

s1\taerisk3c001.sas 200CT2023

Subgroup Category	N	_Plac n	ebo	- <u>N</u>	E pool n	led	p-value *	Risk ratio	E (exact 95% CI) (asymp 95% CI)	poole Odds ratio	d vs Placebo_ (95% CI)		p-value **
Overall	53	2	3.8	52	1	1.9	0.6927	0.51	(0.02,5.59) (0.05,5.45)	0.50	(0.02,6.79)	-0.02 (-0.11,0.07)	

Table 1.1.3	Frequencies	and proportions	of patients	with ad	dverse events	with severe	maximum :	intensity	overall	and by	subgroup	up to '	week 26
	– TS (TG1)		-					-		-		-	

s1\taerisk3c001.sas 200CT2023

Only treatment emergent AEs are displayed (onset between first dose until treatment stop +7 days). Subgroups will only be analysed if at least 10 patients are in each subgroup category and at least 10 patients with event in at least one subgroup category (both treatments combined).

A ratio less than one or risk difference less than zero indicates less risk for E pooled.

Maximum intensity: If a patient has more than one AE only the worst is recorded. MedDRA version: 25.0. N: number of patients. n: number of patients with an AE. Risk ratio exact CI estimated by Chan and Zhang, asymptotic CI by Wald. CIs for odds ratios are exact mid-p estimates. Risk diff. exact CI estimated by Chan and Zhang. * 2*one-sided Suissa-Shuster Z-pooled test. ** Q-test for homogeneity (H0) of risk ratios (treatment by subgroup interaction).

Table 1.1.4 Frequencies and proportions of patients with adverse events leading to treatment discontinuation overall and by subgroup up to week 26 - TS (TG1)

Subgroup	PlaceboE poole									
Category	N	n	010	N	'n	olo				
Overall	53	2	3.8	52	0	0				

Only treatment emergent AEs are displayed (onset between first dose until treatment stop +7 days). N is the number of patients, n the number of patients with at least one event MedDRA version: 25.0.

											d vs Placebo_			
Subgroup Category	N	_Place n	ebo	N	E pool n	ed	p-value *		(exact 95% CI) (asymp 95% CI)		(95% CI)	Risk diff.	(95% CI)	p-value **
Overall	53	33	62.3	52	40	76.9	0.1257	1.24	(0.95,1.64) (0.96,1.60)	2.02	(0.86, 4.82)	0.15	(-0.04,0.32)	
Sex Male	19	14	73.7	19	14	73.7	NC.	1.00	(0.64,1.55) (0.68,1.46)	1.00	(0.22, 4.52)	0.00	(-0.29,0.29)	0.1909
Female	34	19	55.9	33	26	78.8	0.0519	1.41	(0.99,2.12) (1.00,2.00)	2.93	(0.99, 8.94)	0.23	(0.00,0.44)	
Age			<i></i>		1.0									0.7027
<15	26	16	61.5	25	18	72.0	0.5454	1.17	(0.76,1.85) (0.79,1.73)	1.61	(0.48, 5.43)	0.10	(-0.16,0.36)	
>=15 to <18	27	17	63.0	27	22	81.5	0.1466	1.29	(0.92,1.93) (0.92,1.82)	2.59	(0.73, 9.66)	0.19	(-0.06,0.42)	
Region														0.5922
ŬS.	33	22	66.7	36	28	77.8	0.4933	1.17	(0.86,1.66) (0.87,1.57)	1.75	(0.59, 5.26)	0.11	(-0.11,0.33)	
Non-US	20	11	55.0	16	12	75.0	0.2699	1.36	(0.81,2.45) (0.84,2.22)	2.45	(0.57,11.30)	0.20	(-0.14,0.50)	
BMI [kg/m2] at baseline														0.6988
< median	27	16	59.3	26	18	69.2	0.5449	1.17	(0.75,1.87) (0.78,1.75)	1.55	(0.49, 4.96)	0.10	(-0.16,0.36)	
>= median	26	17	65.4	26	22	84.6	0.1264	1.29	(0.93,1.93) (0.94,1.79)	2.91	(0.76,12.30)	0.19	(-0.06,0.43)	

Table 1.2.1	Frequencies and proportions of patients with any adverse events excluding disease-specific adverse events overall and by subgroup up to
	week 26 - TS (TG1)

Only treatment emergent AEs are displayed (onset between first dose until treatment stop +7 days). Subgroups will only be analysed if at least 10 patients are in each subgroup category and at least 10 patients with event in at least one subgroup category (both treatments combined).

A ratio less than one or risk difference less than zero indicates less risk for E pooled.

MedDRA version: 25.0. N: number of patients. n: number of patients with an AE. Risk ratio exact CI estimated by Chan and Zhang, asymptotic CI by Wald. CIs for odds ratios are exact mid-p estimates. Risk diff. exact CI estimated by Chan and Zhang. * 2*one-sided Suissa-Shuster Z-pooled test. ** Q-test for homogeneity (H0) of risk ratios (treatment by subgroup interaction). inf=infinity. NC.=Not calculated.

Cult management		D 1 -	- 1		1.1		Dist			d vs Placebo_	Dist		
Subgroup Category	N	_Place n		E poo n	1ed	p-value *		(exact 95% CI) (asymp 95% CI)		(95% CI)	Risk diff.	(95% CI)	p-value **
BMI Z-Score <=2 (Underweight, normal or overweight)	9	6	66.7 5	5	100.0	0.2005	1.50	(0.67,3.34)	inf	(0.52,inf)	0.33	(-0.23,0.72)	0.6856
>2 to <=3 (Class 1 obesity)	17	9	52.9 21	12	57.1	0.8518	1.08	(0.95,2.38) (0.57,2.31) (0.60,1.93)	1.19	(0.32, 4.43)	0.04	(-0.28,0.36)	
>3 (Class 2 or 3 obesity)	27	18	66.7 26	23	88.5	0.0664	1.33	(0.98,2.00) (0.98,1.79)	3.83	(0.91,19.32)	0.22	(-0.01,0.44)	
HbAlc [%] at baseline <8.0	29	20	69.0 28	22	78.6	0.5414	1.14	(0.81,1.62) (0.83,1.56)	1.65	(0.49, 5.77)	0.10	(-0.15,0.33)	0.7500
8.0 to 9.0	12	7	58.3 12	10	83.3	0.2283	1.43	(0.78, 3.01) (0.83, 2.45)	3.57	(0.51,31.46)	0.25	(-0.14,0.59)	
>9.0	12	6	50.0 12	8	66.7	0.5249	1.33	(0.62,3.08) (0.67,2.67)	2.00	(0.36,11.29)	0.17	(-0.25,0.54)	
FPG [mg/dl] at baseline													0.3222
<126	13	9	69.2 19	14	73.7	0.8991	1.06	(0.66,2.07) (0.68,1.67)	1.24	(0.24, 6.24)	0.04	(-0.28,0.38)	
>=126	39	23	59.0 29	24	82.8	0.0481	1.40	(1.01,2.02) (1.03,1.91)	3.34	(1.06,11.48)	0.24	(0.00,0.44)	
eGFR (Zappitelli) at baseline <120	24	14	58.3 21	16	76.2	0.2846	1 31	(0.82,2.16)	2.29	(0.62, 8.89)	0 18	(-0.12,0.45)	0.8823
120 to <150	24	14	65.2 19	10			1.13	(0.86,1.98) (0.71,1.78)	1.49	(0.38, 6.08)		(-0.21,0.37)	
								(0.76,1.69)		. , .		. , .	
>=150	6	4	66.7 12	10	83.3	0.4982	1.25	(0.69,5.60) (0.67,2.32)	2.50	(0.19,29.87)	0.17	(-0.26,0.64)	

Table 1.2.1	Frequencies and proportions of patients with any adverse events excluding disease-specific adverse events overall and by subgroup up to
	week 26 - TS (TG1)

Only treatment emergent AEs are displayed (onset between first dose until treatment stop +7 days). Subgroups will only be analysed if at least 10 patients are in each subgroup category and at least 10 patients with event in at least one subgroup category (both treatments combined).

A ratio less than one or risk difference less than zero indicates less risk for E pooled.

MedDRA version: 25.0. N: number of patients. n: number of patients with an AE. Risk ratio exact CI estimated by Chan and Zhang, asymptotic CI by Wald. CIs for odds ratios are exact mid-p estimates. Risk diff. exact CI estimated by Chan and Zhang. * 2*one-sided Suissa-Shuster Z-pooled test. ** Q-test for homogeneity (H0) of risk ratios (treatment by subgroup interaction). inf=infinity. NC.=Not calculated.

								poole	d vs Placebo			
Subgroup Category	N	_Place n	ebo N	E poo n	led p-val % *	ue Risk ratio	(exact 9 (asymp 9	Odds ratio	(95% CI)	Risk diff.	(95% CI)	p-value **
Backg. Antidiabetic Med. at baseline												
Metformin only	28	19	67.9 26	19	73.1							
Insulin only	2	1	50.0 3	2	66.7							
Metformin and Insulin	19	11	57.9 22	19	86.4							
None	4	2	50.0 1	0	0							
Time since diagnosis of T2DM												0.9154
<1 year	18	11	61.1 17	13	76.5 0.548	7 1.25	(0.75,2. (0.80,1.	2.07	(0.46, 9.84)	0.15	(-0.17,0.45)	
1 year – 3 years	24	15	62.5 21	17	81.0 0.197	0 1.30	(0.86,2.	2.55	(0.64,11.07)	0.18	(-0.09,0.44)	
>3 years	11	7	63.6 14	10	71.4 0.744	0 1.12	(0.60,2. (0.64,1.	1.43	(0.24, 8.39)	0.08	(-0.32,0.46)	

Table 1.2.1	Frequencies and proportions of patients with any adverse events excluding disease-specific adverse events overall and by subgroup up to
	week 26 - TS (TG1)

Only treatment emergent AEs are displayed (onset between first dose until treatment stop +7 days). Subgroups will only be analysed if at least 10 patients are in each subgroup category and at least 10 patients with event in at least one subgroup category (both treatments combined).

A ratio less than one or risk difference less than zero indicates less risk for E pooled.

MedDRA version: 25.0. N: number of patients. n: number of patients with an AE. Risk ratio exact CI estimated by Chan and Zhang, asymptotic CI by Wald. CIs for odds ratios are exact mid-p estimates. Risk diff. exact CI estimated by Chan and Zhang. * 2*one-sided Suissa-Shuster Z-pooled test. ** Q-test for homogeneity (H0) of risk ratios (treatment by subgroup interaction). inf=infinity. NC.=Not calculated.

Subgroup Category	N	Place n	bo	- <u> </u> E	E pool n	.ed	p-value *	Risk ratio	E (exact 95% CI) (asymp 95% CI)	Òdds	l vs Placebo_ (95% CI)	Risk diff.	(95% CI)	p-value **
Overall	53	1	1.9	52	2	3.8	0.6702	2.04	(0.19,55.36) (0.19,21.80)	2.08	(0.15,62.46)	0.02	(-0.07,0.11)	

Table 1.2.2	quencies and proportions of patients with serious adverse events excluding disease-specific adverse	events overall and by subgroup
	to week 26 - TS (TG1)	

A ratio less than one or risk difference less than zero indicates less risk for E pooled.

Only treatment emergent AEs are displayed (onset between first dose until treatment stop +7 days). Subgroups will only be analysed if at least 10 patients are in each subgroup category and at least 10 patients with event in at least one subgroup category (both treatments combined).

MedDRA version: 25.0. N: number of patients. n: number of patients with an AE. Risk ratio exact CI estimated by Chan and Zhang, asymptotic CI by Wald. CIs for odds ratios are exact mid-p estimates. Risk diff. exact CI estimated by Chan and Zhang. * 2*one-sided Suissa-Shuster Z-pooled test. ** Q-test for homogeneity (H0) of risk ratios (treatment by subgroup interaction).

Subgroup Category	N.	lacebo n %		^E	E poole n	ed	p-value *	Risk ratio	E (exact 95% CI) (asymp 95% CI)		d vs Placebo_ (95% CI)	Risk diff.	(95% CI)	p-value **
Overall	53	2 3	.8	52	1	1.9	0.6927	0.51	(0.02,5.59) (0.05,5.45)	0.50	(0.02,6.79)	-0.02	(-0.11,0.07)	

Table 1.2.3	requencies and proportions of patients with adverse events with severe maximum intensity excluding disease-specific adverse eve	ents
	rerall and by subgroup up to week 26 - TS (TG1)	

Only treatment emergent AEs are displayed (onset between first dose until treatment stop +7 days). Subgroups will only be analysed if at least 10 patients are in each subgroup category and at least 10 patients with event in at least one subgroup category (both treatments combined).

A ratio less than one or risk difference less than zero indicates less risk for E pooled.

Maximum intensity: If a patient has more than one AE only the worst is recorded.

MedDRA version: 25.0. N: number of patients. n: number of patients with an AE. Risk ratio exact CI estimated by Chan and Zhang, asymptotic CI by Wald. CIs for odds ratios are exact mid-p estimates. Risk diff. exact CI estimated by Chan and Zhang. * 2*one-sided Suissa-Shuster Z-pooled test. ** Q-test for homogeneity (H0) of risk ratios (treatment by subgroup interaction).

1.1.3 Adverse events of special interest

											ed vs Placebo_			
Subgroup Category	N	_Plac n	ebo %	- <u>n</u>	E poo n	led	p-value *	Risk ratio	(exact 95% CI (asymp 95% CI) Odds) ratio	(95% CI)	Risk diff.	(95% CI)	p-value **
Overall	53	1	1.9	52	4	7.7	0.2345	4.08	(0.57,103.04) (0.47, 35.27)	4.33	(0.52,109.12)	0.06	(-0.04,0.17)	

Table 1.3.1 Frequencies and proportions of patients with adverse events of special interest overall and by subgroup up to week 26 – TS๋ (TG1) User-defined AE category: Hypersensitivity reactions (narrow SMQ)

Only treatment emergent AEs are displayed (onset between first dose until treatment stop +7 days). Subgroups will only be analysed if at least 10 patients are in each subgroup category and at least 10 patients with event in at least one subgroup category (both treatments combined).

A ratio less than one or risk difference less than zero indicates less risk for E pooled.

MedDRA version: 25.0. N: number of patients. n: number of patients with an AE. Risk ratio exact CI estimated by Chan and Zhang, asymptotic CI by Wald. CIs for odds ratios are exact mid-p estimates. Risk diff. exact CI estimated by Chan and Zhang. * 2*one-sided Suissa-Shuster Z-pooled test. ** Q-test for homogeneity (H0) of risk ratios (treatment by subgroup interaction). NC.=Not calculated.

Table 1.3.1 Frequencies and proportions of patients with adverse events of special interest overall and by subgroup up to week 26 - TS (TG1) User-defined AE category: Skin lesion (narrow SMQ)

There is no data to be displayed.

Subgroup Category	N	_Plac n		- <u> 1</u>		led	p-value *	Risk ratio	(exact (asymp			ed vs P (95% C		Risk diff.	(95% CI)	p-value **
Overall	53	1	1.9	52	0	0	0.5361	0.00	(0.00, NC.	14.86)	0.00	(0.00,	9.17)	-0.02	(-0.10,0.06)	

Table 1.3.1 Frequencies and proportions of patients with adverse events of special interest overall and by subgroup up to week 26 – TS๋ (TG1) User-defined AE category: Pancreatitis (narrow SMQ, PT)

Only treatment emergent AEs are displayed (onset between first dose until treatment stop +7 days). Subgroups will only be analysed if at least 10 patients are in each subgroup category and at least 10 patients with event in at least one subgroup category (both treatments combined).

A ratio less than one or risk difference less than zero indicates less risk for E pooled.

MedDRA version: 25.0. N: number of patients. n: number of patients with an AE. Risk ratio exact CI estimated by Chan and Zhang, asymptotic CI by Wald. CIs for odds ratios are exact mid-p estimates. Risk diff. exact CI estimated by Chan and Zhang. * 2*one-sided Suissa-Shuster Z-pooled test. ** Q-test for homogeneity (H0) of risk ratios (treatment by subgroup interaction). NC.=Not calculated.

Table 1.3.1 Frequencies and proportions of patients with adverse events of special interest overall and by subgroup up to week 26 - TS (TG1) User-defined AE category: Pancreatic cancer (narrow BICMQ)

There is no data to be displayed.

											E pool	ed vs Placebo_			
Subgroup Category	N	_Plac n	ebo %	— <u>N</u>		 ۴	p-value *	e Risk ratio	(exact (asymp	95% CI 95% CI) Odds) ratio	- (95% CI)	Risk diff.	(95% CI)	p-value **
Overall	53	1	1.9	52	2	3.8	0.6702	2.04	(0.19, (0.19,		2.08	(0.15, 62.46)	0.02	(-0.07,0.11)	

Table 1.3.1	Frequencies and	d proportions	of patients	with	adverse	events	of	special	interest	overall	and	by s	subgroup up	to wee	k 26
	– TS (TG1)														
User-defined	AE category: He	epatic injury	(narrow sub	SMQ)											

Only treatment emergent AEs are displayed (onset between first dose until treatment stop +7 days). Subgroups will only be analysed if at least 10 patients are in each subgroup category and at least 10 patients with event in at least one subgroup category (both treatments combined).

A ratio less than one or risk difference less than zero indicates less risk for E pooled.

MedDRA version: 25.0. N: number of patients. n: number of patients with an AE. Risk ratio exact CI estimated by Chan and Zhang, asymptotic CI by Wald. CIs for odds ratios are exact mid-p estimates. Risk diff. exact CI estimated by Chan and Zhang. * 2*one-sided Suissa-Shuster Z-pooled test. ** Q-test for homogeneity (H0) of risk ratios (treatment by subgroup interaction). NC.=Not calculated.

Subgroup Category	N	_Plac n		- <u>-</u> 1	E poc n	led	p-value *	Risk ratio	(exact (asymp				Placebo_ CI)	Risk diff.	(95% CI)	p-value **
Overall	53	1	1.9	52	0	0	0.5361	0.00	(0.00, NC.	14.86)	0.00	(0.00	, 9.17)	-0.02	(-0.10,0.06)	

Table 1.3.1 Frequencies and proportions of patients with adverse events of special interest overall and by subgroup up to week 26 – TS๋ (TG1) User-defined AE category: Decreased renal function (narrow SMQ)

Only treatment emergent AEs are displayed (onset between first dose until treatment stop +7 days). Subgroups will only be analysed if at least 10 patients are in each subgroup category and at least 10 patients with event in at least one subgroup category (both treatments combined).

A ratio less than one or risk difference less than zero indicates less risk for E pooled.

MedDRA version: 25.0. N: number of patients. n: number of patients with an AE. Risk ratio exact CI estimated by Chan and Zhang, asymptotic CI by Wald. CIs for odds ratios are exact mid-p estimates. Risk diff. exact CI estimated by Chan and Zhang. * 2*one-sided Suissa-Shuster Z-pooled test. ** Q-test for homogeneity (H0) of risk ratios (treatment by subgroup interaction). NC.=Not calculated.

Subgroup Category	N	_Plac n		- <u>N</u>		led	p-value *	Risk ratio	(exact (asymp				Placebo_ CI)	Risk diff.	(95% CI)	p-value **
Overall	53	1	1.9	52	0	0	0.5361	0.00	(0.00, NC.	14.86)	0.00	(0.00	, 9.17)	-0.02	(-0.10,0.06)	

Table 1.3.1 Frequencies and proportions of patients with adverse events of special interest overall and by subgroup up to week 26 – TS๋ (TG1) User-defined AE category: Diabetic ketoacidosis (narrow BIcMQ)

Only treatment emergent AEs are displayed (onset between first dose until treatment stop +7 days). Subgroups will only be analysed if at least 10 patients are in each subgroup category and at least 10 patients with event in at least one subgroup category (both treatments combined).

A ratio less than one or risk difference less than zero indicates less risk for E pooled.

MedDRA version: 25.0. N: number of patients. n: number of patients with an AE. Risk ratio exact CI estimated by Chan and Zhang, asymptotic CI by Wald. CIs for odds ratios are exact mid-p estimates. Risk diff. exact CI estimated by Chan and Zhang. * 2*one-sided Suissa-Shuster Z-pooled test. ** Q-test for homogeneity (H0) of risk ratios (treatment by subgroup interaction). NC.=Not calculated.

Page 24

Table 1.3.1 Frequencies and proportions of patients with adverse events of special interest overall and by subgroup up to week 26 - TS (TG1) User-defined AE category: Events leading to lower limb amputation (investigator determined)

There is no data to be displayed.

Table 1.3.2 Frequencies and proportions of patients with serious adverse events of special interest overall and by subgroup up to week 26- TS (TG1) User-defined AE category: Hypersensitivity reactions (narrow SMQ)

There is no data to be displayed.

Table 1.3.2 Frequencies and proportions of patients with serious adverse events of special interest overall and by subgroup up to week 26- TS (TG1) User-defined AE category: Skin lesion (narrow SMQ)

There is no data to be displayed.

Subgroup Category	N	_Plac n	ebo	- <u>N</u>	E poo n	led	p-value *	Risk ratio	E (exact 95% CI) (asymp 95% CI)	Ōdds	l vs Placebo_ (95% CI)	Risk diff.	(95% CI)	p-value **
Overall	53	1	1.9	52	0	0	0.5361	0.00	(0.00,14.86) NC.	0.00	(0.00,9.17)	-0.02	(-0.10,0.06)	

Table 1.3.2 Frequencies and proportions of patients with serious adverse events of special interest overall and by subgroup up to week 26- TS (TG1) User-defined AE category: Pancreatitis (narrow SMQ, PT)

Only treatment emergent AEs are displayed (onset between first dose until treatment stop +7 days). Subgroups will only be analysed if at least 10 patients are in each subgroup category and at least 10 patients with event in at least one subgroup category (both treatments combined).

A ratio less than one or risk difference less than zero indicates less risk for E pooled.

MedDRA version: 25.0. N: number of patients. n: number of patients with an AE. Risk ratio exact CI estimated by Chan and Zhang, asymptotic CI by Wald. CIs for odds ratios are exact mid-p estimates. Risk diff. exact CI estimated by Chan and Zhang. * 2*one-sided Suissa-Shuster Z-pooled test. ** Q-test for homogeneity (H0) of risk ratios (treatment by subgroup interaction). NC.=Not calculated.

Table 1.3.2 Frequencies and proportions of patients with serious adverse events of special interest overall and by subgroup up to week 26- TS (TG1) User-defined AE category: Pancreatic cancer (narrow BIcMQ)

There is no data to be displayed.

Table 1.3.2 Frequencies and proportions of patients with serious adverse events of special interest overall and by subgroup up to week 26- TS (TG1) User-defined AE category: Hepatic injury (narrow sub SMQ)

There is no data to be displayed.

Subgroup Category	N	_Plac n	ebo	- <u>-</u>	E poo n	led	p-value *	Risk ratio	E (exact 95% CI) (asymp 95% CI)	Ōdds	d vs Placebo_ (95% CI)		(95% CI)	p-value **
Overall	53	1	1.9	52	0	0	0.5361	0.00	(0.00,14.86) NC.	0.00	(0.00,9.17)	-0.02	(-0.10,0.06)	

Table 1.3.2 Frequencies and proportions of patients with serious adverse events of special interest overall and by subgroup up to week 26- TS (TG1) User-defined AE category: Decreased renal function (narrow SMQ)

Only treatment emergent AEs are displayed (onset between first dose until treatment stop +7 days). Subgroups will only be analysed if at least 10 patients are in each subgroup category and at least 10 patients with event in at least one subgroup category (both treatments combined).

A ratio less than one or risk difference less than zero indicates less risk for E pooled.

MedDRA version: 25.0. N: number of patients. n: number of patients with an AE. Risk ratio exact CI estimated by Chan and Zhang, asymptotic CI by Wald. CIs for odds ratios are exact mid-p estimates. Risk diff. exact CI estimated by Chan and Zhang. * 2*one-sided Suissa-Shuster Z-pooled test. ** Q-test for homogeneity (H0) of risk ratios (treatment by subgroup interaction). NC.=Not calculated.

Subgroup Category	N	_Plac n	ebo	- <u>N</u>	E poo n	led	p-value *	Risk ratio	E (exact 95% CI) (asymp 95% CI)	Ōdds	d vs Placebo_ (95% CI)	Risk	(95% CI)	p-value **
Overall	53	1	1.9	52	0	0	0.5361	0.00	(0.00,14.86) NC.	0.00	(0.00,9.17)	-0.02	(-0.10,0.06)	

Table 1.3.2 Frequencies and proportions of patients with serious adverse events of special interest overall and by subgroup up to week 26- TS (TG1) User-defined AE category: Diabetic ketoacidosis (narrow BIcMQ)

Only treatment emergent AEs are displayed (onset between first dose until treatment stop +7 days). Subgroups will only be analysed if at least 10 patients are in each subgroup category and at least 10 patients with event in at least one subgroup category (both treatments combined).

A ratio less than one or risk difference less than zero indicates less risk for E pooled.

MedDRA version: 25.0. N: number of patients. n: number of patients with an AE. Risk ratio exact CI estimated by Chan and Zhang, asymptotic CI by Wald. CIs for odds ratios are exact mid-p estimates. Risk diff. exact CI estimated by Chan and Zhang. * 2*one-sided Suissa-Shuster Z-pooled test. ** Q-test for homogeneity (H0) of risk ratios (treatment by subgroup interaction). NC.=Not calculated.

Appendix 1, Table 1.3.2

Table 1.3.2 Frequencies and proportions of patients with serious adverse events of special interest overall and by subgroup up to week 26- TS (TG1) User-defined AE category: Events leading to lower limb amputation (investigator determined)

There is no data to be displayed.

Table 1.3.3 Frequencies and proportions of patients with adverse events of special interest with severe maximum intensity overall and by subgroup up to week 26 - TS (TG1) User-defined AE category: Hypersensitivity reactions (narrow SMQ)

There is no data to be displayed.

Table 1.3.3 Frequencies and proportions of patients with adverse events of special interest with severe maximum intensity overall and by subgroup up to week 26 - TS (TG1) User-defined AE category: Skin lesion (narrow SMQ)

There is no data to be displayed.

Subgroup Category	N	_Plac n	ebo	- <u>-</u>	E poo n	led	p-value *	Risk ratio	E (exact 95% CI) (asymp 95% CI)		l vs Placebo_ (95% CI)		(95% CI)	p-value **
Overall	53	1	1.9	52	0	0	0.5361	0.00	(0.00,14.86) NC.	0.00	(0.00,9.17)	-0.02	(-0.10,0.06)	

Table 1.3.3 Frequencies and proportions of patients with adverse events of special interest with severe maximum intensity overall and by subgroup up to week 26 - TS (TG1) User-defined AE category: Pancreatitis (narrow SMQ, PT)

Only treatment emergent AEs are displayed (onset between first dose until treatment stop +7 days).

Subgroups will only be analysed if at least 10 patients are in each subgroup category and at least 10 patients with event in at least one subgroup category (both treatments combined).

A ratio less than one or risk difference less than zero indicates less risk for E pooled.

Maximum intensity: If a patient has more than one AE only the worst is recorded.

MedDRA version: 25.0. N: number of patients. n: number of patients with an AE. Risk ratio exact CI estimated by Chan and Zhang, asymptotic CI by Wald. CIs for odds ratios are exact mid-p estimates. Risk diff. exact CI estimated by Chan and Zhang. * 2*one-sided Suissa-Shuster Z-pooled test. ** Q-test for homogeneity (H0) of risk ratios (treatment by subgroup interaction). NC.=Not calculated.

Table 1.3.3 Frequencies and proportions of patients with adverse events of special interest with severe maximum intensity overall and by subgroup up to week 26 - TS (TG1) User-defined AE category: Pancreatic cancer (narrow BICMQ)

There is no data to be displayed.

Table 1.3.3 Frequencies and proportions of patients with adverse events of special interest with severe maximum intensity overall and by subgroup up to week 26 - TS (TG1) User-defined AE category: Hepatic injury (narrow sub SMQ)

There is no data to be displayed.

Subgroup Category	N	_Plac n	ebo	- <u>N</u>	E poo n	led	_ p-value *	Risk ratio	E (exact 95% CI) (asymp 95% CI)	Ödds	d vs Placebo_ (95% CI)		(95% CI)	p-value **
Overall	53	1	1.9	52	0	0	0.5361	0.00	(0.00,14.86) NC.	0.00	(0.00,9.17)	-0.02	(-0.10,0.06)	

Table 1.3.3 Frequencies and proportions of patients with adverse events of special interest with severe maximum intensity overall and by subgroup up to week 26 - TS (TG1) User-defined AE category: Decreased renal function (narrow SMQ)

- A ratio less than one or risk difference less than zero indicates less risk for E pooled.
- Maximum intensity: If a patient has more than one AE only the worst is recorded.

Only treatment emergent AEs are displayed (onset between first dose until treatment stop +7 days).

Subgroups will only be analysed if at least 10 patients are in each subgroup category and at least 10 patients with event in at least one subgroup category (both treatments combined).

MedDRA version: 25.0. N: number of patients. n: number of patients with an AE. Risk ratio exact CI estimated by Chan and Zhang, asymptotic CI by Wald. CIs for odds ratios are exact mid-p estimates. Risk diff. exact CI estimated by Chan and Zhang. * 2*one-sided Suissa-Shuster Z-pooled test. ** Q-test for homogeneity (H0) of risk ratios (treatment by subgroup interaction). NC.=Not calculated.

Subgroup Category	N	_Placn]	E poo n	led	_ p-value *	Risk ratio	E (exact 95% CI) (asymp 95% CI)	Ōdds	d vs Placebo_ (95% CI)		(95% CI)	p-value **
Overall	53	1	1.9	52	0	0	0.5361	0.00	(0.00,14.86) NC.	0.00	(0.00,9.17)	-0.02	(-0.10,0.06)	

Table 1.3.3 Frequencies and proportions of patients with adverse events of special interest with severe maximum intensity overall and by subgroup up to week 26 - TS (TG1) User-defined AE category: Diabetic ketoacidosis (narrow BICMQ)

Only treatment emergent AEs are displayed (onset between first dose until treatment stop +7 days).

Subgroups will only be analysed if at least 10 patients are in each subgroup category and at least 10 patients with event in at least one subgroup category (both treatments combined).

A ratio less than one or risk difference less than zero indicates less risk for E pooled.

Maximum intensity: If a patient has more than one AE only the worst is recorded.

MedDRA version: 25.0. N: number of patients. n: number of patients with an AE. Risk ratio exact CI estimated by Chan and Zhang, asymptotic CI by Wald. CIs for odds ratios are exact mid-p estimates. Risk diff. exact CI estimated by Chan and Zhang. * 2*one-sided Suissa-Shuster Z-pooled test. ** Q-test for homogeneity (H0) of risk ratios (treatment by subgroup interaction). NC.=Not calculated.

Appendix 1, Table 1.3.3

Page 40

Table 1.3.3 Frequencies and proportions of patients with adverse events of special interest with severe maximum intensity overall and by subgroup up to week 26 - TS (TG1) User-defined AE category: Events leading to lower limb amputation (investigator determined)

There is no data to be displayed.

Boehringer Ingelheim BI Trial No.: x1218.ped01

Listing 1.3.4 Listing of preferred terms that define adverse events of special interest

Source	Group	Group code Scope	Preferred term code	Preferred term
Acute pancreatitis	Pancreatitis	000000005 Narrow	$\begin{array}{c} 10033625\\ 10033635\\ 10033645\\ 10033647\\ 10033657\\ 10033657\\ 10048984\\ 10052400\\ 10056277\\ 10056975\\ 10059029\\ 10066127\\ 10075426\\ 10075426\\ 10075426\\ 10076058\\ 10081762\\ 10082531\\ 10083072\\ 10083813\\ 10083813\\ 10084554\\ 10085347\\ \end{array}$	Pancreatic haemorrhage Pancreatic pseudocyst Pancreatic pseudocyst drainage Pancreatitis Pancreatitis acute Pancreatitis necrotising Pancreatitis necrotising Pancreatic abscess Oedematous pancreatitis Pancreatorenal syndrome Pancreatic phlegmon Cullen's sign Ischaemic pancreatitis Grey Turner's sign Haemorrhagic necrotic pancreatitis Pancreatic pseudoaneurysm Pancreatic pseudoaneurysm Pancreatic pseudocyst rupture Pancreatic pseudocyst haemorrhage Subacute pancreatitis Walled-off pancreatic necrosis
Acute renal failure	Decreased renal function	000000008 Narrow	10002847 10003885 10018875 10029155 1003002 10034660 10038435 10038447 10049776 10049778 10049778 10053090 10061105 10062237 10066338 10069389 10069688 10072370 10078987	Anuria Azotaemia Haemodialysis Nephropathy toxic Oliguria Peritoneal dialysis Renal failure Renal failure neonatal Renal impairment neonatal Neonatal anuria Haemofiltration Dialysis Renal impairment Continuous haemodiafiltration Acute kidney injury Acute phosphate nephropathy Prerenal failure Foetal renal impairment

s1\laesi1001.sas 200CT2023

Source	Group	Group code Scope	Preferred term code	Preferred term
Acute renal failure	Decreased renal function	0000000008 Narrow	10081980	Subacute kidney injury
Cholestasis and jaundice of hepatic origin	Hepatic injury	000000007 Narrow	10008635 10019754 10021209 10023126 10023129 10023136 10048611 10058117 10061009 10064190 10066758 1006758 10072268 10074151	Cholestasis Hepatitis cholestatic Icterus index increased Jaundice Jaundice cholestatic Jaundice hepatocellular Cholaemia Ocular icterus Bilirubin excretion disorder Cholestatic pruritus Mixed liver injury Cholestatic liver injury Drug-induced liver injury Parenteral nutrition associated liver disease
Hepatic failure, fibrosis and cirrhosis and other liver damage-related conditions	Hepatic injury	000000007 Narrow	10000804 10003547 10004659 10004664 10010075 10019637 10019660 10019663 10019663 10019692 10019708 10019837 10019845 10019845 10019845 10019845 10019845 10024570 10024714 10025129 10029530 10030210	Acute hepatic failure Asterixis Biliary cirrhosis Biliary fibrosis Coma hepatic Hepatic atrophy Hepatic cirrhosis Hepatic circhosis Hepatic failure Hepatic failure Hepatic steatosis Hepatocellular injury Hepatorenal failure Hepatorenal failure Hepatorenal syndrome Hepatotoxicity Liver disorder Liver transplant Lupoid hepatic cirrhosis Non-alcoholic fatty liver Oesophageal varices haemorrhage Portal hypertension Reye's syndrome

s1\laesi1001.sas 200CT2023

Appendix 1, Listing 1.3.4

Listing 1.3.4 Listing of preferred terms that define adverse events of special interest

lource	Group	Group code Scope	Preferred term code	Preferred term
Mepatic failure, fibrosis and cirrhosis and bther liver damage-related conditions	Hepatic injury	0000000007 Narrow	10050897	Portal hypertensive gastropathy
			10051010	Duodenal varices
			10051012	Gastric varices
			10051081	Nodular regenerative hyperplasia
			10052274	Hepatopulmonary syndrome
			10052279	Renal and liver transplant
			10053244	Hepatocellular foamy cell syndrome
			10056091	Varices oesophageal
			10056956	Subacute hepatic failure
			10057572	Gastric varices haemorrhage
			10057573	Chronic hepatic failure
			10061135	Spontaneous bacterial peritonitis
			10061997	Hepatectomy
			10061998	Hepatic lesion
			10062000	Hepatobiliary disease
			10062040	Liver operation
			10063075	Cryptogenic cirrhosis
			10064668	Hepatic infiltration eosinophilic
			10065274	Hepatic calcification
			10066597	Gastrooesophageal variceal haemorrhag
				prophylaxis
			10066599	Hepatic encephalopathy prophylaxis
			10067125	Liver injury
			10067281	Portopulmonary hypertension
			10067823	Splenic varices
			10068662	Splenic varices haemorrhage
			10068923	Portal hypertensive enteropathy
			10070815 10070953	Acute yellow liver atrophy Reynold's syndrome
			10070953	Diabetic hepatopathy
			10071502	Intestinal varices
			10072284	Varicose veins of abdominal wall
			10072319	Gallbladder varices
			10073209	Portal vein dilatation
			10073215	Peripancreatic varices
			10073979	Portal vein cavernous transformation
			10074726	Portal fibrosis
			10076237	Gastric variceal injection
			10076238	Gastric variceal ligation
			10076640	Liver dialysis
			10077215	Hepatic steato-fibrosis
			10077259	Non-cirrhotic portal hypertension

s1\laesi1001.sas 200CT2023

Appendix 1, Listing 1.3.4

Listing 1.3.4 Listing of preferred terms that define adverse events of special interest

Source	Group	Group code	Scope	Preferred term code	Preferred term
Hepatic failure, fibrosis and cirrhosis and other liver damage-related conditions	Hepatic injury	0000000007	Narrow	10077305	Acute on chronic liver failure
ocher fiver damage-refated conditions				10078058 10079446 10080429 10080679 10080860 10082480 10083010 10083406 10083521 10084797 10087030	Intestinal varices haemorrhage Portal hypertensive colopathy Primary biliary cholangitis Regenerative siderotic hepatic nodule Acquired hepatocerebral degeneration Cardiohepatic syndrome Sugiura procedure Immune-mediated cholangitis Immune-mediated hepatic disorder Flood syndrome Omental oedema
Hepatitis, non-infectious	Hepatic injury	000000007	Narrow	10003827 10008909 10019717 10019727 10019755 10019759 10019759 10023025 10049199 10051015 10053219 10064676 10066263 10067737 10071198 10072160 10076331 10078962 10080576	Autoimmune hepatitis Chronic hepatitis Hepatitis Hepatitis acute Hepatitis chronic active Hepatitis chronic persistent Hepatitis fulminant Hepatitis toxic Ischaemic hepatitis Hepatic cytolysis Radiation hepatitis Non-alcoholic steatohepatitis Graft versus host disease in liver Acute graft versus host disease in liver Lupus hepatitis Allergic hepatitis Chronic graft versus host disease in liver Steatohepatitis Immune-mediated hepatitis Alloimmune hepatitis
Hypersensitivity	Hypersensitivity reactions	000000003	Narrow		Anaphylactic reaction
				10002199 10002216 10002222 10002424	Anaphylactic shock Anaphylactoid reaction Anaphylaxis treatment Angloedema
				10003036	Application site dermatitis

s1\laesi1001.sas 200CT2023

Page

5

Listing 1.3.4 Listing of preferred terms that define adverse events of special interest

Source	Group	Group code Scope	Preferred term code	Preferred term
Hypersensitivity	Hypersensitivity reactions	000000003 Narrow	10003054	Application site rash
			10003645	Atopy
			10005149	Blepharitis allergic
			10005589	Blood immunoglobulin E abnormal
			10005591	Blood immunoqlobulin E increased
			10006404	Bromoderma
			10006482	Bronchospasm
			10009192	Circulatory collapse
			10010726	Conjunctival oedema
			10010744	Conjunctivitis allergic
			10010836	Contrast media reaction
			10011033	Corneal oedema
			10011411	Cross sensitivity reaction
			10011686	Cutaneous vasculitis
			10012431	Dermatitis
			10012432	Dermatitis acneiform
			10012434	Dermatitis allergic
			10012438	Dermatitis atopic
			10012441	Dermatitis bullous
			10012442	Dermatitis contact
			10012455	Dermatitis exfoliative
			10012456	Dermatitis exfoliative generalised
			10012468	Dermatitis herpetiformis
			10012470	Dermatitis infected
			10013687	Drug eruption
			10013700	Drug hypersensitivity
			10014184	Eczema
			10014198	Eczema infantile
			10014201	Eczema nummular
			10014627	Encephalopathy allergic
			10014989	Epidermolysis bullosa
			10015029	Epiglottic oedema
			10015218	Erythema multiforme
			10015226	Erythema nodosum
			10015907	Eye allergy
			10015967	Eye swelling
			10015993	Eyelid oedema
			10016029	Face oedema
			10016741	Fixed eruption
			10018258	Giant papillary conjunctivitis
			10018291	Gingival swelling
			10019617	Henoch-Schonlein purpura

Appendix 1, Listing 1.3.4

Page 46

Listing 1.3.4 Listing of preferred terms that define adverse events of special interest

Source	Group	Group code Scope	Preferred term code	Preferred term
Hypersensitivity	Hypersensitivity reactions	000000003 Narrow	10020751	Hypersensitivity
			10020764	Hypersensitivity vasculitis
			10021247	Idiopathic urticaria
			10022056	Injection site dermatitis
			10022071	Injection site hypersensitivity
			10022094	Injection site rash
			10022107	Injection site urticaria
			10023845	Laryngeal oedema
			10023891	Laryngospasm
			10023893	Laryngotracheal oedema
			10024558	Lip oedema
			10024570	Lip swelling
			10028164	Multiple allergies
			10029120	Nephritis allergic
			10029415	Nikolsky's sign
			10030081	Oculomucocutaneous syndrome
			10030110	Oedema mouth
			10031111	Oropharyngeal spasm
			10031118	Oropharyngeal swelling
			10034541	Perioral dermatitis
			10034545	Periorbital oedema
			10034829	Pharyngeal oedema
			10037789	Radioallergosorbent test positive
			10037844	Rash
			10037855	Rash erythematous
			10037857	Rash follicular
			10037867	Rash macular
			10037868	Rash maculo-papular
			10037870	Rash morbilliform
			10037871	Rash neonatal
			10037879	Rash papulosquamous
			10037884	Rash pruritic
			10037888	Rash pustular
			10037890	Rash scarlatiniform
			10037898	Rash vesicular
			10037973	Reaction to azo-dyes
			10037974	Reaction to colouring
			10037977	Reaction to food additive
			10039085	Rhinitis allergic
			10039755	Scrotal oedema
			10040400	Serum sickness
			10040402	Serum sickness-like reaction

MedDRA version: 25.0

s1\laesi1001.sas 200CT2023

Source	Group	Group code Scope	Preferred term code	Preferred term
Hypersensitivity	Hypersensitivity reactions	000000003 Narrow	10040560	Shock
			10040581	Shock symptom
			10040893	Skin necrosis
			10040914	Skin reaction
			10040934	Skin test positive
			10041307	Solar urticaria
			10041316	Solvent sensitivity
			10042033	Stevens-Johnson syndrome
			10042682	Swelling face
			10042690	Swelling of eyelid
			10042727	Swollen tongue
			10043967	Tongue oedema
			10044223	Toxic epidermal necrolysis
			10044296	Tracheal oedema
			10045240	Type I hypersensitivity
			10046735	Urticaria
			10046740	Urticaria cholinergic
			10046742	Urticaria contact
			10046750	Urticaria papular
			10046751	Urticaria physical
			10046752	Urticaria pigmentosa
			10046755	Urticaria vesiculosa
			10046943	Vaginal ulceration
			10047111	Vasculitic rash
			10047768	Vulval ulceration
			10048799	Acute generalised exanthematous pustulosis
			10048820	Urticarial vasculitis
			10049153	Allergic sinusitis
			10049305	Gingival oedema
			10050004	Rash maculovesicular
			10050099	Application site eczema
			10050104	Application site urticaria
			10050181	Vulvovaginal ulceration
			10050639	Allergic pharyngitis
			10050894	Anti-neutrophil cytoplasmic antibody positive vasculitis
			10051126	Scleritis allergic
			10051394	Allergic cystitis
			10051792	Infusion related reaction
			10052098	Iodine allergy
			10052139	Eye oedema

s1\laesi1001.sas 200CT2023

Source	Group	Group code Scope	Preferred term code	Preferred term
Hypersensitivity	Hypersensitivity reactions	000000003 Narrow	10052250	Circumoral oedema
			10052271	Catheter site rash
			10052272	Catheter site urticaria
			10052568	Urticaria chronic
			10052613	Allergic bronchitis
			10053177	Epidermolysis
			10053613	Type IV hypersensitivity reaction
			10053614	Type III immune complex mediated reaction
			10053779	Allergic cough
			10054000	Type II hypersensitivity
			10055048	Allergy to vaccine
			10055182	Eczema weeping
			10056352	Allergy test positive
			10056387	Encephalitis allergic
			10056647	Periorbital swelling
			10056671	Mucocutaneous rash
			10056872	Palpable purpura
			10056998	Palatal oedema
			10057380	Allergic keratitis
			10057431	Scleral oedema
			10057970	Toxic skin eruption
			10057984	Rash rubelliform
			10058675	Dermatitis psoriasiform
			10058681 10058898	Eczema vesicular Hand dermatitis
			10058898	Stoma site rash
			10059284	Epidermal necrosis
			10059284	Allergic colitis
			10059499	Haemorrhagic urticaria
			10059830	Infusion site rash
			10060934	Allergic oedema
			10061430	Arthritis allergic
			10061557	Allergic otitis media
			10062506	Heparin-induced thrombocytopenia
			10062918	Dennie-Morgan fold
			10063119	Anaphylactoid shock
			10063438	Pruritus allergic
			10063527	Allergic respiratory symptom
			10063532	Allergic respiratory disease
			10063683	Application site hypersensitivity
			10063786	Implant site rash

s1\laesi1001.sas 200CT2023

Source	Group	Group code Scope	Preferred term code	Preferred term
Hypersensitivity	Hypersensitivity reactions	000000003 Narrow	10063787	Implant site urticaria
			10063855	Implant site dermatitis
			10063858	Implant site hypersensitivity
			10064059	Antiallergic therapy
			10064579	Exfoliative rash
			10064788	Reaction to preservatives
			10064866	Laryngitis allergic
			10065458	Infusion site dermatitis
			10065471	Infusion site hypersensitivity
			10065490	Infusion site urticaria
			10065514	Antiendomysial antibody positive
			10066042	Eczema vaccinatum
			10066173	Allergic transfusion reaction
			10066221	Injection site eczema
			10066273	Vulval eczema
			10066797	Injection site recall reaction
			10066837 10066973	Gleich's syndrome
			10066973	Contrast media allergy Anaphylactic transfusion reaction
			10067113	Immediate post-injection reaction
			10067317	Oculorespiratory syndrome
			10067510	Contact stomatitis
			10067950	Oropharyngeal blistering
			10067972	Interstitial granulomatous dermatitis
			10067995	Injection site vasculitis
			10068355	Oral allergy syndrome
			10068809	Palisaded neutrophilic granulomatous
				dermatitis
			10068880	Vaccination site hypersensitivity
			10069167	Kounis syndrome
			10069440	Henoch-Schonlein purpura nephritis
			10069477	Vaccination site dermatitis
			10069482	Vaccination site rash
			10069489	Vaccination site exfoliation
			10069622	Vaccination site urticaria
			10069623	Vaccination site vesicles
			10069773	Administration related reaction
			10070492	Limbal swelling
			10070559	Distributive shock
			10070581	Immune tolerance induction
			10071152	Injection related reaction
			10071156	Administration site rash

s1\laesi1001.sas 200CT2023

Source	Group	Group code Scope	Preferred term code	Preferred term
Iypersensitivity	Hypersensitivity reactions	000000003 Narrow	10071198	Allergic hepatitis
			10071380	Chronic hyperplastic eosinophilic sinusitis
			10071399	Chronic eosinophilic rhinosinusitis
			10071588	Vulvovaginal rash
			10072867	Device allergy
			10073168	Incision site dermatitis
			10073411	Incision site rash
			10073508	Drug reaction with eosinophilia and
				systemic symptoms
			10073612	Instillation site hypersensitivity
			10073622	Instillation site rash
			10073627	Instillation site urticaria
			10073992	Catheter site dermatitis
			10073995	Catheter site eczema
			10073998	Catheter site hypersensitivity
			10074014	Catheter site vasculitis
			10074079	Allergy to immunoglobulin therapy
			10074332	Pathergy reaction
			10074350	Drug provocation test
			10074403	Palatal swelling
			10074509	Stoma site hypersensitivity
			10074850	Infusion site eczema
			10074851	Infusion site vasculitis
			10075072	Allergic otitis externa
			10075084 10075096	Aspirin-exacerbated respiratory diseas Administration site dermatitis
			10075096	
			10075102	Administration site eczema Administration site hypersensitivity
			10075102	Administration site urticaria
			10075185	Allergic eosinophilia
			10075203	Mouth swelling
			10075217	Mast cell activation syndrome
			10075308	Allergic gastroenteritis
			10075479	Allergy alert test positive
			10075572	Medical device site dermatitis
			10075575	Medical device site eczema
			10075579	Medical device site hypersensitivity
			10075585	Medical device site rash
			10075588	Medical device site urticaria
			10075807	Nodular rash
			10075964	Administration site recall reaction

s1\laesi1001.sas 200CT2023

Appendix 1, Listing 1.3.4

Listing 1.3.4 Listing of preferred terms that define adverse events of special interest

Source	Group	Group code S	cope	Preferred term code	Preferred term
lypersensitivity	Hypersensitivity reactions	000000003 1	larrow	10075969	Administration site vasculitis
				10076024	Application site recall reaction
				10076027	Application site vasculitis
				10076085	Infusion site recall reaction
				10076140	Medical device site recall reaction
				10076161	Vaccination site eczema
				10076188	Vaccination site recall reaction
				10076191	Vaccination site vasculitis
				10076229	Intestinal angioedema
				10076470	Documented hypersensitivity to
				10076606	administered product
				10076606 10076665	Mast cell degranulation present Dialysis membrane reaction
				10077117	Vessel puncture site rash
				10077279	Allergy to surgical sutures
				10077813	Vessel puncture site vesicles
				10078117	Eosinophilic granulomatosis with
				100/011/	polyangiitis
				10078325	Symmetrical drug-related intertrigino
					and flexural exanthema
				10078682	Anal eczema
				10078783	Oropharyngeal oedema
				10078853	Allergic reaction to excipient
				10079554	Allergic stomatitis
				10079925	Reaction to excipient
				10080783	Vulvovaginitis allergic
				10080894	Procedural shock
				10081000	Vernal keratoconjunctivitis
				10081004	Hypersensitivity myocarditis
				10081035	Acquired C1 inhibitor deficiency
				10081492	Atopic cough Circumoral swelling
				10081703	
				10081988 10082270	Hypersensitivity pneumonitis Pharyngeal swelling
				10082290	Urticarial dermatitis
				10082290	Reaction to flavouring
				10082742	Infusion related hypersensitivity
				10002/12	reaction
				10083164	SJS-TEN overlap
				10083260	Scrotal dermatitis
				10083809	Bullous haemorrhagic dermatosis
				10083842	Immune thrombocytopenia

s1\laesi1001.sas 200CT2023

Source	Group	Group code Scope	Preferred term code	Preferred term
Hypersensitivity	Hypersensitivity reactions	000000003 Narrow	10084049	Nutritional supplement allergy
			10084905 10085938 10085939 10086007 10086347 10086454 10086476 10086737 10087203 10087325	Generalised bullous fixed drug eruption Vascular access site dermatitis Vascular access site eczema Allergic lymphangitis Polymers allergy Reaction to sweetener Dermal filler reaction Vancomycin infusion reaction Periorbital dermatitis Bone cement allergy
Ketoacidosis	Diabetic ketoacidosis	0000000009 Narrow		Diabetic hyperglycaemic coma
			10012671 10012672	Diabetic ketoacidosis Diabetic ketoacidotic hyperglycaemic coma
			10023379 10080061	Ketoacidosis Euglycaemic diabetic ketoacidosis
Liver related investigations, signs and symptoms	Hepatic injury	0000000007 Narrow	10001547	Alanine aminotransferase abnormal
			10001551 10001942 10003445 10003445 10003477 10003481 10004685 10004792 10005364 10005370 10006408 10017688 10017693 10019621 10019621 10019622 10019670 10019705 10019847 10020575	Alanine aminotransferase increased Ammonia abnormal Ammonia increased Ascites Aspartate aminotransferase abnormal Aspartate aminotransferase increased Bilirubin conjugated increased Biood bilirubin increased Blood bilirubin increased Blood bilirubin unconjugated increased Bromosulphthalein test abnormal Gamma-glutamyltransferase abnormal Gamma-glutamyltransferase increased Hepaplastin abnormal Hepaplastin decreased Hepatic function abnormal Hepatosplenomegaly Hepatosplenomegaly Hyperammonaemia

s1\laesi1001.sas 200CT2023

Source	Group	Group code Scope	Preferred term code	Preferred term
Liver related investigations, signs and symptoms	Hepatic injury	0000000007 Narrow	10020578	Hyperbilirubinaemia
			10023321	Kayser-Fleischer ring
			10024690	Liver function test abnormal
			10024712	Liver tenderness
			10045428	Ultrasound liver abnormal
			10049631	Oedema due to hepatic disease
			10050792	Urine bilirubin increased
			10051333	Guanase increased
			10051343	Bile output decreased
			10051344	Bile output abnormal
			10051924	Hypercholia
			10052550	Liver induration
			10052554	Foetor hepaticus
			10054125	Perihepatic discomfort
			10054889	Transaminases increased
			10056536	X-ray hepatobiliary abnormal
			10057110	Hepatic mass
			10058477	Blood bilirubin abnormal
			10059710	Galactose elimination capacity test
			10050510	abnormal
			10059712	Galactose elimination capacity test
			10000107	decreased
			10060107	Liver-kidney microsomal antibody
			10000704	positive Nametic and descended
			10060794	Hepatic enzyme decreased
			10060795	Hepatic enzyme increased
			10061947	Liver scan abnormal
			10062685 10062688	Hepatic enzyme abnormal Transaminases abnormal
			10062688	Transaminases abnormal Total bile acids increased
			10064558	
			10004/12	Mitochondrial aspartate aminotransferase increased
			10066195	Hepatobiliary scan abnormal
			10066195	Hepatic sequestration
			10066244	Molar ratio of total branched-chain
			10000009	amino acid to tyrosine
			10067338	Retrograde portal vein flow
			10067365	Hepatic hydrothorax
			10067305	Bilirubin conjugated abnormal
			10068237	Hypertransaminasaemia
			10068287	Child-Pugh-Turcotte score increased
			10068358	Hepatic vascular resistance increased
			T00000000	inchange Aspentar reprovance luciessed

s1\laesi1001.sas 200CT2023

Appendix 1, Listing 1.3.4

Listing 1.3.4 Listing of preferred terms that define adverse events of special interest

Source	Group	Group code Scope	Preferred term code	Preferred term
viver related investigations, signs and	Hepatic injury	0000000007 Narrow	10068547	Bacterascites
-7 mp - 5 mp			10068997	Hepatic artery flow decreased
			10074150 10075895	Biliary ascites Liver palpable
			10076254	Hepatic hypertrophy
			10077020	Child-Pugh-Turcotte score abnormal
			10077356	Bilirubin urine present
			10077677	Liver function test decreased
			10077692	Liver function test increased
			10078360	Computerised tomogram liver abnormal
			10078438	White nipple sign
			10082443	Magnetic resonance proton density fat
				fraction measurement
			10082832	AST/ALT ratio abnormal
			10083171	Hepatic venous pressure gradient increased
			10083172	Hepatic venous pressure gradient abnormal
			10084058	Congestive hepatopathy
			10084751	Hepatic hypoperfusion
			10085121	Magnetic resonance imaging
				hepatobiliary abnormal
			10086006	Acquired factor V deficiency
			10086970	Anti-liver cytosol antibody type 1
				positive
ancreatic neoplasms	Pancreatic cancer	0000000006 Narrow		Benign neoplasm of islets of Langerham
			10017852	Gastrinoma
			10018404	Glucagonoma
			10022498 10025997	Insulinoma Malignant neoplasm of islets of
			10025997	Langerhans
			10029341	Neurotensinoma
			10033609	Pancreatic carcinoma
			10033610	Pancreatic carcinoma metastatic
			10033613	Pancreatic carcinoma recurrent
			10041329	Somatostatinoma
			10047430	Vipoma
			10051709	Gastrinoma malignant
			10052747	Adenocarcinoma pancreas
			10055006	Pancreatic sarcoma
			10055007	Carcinoid tumour of the pancreas

s1\laesi1001.sas 200CT2023

Source	Group	Group code Scope	Preferred term code	Preferred term
Pancreatic neoplasms	Pancreatic cancer	000000006 Narrow	10059320 10059321 10059322 10059323 10059323 10065908 10061902 10065908 10067517 10068909 10069345 10070399 10073363 10073365 10073365 10073367 10075245 10077559	Pancreatic carcinoma stage 0 Pancreatic carcinoma stage I Pancreatic carcinoma stage II Pancreatic carcinoma stage III Pancreatic carcinoma stage IV Benign pancreatic neoplasm Cystadenocarcinoma pancreas Pancreatic neuroendocrine tumour Pancreatic neuroendocrine tumour Pancreatic neuroendocrine tumour metastatic Solid pseudopapillary tumour of the pancreas Intraductal papillary mucinous neoplasm Acinar cell carcinoma of pancreas Ductal adenocarcinoma of pancreas Intraductal papillary-mucinous carcinoma of pancreas Pancreatoblastoma Metastatic glucagonoma Gastroenteropancreatic neuroendocrine tumour disease Pancreatic haemangioma
Pancreatitis chronic	Pancreatitis	000000005	10033649	Pancreatitis chronic
Severe cutaneous adverse reactions	Skin lesions	000000004 Narrow	10011686 10012441 10012455 10012456 10015218 10040893 10042033 10042033 1004223 1004223 10044223 10048799 10057970 10059284 10064579 10073508	Cutaneous vasculitis Dermatitis bullous Dermatitis exfoliative Dermatitis exfoliative generalised Erythema multiforme Oculomucocutaneous syndrome Skin necrosis Stevens-Johnson syndrome Toxic epidermal necrolysis Acute generalised exanthematous pustulosis Toxic skin eruption Epidermal necrosis Exfoliative rash Drug reaction with eosinophilia and systemic symptoms Target skin lesion

s1\laesi1001.sas 200CT2023

Appendix 1, Listing 1.3.4

Page 56

Listing 1.3.4 Listing of preferred terms that define adverse events of special interest

Source	Group	Preferred Group code Scope term code	
Severe cutaneous adverse reactions	Skin lesions	0000000004 Narrow 10082985 10083164 10083809 10084905 10085778	Erythrodermic atopic dermatitis SJS-TEN overlap Bullous haemorrhagic dermatosis Generalised bullous fixed drug eruption Severe cutaneous adverse reaction

MedDRA version: 25.0

s1\laesi1001.sas 200CT2023

1.1.4 Specific adverse events

Boehringer Ingelheim BI Trial No.: x1218.ped01

		_									ed vs Placebo_			
Subgroup Category	N	_Place n	ebo %	N	E pool n	led	p-value *		(exact 95% ((asymp 95% ((95% CI)	Risk diff.	(95% CI)	p-value **
Overall	53	5	9.4	52	12	23.1	0.0656	2.45	(0.95, 11.59 (0.93, 6.40		(0.94, 9.69)	0.14	(-0.01,0.29)	
Sex Male	19	1	5.3	19	6	31.6	0.0486	6.00	(1.01,155.79 (0.80, 45.20		(1.01,202.07)	0.26	(0.00,0.52)	0.2547
Female	34	4	11.8	33	6	18.2	0.5424	1.55	(0.46, 6.19 (0.48, 4.98	9) 1.67	(0.41, 7.30)	0.06	(-0.12,0.25)	
Age <15	26	4	15.4	25	6	24.0	0.5454	1.56	(0.49, 5.9 [°] (0.50, 4.88		(0.41, 7.85)	0.09	(-0.16,0.32)	0.2601
>=15 to <18	27	1	3.7	27	6	22.2	0.0538	6.00	(0.98,153.9 (0.77, 46.5	7) 7.43	(0.96,178.06)	0.19	(0.00,0.38)	
Region									(a ==		()		()	0.9824
US	33	3	9.1	36	8	22.2	0.2086	2.44	(0.75, 13.63)		(0.69, 14.27)	0.13	(-0.05,0.32)	
Non-US	20	2	10.0	16	4	25.0	0.2885	2.50	(0.48, 18.20 (0.52, 11.90	6) 3.00	(0.45, 25.77)	0.15	(-0.11,0.44)	
BMI [kg/m2] at baseline	:													0.2596
< median	27	4	14.8	26	6	23.1	0.5449	1.56	(0.48, 5.99)		(0.41, 7.76)	0.08	(-0.14,0.31)	
>= median	26	1	3.8	26	6	23.1	0.0533	6.00	(0.98,154.12 (0.78, 46.42	2) 7.50	(0.97,180.01)	0.19	(0.00,0.40)	
BMI Z-Score <=2 (Underweight, normal or overweight)	9	0	0	5	2	40.0								
>2 to <=3 (Class 1	17	3	17.6	21	4	19.0								
obesity) >3 (Class 2 or 3 obesity)	27	2	7.4	26	6	23.1								

Table 1.4.1 Frequencies and proportions of patients with specific adverse events overall and by subgroup up to week 26 – TS๋ (TG1) User-defined AE category: Hypoglycaemia (reported)

Only treatment emergent AEs are displayed (onset between first dose until treatment stop +7 days). Subgroups will only be analysed if at least 10 patients are in each subgroup category and at least 10 patients with event in at least one subgroup category (both treatments combined).

A ratio less than one or risk difference less than zero indicates less risk for E pooled.

MedDRA version: 25.0. N: number of patients. n: number of patients with an AE. Risk ratio exact CI estimated by Chan and Zhang, asymptotic CI by Wald. CIs for odds ratios are exact mid-p estimates. Risk diff. exact CI estimated by Chan and Zhang. * 2*one-sided Suissa-Shuster Z-pooled test. ** Q-test for homogeneity (H0) of risk ratios (treatment by subgroup interaction). NC.=Not calculated.

													d vs	Placebo			
Subgroup Category	N	_Place n	ebo %		_E pool n	led %	p-value *		(exact (asymp				(95%	CI)	Risk diff.	(95% CI)	p-value **
HbA1c [%] at baseline																	
<8.0	29	2	6.9	28	6	21.4											
8.0 to 9.0	12	1	8.3	12	3	25.0											
>9.0	12	2	16.7	12	3	25.0											
FPG [mg/dl] at baseline																	0.1894
<126	13	2	15.4	19	3	15.8	1.0000	1.03	(0.18, (0.20,			1.03	(0.13	, 9.89)	0.00	(-0.31,0.28)	
>=126	39	3	7.7	29	9	31.0	0.0147	4.03	(1.17, (1.20,	19.97) 5	5.40	(1.32	, 26.52)	0.23	(0.04,0.44)	
eGFR (Zappitelli) at baseline																	0.9636
<120	24	1	4.2	21	3	14.3	0.2877	3.43	(0.37, (0.39,			3.83	(0.37	,104.96)	0.10	(-0.09,0.33)	
120 to <150	23	3	13.0	19	9	47.4	0.0168	3.63	(1.18, (1.14,	17.76	i) e	6.00	(1.31	, 31.41)	0.34	(0.06,0.60)	
>=150	6	1	16.7	12	0	0	0.3018	0.00	(0.00, NC.			0.00	(0.00	, 4.50)	-0.17	(-0.64,0.14)	

Table 1.4.1 Frequencies and proportions of patients with specific adverse events overall and by subgroup up to week 26 - TS (TG1) User-defined AE category: Hypoglycaemia (reported)

Only treatment emergent AEs are displayed (onset between first dose until treatment stop +7 days).

4

2

6

0

4

5

3

15.4

66.7

27.3

23.5

23.8

21.4

0

Subgroups will only be analysed if at least 10 patients are in each subgroup category and at least 10 patients with event in at least one subgroup category (both treatments combined).

A ratio less than one or risk difference less than zero indicates less risk for E pooled.

Med. at baseline Metformin only

Insulin only

Time since diagnosis

1 year - 3 years

None

of T2DM <1 year

>3 years

Metformin and Insulin 19

28

2

4

18

24

11

2

0

3

0

2

2

1

7.1 26

15.8 22

11.1 17

8.3 21

9.1 14

0

0

3

1

MedDRA version: 25.0. N: number of patients. n: number of patients with an AE. Risk ratio exact CI estimated by Chan and Zhang, asymptotic CI by Wald. CIs for odds ratios are exact mid-p estimates. Risk diff. exact CI estimated by Chan and Zhang. * 2*one-sided Suissa-Shuster Z-pooled test. ** Q-test for homogeneity (H0) of risk ratios (treatment by subgroup interaction). NC.=Not calculated.

												ed vs Placebo			
Subgroup Category	N	_Place n	ebo %	- <u>N</u>	E pool n	.ed	p-value *	e Risk ratio	(exact (asymp	95% CI) 95% CI)	Odds ratio	(95% CI)	Risk diff.	(95% CI)	p-value **
Overall	53	1	1.9	52	3	5.8	0.3583	3.06		78.52) 28.45)	3.18	(0.32, 85.31)	0.04	(-0.05,0.14)	

Table 1.4.1 Frequencies and proportions of patients with specific adverse events overall and by subgroup up to week 26 – TS๋ (TG1) User-defined AE category: Urinary tract infection (narrow sub BICMQ)

Only treatment emergent AEs are displayed (onset between first dose until treatment stop +7 days). Subgroups will only be analysed if at least 10 patients are in each subgroup category and at least 10 patients with event in at least one subgroup category (both treatments combined).

A ratio less than one or risk difference less than zero indicates less risk for E pooled.

MedDRA version: 25.0. N: number of patients. n: number of patients with an AE. Risk ratio exact CI estimated by Chan and Zhang, asymptotic CI by Wald. CIs for odds ratios are exact mid-p estimates. Risk diff. exact CI estimated by Chan and Zhang. * 2*one-sided Suissa-Shuster Z-pooled test. ** Q-test for homogeneity (H0) of risk ratios (treatment by subgroup interaction). NC.=Not calculated.

Subgroup Category	N	_Place n	ebo]	E poole n	ed	p-value *	Risk ratio	(exact (asymp		ed vs Placebo_ (95% CI)	Risk diff.	(95% CI)	p-value **
Overall	53	1	1.9	52	1	1.9	1.0000	1.02	(0.03, (0.07,	1.02	(0.03, 40.49)	0.00	(-0.08,0.09)	

Table 1.4.1	Frequencies and p	proportions of	patients	with	specific	adverse	events	overall	and by	subgroup	up	to w	reek 26
	- TS (TG1)												
User-defined	AE category: Gen:	ital infection	(narrow	sub BI	cMQ)								

Only treatment emergent AEs are displayed (onset between first dose until treatment stop +7 days). Subgroups will only be analysed if at least 10 patients are in each subgroup category and at least 10 patients with event in at least one subgroup category (both treatments combined).

A ratio less than one or risk difference less than zero indicates less risk for E pooled.

MedDRA version: 25.0. N: number of patients. n: number of patients with an AE. Risk ratio exact CI estimated by Chan and Zhang, asymptotic CI by Wald. CIs for odds ratios are exact mid-p estimates. Risk diff. exact CI estimated by Chan and Zhang. * 2*one-sided Suissa-Shuster Z-pooled test. ** Q-test for homogeneity (H0) of risk ratios (treatment by subgroup interaction). NC.=Not calculated.

Appendix 1, Table 1.4.1

Table 1.4.1 Frequencies and proportions of patients with specific adverse events overall and by subgroup up to week 26 - TS (TG1) User-defined AE category: Acute pyelonephritis (narrow sub BIcMQ) or Urosepsis (PT)

There is no data to be displayed.

Table 1.4.1 Frequencies and proportions of patients with specific adverse events overall and by subgroup up to week 26 - TS (TG1) User-defined AE category: Bone fracture (narrow BIcMQ)

There is no data to be displayed.

Subgroup Category	N	_Plac n		N	E pool n	ed	p-value *	Risk ratio	(exact (asymp	95% CI) 95% CI)	E poole Odds ratio	ed vs Placebo_ (95% CI)	Risk	(95% CI)	p-value **
Overall	53	1	1.9	52	1	1.9	1.0000	1.02	(0.03, (0.07,		1.02	(0.03, 40.49)	0.00	(-0.08,0.09)	

Table 1.4.1	Frequencies and	proportions	of patients	with	specific	adverse	events	overall	and by	subgroup	up to	week 26
	– TS (TG1)											
User-defined	AE category: Ar	thralgia (HLG	T-primary p	ath)								

Only treatment emergent AEs are displayed (onset between first dose until treatment stop +7 days). Subgroups will only be analysed if at least 10 patients are in each subgroup category and at least 10 patients with event in at least one subgroup category (both treatments combined).

A ratio less than one or risk difference less than zero indicates less risk for E pooled.

MedDRA version: 25.0. N: number of patients. n: number of patients with an AE. Risk ratio exact CI estimated by Chan and Zhang, asymptotic CI by Wald. CIs for odds ratios are exact mid-p estimates. Risk diff. exact CI estimated by Chan and Zhang. * 2*one-sided Suissa-Shuster Z-pooled test. ** Q-test for homogeneity (H0) of risk ratios (treatment by subgroup interaction). NC.=Not calculated.

Table 1.4.1 Frequencies and proportions of patients with specific adverse events overall and by subgroup up to week 26 - TS (TG1)

User-defined AE category: Pemphigoid in bullous conditions (HLT-primary path)

There is no data to be displayed.

Boehringer Ingelheim BI Trial No.: x1218.ped01

Subgroup Category	N	_Plac n		- <u>N</u>	E pool n	.ed	p-value *	Risk ratio	(exact (asymp				Placebo_ CI)	Risk diff.	(95% CI)	p-value **
Overall	53	1	1.9	52	0	0	0.5361	0.00	(0.00, NC.	14.86)	0.00	(0.00	, 9.17)	-0.02	(-0.10,0.06)	

Table 1.4.1 Frequencies and proportions of patients with specific adverse events overall and by subgroup up to week 26 – TS๋ (TG1) User-defined AE category: Volume depletion (narrow BIcMQ)

Only treatment emergent AEs are displayed (onset between first dose until treatment stop +7 days). Subgroups will only be analysed if at least 10 patients are in each subgroup category and at least 10 patients with event in at least one subgroup category (both treatments combined).

A ratio less than one or risk difference less than zero indicates less risk for E pooled.

MedDRA version: 25.0. N: number of patients. n: number of patients with an AE. Risk ratio exact CI estimated by Chan and Zhang, asymptotic CI by Wald. CIs for odds ratios are exact mid-p estimates. Risk diff. exact CI estimated by Chan and Zhang. * 2*one-sided Suissa-Shuster Z-pooled test. ** Q-test for homogeneity (H0) of risk ratios (treatment by subgroup interaction). NC.=Not calculated.

Subgroup Category	N	_Place n		N	E pool n	ed	p-value *	Risk ratio	(exact (asymp		ed vs Placebo_ (95% CI)	Risk diff.	(95% CI)	p-value **
Overall	53	2	3.8	52	2	3.8	1.0000	1.02	(0.07, (0.15,	1.02	(0.10, 10.11)	0.00	(-0.10,0.10)	

Table 1.4.1	Frequencies	and proportic	ns of patie	nts with	specific	adverse	events	overall	and by	subgroup	up to	week 26
	– TS (TG1)											
User-defined	AE category:	Ketone measu	rements rep	orted as 1	AE (narro	ow BICMQ))					

Only treatment emergent AEs are displayed (onset between first dose until treatment stop +7 days). Subgroups will only be analysed if at least 10 patients are in each subgroup category and at least 10 patients with event in at least one subgroup category (both treatments combined).

A ratio less than one or risk difference less than zero indicates less risk for E pooled.

MedDRA version: 25.0. N: number of patients. n: number of patients with an AE. Risk ratio exact CI estimated by Chan and Zhang, asymptotic CI by Wald. CIs for odds ratios are exact mid-p estimates. Risk diff. exact CI estimated by Chan and Zhang. * 2*one-sided Suissa-Shuster Z-pooled test. ** Q-test for homogeneity (H0) of risk ratios (treatment by subgroup interaction). NC.=Not calculated.

Table 1.4.2 Frequencies and proportions of patients with serious specific adverse events overall and by subgroup up to week 26 - TS (TG1) User-defined AE category: Hypoglycaemia (reported)

There is no data to be displayed.

Table 1.4.2 Frequencies and proportions of patients with serious specific adverse events overall and by subgroup up to week 26 - TS (TG1) User-defined AE category: Urinary tract infection (narrow sub BIcMQ)

There is no data to be displayed.

Table 1.4.2 Frequencies and proportions of patients with serious specific adverse events overall and by subgroup up to week 26 - TS (TG1) User-defined AE category: Genital infection (narrow sub BICMQ)

There is no data to be displayed.

Table 1.4.2 Frequencies and proportions of patients with serious specific adverse events overall and by subgroup up to week 26 - TS (TG1) User-defined AE category: Acute pyelonephritis (narrow sub BIcMQ) or Urosepsis (PT)

There is no data to be displayed.

Table 1.4.2 Frequencies and proportions of patients with serious specific adverse events overall and by subgroup up to week 26 - TS (TG1) User-defined AE category: Bone fracture (narrow BIcMQ)

There is no data to be displayed.

Table 1.4.2 Frequencies and proportions of patients with serious specific adverse events overall and by subgroup up to week 26 - TS (TG1) User-defined AE category: Arthralgia (HLGT-primary path)

There is no data to be displayed.

Table 1.4.2 Frequencies and proportions of patients with serious specific adverse events overall and by subgroup up to week 26 - TS (TG1) User-defined AE category: Pemphigoid in bullous conditions (HLT-primary path)

There is no data to be displayed.

Subgroup Category	N	_Plac n	ebo		E poo n	led %	p-value *	Risk ratio	E (exact 95% CI) (asymp 95% CI)	Ōdds	d vs Placebo_ (95% CI)	Risk	(95% CI)	p-value **
Overall	53	1	1.9	52	0	0	0.5361	0.00	(0.00,14.86) NC.	0.00	(0.00,9.17)	-0.02	(-0.10,0.06)	

Table 1.4.2	Frequencies and	proportions of	f patients	with	serious	specific	adverse	events	overall a	nd by	subgroup up	to week 26
	- TS (TG1)											
User-defined	AE category: Vol	ume depletion	(narrow B	ICMQ)								

Only treatment emergent AEs are displayed (onset between first dose until treatment stop +7 days). Subgroups will only be analysed if at least 10 patients are in each subgroup category and at least 10 patients with event in at least one subgroup category (both treatments combined).

A ratio less than one or risk difference less than zero indicates less risk for E pooled.

MedDRA version: 25.0. N: number of patients. n: number of patients with an AE. Risk ratio exact CI estimated by Chan and Zhang, asymptotic CI by Wald. CIs for odds ratios are exact mid-p estimates. Risk diff. exact CI estimated by Chan and Zhang. * 2*one-sided Suissa-Shuster Z-pooled test. ** Q-test for homogeneity (H0) of risk ratios (treatment by subgroup interaction). NC.=Not calculated.

Table 1.4.2 Frequencies and proportions of patients with serious specific adverse events overall and by subgroup up to week 26 - TS (TG1) User-defined AE category: Ketone measurements reported as AE (narrow BICMQ)

There is no data to be displayed.

Boehringer Ingelheim BI Trial No.: x1218.ped01

Page 77

Table 1.4.3 Frequencies and proportions of patients with specific adverse events with severe maximum intensity overall and by subgroup up to week 26 - TS (TG1) User-defined AE category: Hypoglycaemia (reported)

There is no data to be displayed.

Table 1.4.3 Frequencies and proportions of patients with specific adverse events with severe maximum intensity overall and by subgroup up to week 26 - TS (TG1) User-defined AE category: Urinary tract infection (narrow sub BICMQ)

There is no data to be displayed.

Table 1.4.3 Frequencies and proportions of patients with specific adverse events with severe maximum intensity overall and by subgroup up to week 26 - TS (TG1) User-defined AE category: Genital infection (narrow sub BICMQ)

There is no data to be displayed.

Appendix 1, Table 1.4.3

Table 1.4.3 Frequencies and proportions of patients with specific adverse events with severe maximum intensity overall and by subgroup up to week 26 - TS (TG1) User-defined AE category: Acute pyelonephritis (narrow sub BIcMQ) or Urosepsis (PT)

There is no data to be displayed.

Boehringer Ingelheim BI Trial No.: x1218.ped01

Page 81

s1\taerisk4c001.sas 200CT2023

Table 1.4.3 Frequencies and proportions of patients with specific adverse events with severe maximum intensity overall and by subgroup up to week 26 - TS (TG1) User-defined AE category: Bone fracture (narrow BIcMQ)

There is no data to be displayed.

Page 82

s1\taerisk4c001.sas 200CT2023

Table 1.4.3 Frequencies and proportions of patients with specific adverse events with severe maximum intensity overall and by subgroup up to week 26 - TS (TG1) User-defined AE category: Arthralgia (HLGT-primary path)

There is no data to be displayed.

Table 1.4.3 Frequencies and proportions of patients with specific adverse events with severe maximum intensity overall and by subgroup up to week 26 - TS (TG1) User-defined AE category: Pemphigoid in bullous conditions (HLT-primary path)

There is no data to be displayed.

Subgroup Category	N	_Plac n	ebo	- <u>N</u>	E poo n	led	p-value *	Risk ratio	E (exact 95% CI) (asymp 95% CI)		d vs Placebo_ (95% CI)		(95% CI)	p-value **
Overall	53	1	1.9	52	0	0	0.5361	0.00	(0.00,14.86) NC.	0.00	(0.00,9.17)	-0.02	(-0.10,0.06)	

Table 1.4.3 Frequencies and proportions of patients with specific adverse events with severe maximum intensity overall and by subgroup up to week 26 - TS (TG1) User-defined AE category: Volume depletion (narrow BICMQ)

Only treatment emergent AEs are displayed (onset between first dose until treatment stop +7 days).

Subgroups will only be analysed if at least 10 patients are in each subgroup category and at least 10 patients with event in at least one subgroup category (both treatments combined).

A ratio less than one or risk difference less than zero indicates less risk for E pooled.

Maximum intensity: If a patient has more than one AE only the worst is recorded.

MedDRA version: 25.0. N: number of patients. n: number of patients with an AE. Risk ratio exact CI estimated by Chan and Zhang, asymptotic CI by Wald. CIs for odds ratios are exact mid-p estimates. Risk diff. exact CI estimated by Chan and Zhang. * 2*one-sided Suissa-Shuster Z-pooled test. ** Q-test for homogeneity (H0) of risk ratios (treatment by subgroup interaction). NC.=Not calculated.

Boehringer Ingelheim BI Trial No.: x1218.ped01

Page 85

Table 1.4.3 Frequencies and proportions of patients with specific adverse events with severe maximum intensity overall and by subgroup up to week 26 - TS (TG1)
User-defined AE category: Ketone measurements reported as AE (narrow BIcMQ)

There is no data to be displayed.

Source	Group	Group code Scope	Preferred term code	Preferred term
Bone fractures	Bone fractures	000000014 Narrow	10000397 10002544 10009245 10009245 10010149 10010214 10015741 10016450 10016450 10016454 10016667 10016997 10016997 10017085 10017085 10017088 10017081 10017085 10017088 10017107 10017296 10017308 10017308 10017310 10018720 10017310 10018720 10017310 10018720 10017310 10020462 10021349 10022576 10023149 10022576 10030682 10030684 10031290 10034122 10034156 10039117 10039579 10040960 10041541 10041569 10042015	Acetabulum fracture Ankle fracture Clavicle fracture Closed fracture manipulation Complicated fracture External fixation of fracture Facial bones fracture Femur fracture Femur fracture Fibula fracture Flail chest Foot fracture Fracture delayed union Fracture delayed union Fracture adunion Fracture of clavicle due to birth trauma Fracture delayed union Fracture delayed union Fracture of clavicle due to birth trauma Fracture delayed union Fracture delayed union Fracture stulla elevation Fracture delayed union Fracture malunion Fracture maxilla elevation Fracture delayed union Fracture delayed union Fracture Humerus fracture Humerus fracture Multiple fractures Open reduction of fracture Open reduction of fracture Open reduction of spinal fracture Open reduction of spinal fracture Open reduction of spinal fracture Radius fracture Radius fracture Radius fracture Scapula fracture Skull fracture Sternal fracture

MedDRA version: 25.0

s1\laesi1001.sas 200CT2023

98

Page

Source	Group	Group code Scope	Preferred term code	Preferred term
Bone fractures	Bone fractures	0000000014 Narrow	10042212	Stress fracture
	Done Haccareb	occorrent marrow	10043827	Tibia fracture
			10045375	Ulna fracture
			10048049	Wrist fracture
			10048617	Pseudarthrosis
			10049164	Fractured coccyx
			10049514	Traumatic fracture
			10049946	Cervical vertebral fracture
			10049947	Lumbar vertebral fracture
			10049948	Thoracic vertebral fracture
			10052614	Comminuted fracture
			10053206	Fracture displacement
			10053962	Epiphyseal fracture
			10057147	Fracture debridement
			10057609	Fracture reduction
			10059362	Fractured zygomatic arch elevation
			10061161	Pelvic fracture
			10061365	Skull fracture
			10061394	Upper limb fracture
			10061599	Lower limb fracture
			10061959	Fracture treatment
			10064210	Bone fissure
			10064211	Bone fragmentation
			10066094	Torus fracture
			10066184	Avulsion fracture
			10066386	Impacted fracture
			10069066	Intramedullary rod insertion
			10069135	Periprosthetic fracture
			10069723	Loss of anatomical alignment after fracture reduction
			10070884	Atypical femur fracture
			10072132	Fracture pain
			10072395	Atypical fracture
			10073162	Chance fracture
			10073853	Osteochondral fracture
			10074362	Sacroiliac fracture
			10074551	Limb fracture
			10074807	Spinal fusion fracture
			10077270	Surgical fixation of rib fracture
			10077603	Craniofacial fracture
			10078749	Lisfranc fracture
			10079423	Fracture blisters
			10079667	Metaphyseal corner fracture

MedDRA version: 25.0

s1\laesi1001.sas 200CT2023

87

Page

Source	Group	Group code Scope	Preferred term code	Preferred term
Bone fractures	Bone fractures	000000014 Narrow	10079813 10079864 10080550 10081343 10081442 10083585 10083586 10085543 10085543 10085774 10087273	Fracture infection Subchondral insufficiency fracture Osteophyte fracture Maisonneuve fracture Stapes fracture Skull fracture treatment Spinal fracture treatment Neurogenic fracture Microfracture surgery Depressed fracture
Bullous conditions	Pemphigoid in bullous conditions	000000011 Primar y Path		Blister Blood blister Dermatitis bullous Dermatitis herpetiformis Erythema multiforme Herpes gestationis Linear IgA disease Oculomucocutaneous syndrome Pemphigoid Pemphigus Pseudoporphyria Stevens-Johnson syndrome Toxic epidermal necrolysis Epidermolysis Acquired epidermolysis bullosa Paraneoplastic pemphigus Diabetic bullosis Coma blister Blister rupture Fracture blisters Ocdema blister SJS-TEN overlap Bullous haemorrhagic dermatosis Autoimmune blistering disease Generalised bullous fixed drug eruption Mucous membrane pemphigoid
Genital tract infections predisposed by glucosuria	Genital infections	0000000001 Narrow	10004055 10004074 10004078	Bacterial vaginosis Balanitis candida Balanoposthitis

MedDRA version: 25.0

Source	Group	Group code Scope	Preferred term code	Preferred term
Genital tract infections predisposed by Alucosuria	Genital infections	0000000001 Narrow	10004138	Bartholin's abscess
J			10004142	Bartholinitis
			10008323	Cervicitis
			10014791	Endometritis
			10015000	Epididymitis
			10015001	Epididymitis blastomyces
			10018143	Genital candidiasis
			10020497	Hydrocele male infected
			10030345	Oophoritis
			10031064	Orchitis
			10033119	Ovarian abscess
			10033847	Parametritis
			10034236	Pelvic abscess
			10034254	Pelvic inflammatory disease
			10034256	Pelvic inflammatory disease mycoplasmal
			10034294	Penile abscess
			10036934	Prostatic abscess
			10036978	Prostatitis
			10037651	Pyometra
			10039453	Salpingitis
			10039748	Scrotal gangrene
			10039954	Seminal vesiculitis
			10044250	Toxic shock syndrome staphylococcal
			10044251	Toxic shock syndrome streptococcal
			10046470	Urethral stricture post infection
			10046914	Vaginal infection
			10046957	Vaginitis gardnerella
			10047732	Vulval abscess
			10047752	Vulval cellulitis
			10047780	Vulvitis
			10047784	Vulvovaginal candidiasis
			10047794	Vulvovaginitis
			10048461	Genital infection
			10049205	Clitoris abscess
			10049571	Scrotal abscess
			10049573	Vaginal abscess
			10049677	Salpingo-oophoritis
			10050428	Fallopian tube abscess
			10050662	Prostate infection
			10050739	Erosive balanitis
			10051458 10051483	Myometritis Prostatovesiculitis

MedDRA version: 25.0

s1\laesi1001.sas 200CT2023

89

Page

Source	Group	Group code Scope	Preferred term code	Preferred term
Genital tract infections predisposed by glucosuria	Genital infections	0000000001 Narrow	10052301	Vaginal cellulitis
-			10052457 10053043	Perineal abscess Epididymitis ureaplasmal
			10054259	Escherichia vaginitis
			10054824 10056254	Tubo-ovarian abscess Intrauterine infection
			10056345	Rectovaginal septum abscess
			10056628	Ovarian bacterial infection
			10057001	Seminal vesicular infection
			10058674	Pelvic infection
			10059070	Pelvic sepsis
			10061179	Genital infection bacterial
			10061180	Genital infection fungal
			10061182 10061912	Genitourinary tract infection Penile infection
			10061912	Genital infection female
			10062156	Scrotal infection
			10062233	Uterine infection
			10062316	Genital abscess
			10062521	Genital infection male
			10062707	Parametric abscess
			10063012	Uterine abscess
			10064501	Spermatic cord funiculitis
			10064724	Testicular abscess
			10064899	Vulvovaginal mycotic infection
			10064929	Cellulitis of male external genital
			10065583	organ Urogenital infection bacterial
			10066876	Perineal infection
			10067185	Vulvovaginitis streptococcal
			10067236	Cervicitis streptococcal
			10067320	Prostatitis Escherichia coli
			10067741	Balanoposthitis infective
			10068682	Gangrenous balanitis
			10069918	Bacterial prostatitis
			10071209	Candida cervicitis
			10072020	Pyospermia Enderstruitis hestorial
			10074861 10074997	Endometritis bacterial
			10074997	Mycoplasma genitalium infection Cervicitis mycoplasmal
			10075620	Seminal vesicle abscess

s1\laesi1001.sas 200CT2023

90

Page

MedDRA version: 25.0

Source	Group	Group code Scope	Preferred term code	Preferred term
Genital tract infections predisposed by glucosuria	Genital infections	0000000001 Narrow	10079520	Vulvovaginitis staphylococcal
			10079521	Fungal balanitis
			10079528	Bacterial vulvovaginitis
			10081280	Ureaplasmal vulvovaginitis
			10082162 10083412	Ureaplasma cervicitis Neovaginal infection
			10084348	Scrotal cellulitis
			10085545	Penile gangrene
Increased ketones excluding acidosis and	Ketone measurements	0000000015 Narrow	10000410	Acetonaemia
liabetic ketoacidosis	reported as AE		10012673	Diabetic ketosis
			10012673	Ketonuria
			10023391	Ketosis
			10057594	Blood ketone body increased
			10057597	Urine ketone body present
			10057598	Blood ketone body present
			10058938	Acetonaemic vomiting
Joint disorders	Arthralgia	0000000010 Primar y Path		Ankylosing spondylitis
		-	10003239	Arthralgia
			10003246	Arthritis
			10003251	Arthritis climacteric
			10003253	Arthritis enteropathic
			10003267 10003285	Arthritis reactive Arthropathy
			10003285	Articular calcification
			10003433	Articular disc disorder
			10008690	Chondrocalcinosis pyrophosphate
			10008729	Chondromalacia
			10016386	Felty's syndrome
			10018634	Gouty arthritis
			10018641	Gouty tophus
			10018829	Haemarthrosis
			10020677 10023198	Hypermobility syndrome Joint ankylosis
			10023201	Joint contracture
			10023202	Joint deposit
			10023203	Joint destruction
			10023206	Joint dislocation pathological
			10023215	Joint effusion

MedDRA version: 25.0

Boehringer Ingelheim BI Trial No.: x1218.ped01

Appendix 1, Listing 1.4.4

Page 92

 		Path	
	Y ·	10023232	Joint swelling
			Ligament laxity
		10024829	Loose body in joint
		10029326	Neuropathic arthropathy
		10029328	Nodal osteoarthritis
		10029489	Osteoarthritis
		10031173	Osteoarthropathy
		10033534	Palindromic rheumatism
		10034464	Periarthritis
		10036030	Polyarthritis
		10037162	Psoriatic arthropathy
		10039054	Rheumatic fever
		10039073	Rheumatoid arthritis
		10039227	Rotator cuff syndrome
		10039361	Sacroiliitis
		10040968	SLE arthritis
		10041591	Spinal osteoarthritis
		10042061	Still's disease
		10042744	Sympathetic posterior cervical syndrome
		10043220	Temporomandibular joint syndrome
		10048694	Rheumatoid nodule
		10048706	Joint range of motion decreased
		10048745	Periarticular disorder
		10049143	Patellofemoral pain syndrome
		10050506	Spinal fusion acquired
		10051265	Spondyloarthropathy
		10054106	Joint warmth
		10054813	Facet joint syndrome
		10055042	Vertebral osteophyte
		10058029	Arthrofibrosis
		10058031	Joint adhesion
		10059176	Juvenile idiopathic arthritis
		10061258	Joint lock
		10061371	Spondylitis
		10061419	Crystal arthropathy
		10061430	Arthritis allergic
		10061761	Chondrocalcinosis
		10062164	Seronegative arthritis
		10062310	Joint hyperextension
		10062686	Carpal collapse
		10063580	Atlantoaxial instability

Preferred

Joint stiffness

Group code Scope term code Preferred term

0000000010 Primar 10023230

Listing 1.4.4 Listing of preferred terms that define specific adverse events

Group

Arthralgia

MedDRA version: 25.0

Source

Joint disorders

Source	Group	Group code	Scope	Preferred term code	Preferred term
oint disorders	Arthralgia	000000010	Primar y Path		Amyloid arthropathy
			1	10064931	Joint instability
				10065057	Haemophilic arthropathy
				10065564	Floating patella
				10065568	Lateral patellar compression syndrome
				10066850	Plica syndrome
				10068323	Arthrotoxicity
				10069429	Ulnocarpal abutment syndrome
				10069494	Carcinomatous polyarthritis
				10069498	Knee impingement syndrome
				10069690	Vertebral foraminal stenosis
				10070874	Joint laxity
				10070899	Femoroacetabular impingement
				10071155	Autoimmune arthritis
				10071400 10071742	Axial spondyloarthritis Poncet's disease
				10071742	Ankle impingement
				10072125	Infrapatellar fat pad inflammation
				10073029	Antithyroid arthritis syndrome
				10074327	Joint vibration
				10074329	Joint noise
				10075005	Crowned dens syndrome
				10075201	Rapidly progressive osteoarthritis
				10076549	Enteropathic spondylitis
				10076674	Juvenile psoriatic arthritis
				10076675	Juvenile spondyloarthritis
				10077089	Jaw clicking
				10077507	Paraneoplastic arthritis
				10077666	Joint microhaemorrhage
				10078014	Interspinous osteoarthritis
				10078114	Destructive spondyloarthropathy
				10079555	Scapular dyskinesis
				10079942	Joint space narrowing
				10080059	Diffuse idiopathic skeletal hyperostos
				10080832	Snapping hip syndrome
				10081395	Spinal segmental dysfunction
				10081448	Scapholunate dissociation
				10081810	Pustulotic arthro-osteitis
				10082100	Oligoarthritis
				10083155 10083266	Immune-mediated arthritis
				10083266	Paralytic hip dislocation Atlantoaxial subluxation

s1\laesi1001.sas 200CT2023

93

Page

MedDRA version: 25.0

Boehringer Ingelheim BI Trial No.: x1218.ped01

Appendix 1, Listing 1.4.4

Page 94

Listing 1.4.4 Listing of preferred terms that define specific adverse events

ource	Group	Group code	Scope	Preferred term code	Preferred term
oint disorders	Arthralgia	0000000010	Primar y Path		Rotator cuff injury of hip
			1	10085378	Hydroxyapatite crystal deposition disease
				10085600	Acute aseptic arthritis
				10085753	Peripheral spondyloarthritis
				10086187	Undifferentiated spondyloarthritis
				10086277	Joint fistula
				10086279	Rheumatoid bursitis
				10086355	Rotator cuff tear arthropathy
				10087218	Joint impingement
				10087333	Greater trochanteric pain syndrome
enal infections predisposed by glucosuria	Acute pyelonephritis or urosepsis	000000013	Narrow	10023424	Kidney infection
	d1000p010			10034531	Perinephric abscess
				10037584	Pyelitis
				10037596	Pyelonephritis
				10037597	Pyelonephritis acute
				10037601	Pyelonephritis chronic
				10037603	Pyelonephritis mycoplasmal
				10037653	Pyonephrosis
				10038351	Renal abscess
				10049100	Pyelocystitis
				10058596	Renal cyst infection
				10059517	Bacterial pyelonephritis
				10065214	Pyelonephritis fungal
				10068822	Emphysematous pyelonephritis
				10072058	Perinephritis
				10074409 10078229	Escherichia pyelonephritis
				10078229	Renal graft infection Nephritis bacterial
				10082040	Infected urinoma
TI predisposed by glucosuria	Urinary tract infections	0000000002	Narrow	10004056	Bacteriuria
	111200010110			10004058	Bacteriuria in pregnancy
				10011781	Cystitis
				10011790	Cystitis escherichia
				10011792	Cystitis gonococcal
				10011793	Cystitis haemorrhagic
				10011797	Cystitis klebsiella

MedDRA version: 25.0

MedDRA version: 25.0

Source	Group	Group code Scope	Preferred term code	Preferred term
JTI predisposed by glucosuria	Urinary tract infections	0000000002 Narrow	10011799	Cystitis pseudomonal
			10017525	Fungal cystitis
			10023424	Kidney infection
			10034531	Perinephric abscess
			10037584	Pyelitis
			10037596	Pyelonephritis
			10037597	Pyelonephritis acute
			10037601	Pyelonephritis chronic
			10037603	Pyelonephritis mycoplasmal
			10037653	Pyonephrosis
			10038351	Renal abscess
			10046424	Urethral abscess
			10046470	Urethral stricture post infection
			10046480	Urethritis
			10046482	Urethritis chlamydial
			10046483	Urethritis gonococcal
			10046489	Urethritis trichomonal
			10046490	Urethritis ureaplasmal
			10046571	Urinary tract infection
			10046572	Urinary tract infection enterococcal
			10046573	Urinary tract infection neonatal
			10046704	Urogenital trichomoniasis
			10048709	Urosepsis
			10049059	Urinary tract infection fungal
			10049100	Pyelocystitis
			10051250	Ureteritis
			10051959	Urinary bladder abscess
			10052238	Escherichia urinary tract infection
			10052299	Urethral carbuncle
			10054088	Urinary tract infection bacterial
			10056351	Emphysematous cystitis
			10056396	Asymptomatic bacteriuria
			10058523	Bladder candidiasis
			10058596	Renal cyst infection
			10059517	Bacterial pyelonephritis
			10061181	Genitourinary tract gonococcal infecti
			10061395	Ureter abscess
			10062279	Urinary tract infection pseudomonal
			10062280	Urinary tract infection staphylococcal
			10064850	Cystitis erosive
			10065198	Cystitis bacterial
			10065214	Pyelonephritis fungal

Source	Group	Group code Scope	Preferred term code	Preferred term
UTI predisposed by glucosuria	Urinary tract infections	0000000002 Narrow	10065582	Urogenital infection fungal
			10065583 10066757 10068822 10070300 10072058 10074409 10074457 10075063 10077375 10078665 10078665 10078666 10081163 10081185 10081262 10082040 10082818 10083162 10083524 10084121 10084826	Urogenital infection bacterial Urinary tract abscess Emphysematous pyelonephritis Streptococcal urinary tract infection Perinephritis Escherichia pyelonephritis Bladder diverticulitis Urethritis mycoplasmal Funguria Renal graft infection Bacterial urethritis Bacterial urethritis Fungal urethritis Fungal urethritis Nephritis bacterial Providencia urinary tract infection Urinary tract candidiasis Campylobacter urinary tract infection Infected urinoma Aerococcus urinae infection
Jrosepsis	Acute pyelonephritis or urosepsis	000000013	10048709	Urosepsis
Volume depletion and hypotension due to dehydration	Volume depletion	0000000012 Narrow	10005731	Blood pressure ambulatory decreased
			10005734 10005737 10005758 10009192 10012174 10021097 10021137 10021138 10026983 10031127 10036653 10042772 10053356	Blood pressure decreased Blood pressure diastolic decreased Circulatory collapse Dehydration Hypotension Hypovolaemia Hypovolaemic shock Mean arterial pressure decreased Orthostatic hypotension Presyncope Syncope Blood pressure orthostatic decreased

MedDRA version: 25.0

		a 1.a	Preferred	
Source	Group	Group code Scope	term code	Preferred term
Volume depletion and hypotension due to dehydration	Volume depletion	0000000012 Narrow	10066077	Diastolic hypotension
			10078280 10083659 10084012	CT hypotension complex Hypotensive crisis Dialysis hypotension

MedDRA version: 25.0

1.1.5 Adverse events on SOC level

1.5

System organ class: Infections and infestations

Subgroup Category	N	_Plac n	ebo	- <u>N</u>	E pool n	Led	p-value *	Risk ratio	(exact (asymp	95% CI) 95% CI)	E poole Odds ratio	ed vs Plac (95% CI)	cebo_	Risk diff.	(95% CI)	p-value **
Overall			24.5						(0.77,					0.10	(-0.08, 0.2	28)
Overall comparison of treatments is not significant on 5% level.																

Only treatment emergent AEs are displayed (onset between first dose until treatment stop +7 days). Subgroups will only be analysed if at least 10 patients are in each subgroup category and at least 10 patients with event in at least one subgroup category (both treatments combined).

A ratio less than one or risk difference less than zero indicates less risk for E pooled.

MedDRA version: 25.0. N: number of patients. n: number of patients with an AE. Risk ratio exact CI estimated by Chan and Zhang, asymptotic CI by Wald. CIs for odds ratios are exact mid-p estimates. Risk diff. exact CI estimated by Chan and Zhang. * 2*one-sided Suissa-Shuster Z-pooled test. ** Q-test for homogeneity (H0) of risk ratios (treatment by subgroup interaction).

System organ class: Metabolism and nutrition disorders

Subgroup Category	N	_Placon	ebo	N	E pool n	Led	p-value *	Risk ratio	(exact (asymp	95% CI) 95% CI)	E poole Odds ratio	ed vs Placebo_ (95% CI)	Risk diff.	(95% CI)	p-value **
Overall	53	12	22.6	52	16	30.8	0.5361	1.36		2.84) 2.59)	1.52	(0.63, 3.70)	0.08	(-0.10, 0.25)	
Overall comparison of treatments is not significant on 5% level.															

Only treatment emergent AEs are displayed (onset between first dose until treatment stop +7 days). Subgroups will only be analysed if at least 10 patients are in each subgroup category and at least 10 patients with event in at least one subgroup category (both treatments combined).

A ratio less than one or risk difference less than zero indicates less risk for E pooled.

MedDRA version: 25.0. N: number of patients. n: number of patients with an AE. Risk ratio exact CI estimated by Chan and Zhang, asymptotic CI by Wald. CIs for odds ratios are exact mid-p estimates. Risk diff. exact CI estimated by Chan and Zhang. * 2*one-sided Suissa-Shuster Z-pooled test. ** Q-test for homogeneity (H0) of risk ratios (treatment by subgroup interaction).

System organ class: Gastrointestinal disorders

Subgroup Category	N	_Plac n	ebo	- <u>N</u>	E pool n	led	p-value *	Risk ratio	(exact (asymp	95% CI) 95% CI)	E poole Odds ratio	ed vs Placeb (95% CI)	Risk	(95% CI)	p-value **
Overall	53	10	18.9	52	12	23.1	0.6927	1.22		2.85) 2.58)	1.29	(0.49, 3.4	0) 0.04	(-0.12, 0.21)	
Overall comparison of treatments is not significant on 5% level.															

Only treatment emergent AEs are displayed (onset between first dose until treatment stop +7 days). Subgroups will only be analysed if at least 10 patients are in each subgroup category and at least 10 patients with event in at least one subgroup category (both treatments combined).

A ratio less than one or risk difference less than zero indicates less risk for E pooled.

MedDRA version: 25.0. N: number of patients. n: number of patients with an AE. Risk ratio exact CI estimated by Chan and Zhang, asymptotic CI by Wald. CIs for odds ratios are exact mid-p estimates. Risk diff. exact CI estimated by Chan and Zhang. * 2*one-sided Suissa-Shuster Z-pooled test. ** Q-test for homogeneity (H0) of risk ratios (treatment by subgroup interaction).

System organ class: Nervous system disorders

Subgroup Category	N	_Plac n	ebo	- <u>-</u>	E pool n	led	p-value *	Risk ratio	(exact (asymp	95% CI) 95% CI)	E poole Odds ratio	ed vs Placebo_ (95% CI)	Risk diff.	(95% CI)	p-value **
Overall	53	11	20.8	52	11	21.2	1.0000	1.02		2.24) 2.14)	1.02	(0.39, 2.68)	0.00	(-0.16, 0.17)	
Overall comparison of treatments is not significant on 5% level.															

Page

102

Only treatment emergent AEs are displayed (onset between first dose until treatment stop +7 days). Subgroups will only be analysed if at least 10 patients are in each subgroup category and at least 10 patients with event in at least one subgroup category (both treatments combined).

A ratio less than one or risk difference less than zero indicates less risk for E pooled.

MedDRA version: 25.0. N: number of patients. n: number of patients with an AE. Risk ratio exact CI estimated by Chan and Zhang, asymptotic CI by Wald. CIs for odds ratios are exact mid-p estimates. Risk diff. exact CI estimated by Chan and Zhang. * 2*one-sided Suissa-Shuster Z-pooled test. ** Q-test for homogeneity (H0) of risk ratios (treatment by subgroup interaction).

												ed vs Pi				
Subgroup Category	N	_Plac n				.ed		Risk ratio	(exact (asymp	95% CI) 95% CI)	Odds ratio	(95% C	[)	Risk diff.	(95% CI)	p-value **
Overall	53	8	15.1	52	2	3.8	0.0583	0.25	(0.03, (0.06,		0.23	(0.03,	1.05)	-0.11	(-0.24, 0.00)	

Table 1.5.1 Frequencies and proportions of patients with adverse events with >=10% occurrence in at least one treatment arm on SOC level overall and by subgroup up to week 26 - TS (TG1) System organ class: Respiratory, thoracic and mediastinal disorders

Only treatment emergent AEs are displayed (onset between first dose until treatment stop +7 days).

Subgroups will only be analysed if at least 10 patients are in each subgroup category and at least 10 patients with event in at least one subgroup category (both treatments combined).

A ratio less than one or risk difference less than zero indicates less risk for E pooled.

MedDRA version: 25.0. N: number of patients. n: number of patients with an AE. Risk ratio exact CI estimated by Chan and Zhang, asymptotic CI by Wald. CIs for odds ratios are exact mid-p estimates. Risk diff. exact CI estimated by Chan and Zhang. * 2*one-sided Suissa-Shuster Z-pooled test. ** Q-test for homogeneity (H0) of risk ratios (treatment by subgroup interaction).

Appendix 1, Table 1.5.1

Page

103

Table 1.5.1	Frequencies and	l proportions of	patients with	adverse	events wi	th >=10%	occurrence	in at	least	one t	reatment	arm on	SOC	level	overall	
	and by subgroup	up to week 26	- TS (TG1)													
System organ	clace. Injury	noisoning and n	rocedural comm	lications	2											

System organ class: Injury, poisoning and procedural complications

												ed vs Pl				
Subgroup Category	N	_Plac n	ebo %	- <u>N</u>	E pool n	ed %	p-value *	Risk ratio	(exact (asymp	95% CI) 95% CI)	Odds ratio	(95% CI	.)	Risk diff.	(95% CI)	p-value **
Overall	53	7	13.2	52	3	5.8	0.2490	0.44	(0.07, (0.12,		0.40	(0.08,	1.64)	-0.07	(-0.21, 0.04)	

Appendix 1, Table 1.5.1

Only treatment emergent AEs are displayed (onset between first dose until treatment stop +7 days). Subgroups will only be analysed if at least 10 patients are in each subgroup category and at least 10 patients with event in at least one subgroup category (both treatments combined).

A ratio less than one or risk difference less than zero indicates less risk for E pooled.

MedDRA version: 25.0. N: number of patients. n: number of patients with an AE. Risk ratio exact CI estimated by Chan and Zhang, asymptotic CI by Wald. CIs for odds ratios are exact mid-p estimates. Risk diff. exact CI estimated by Chan and Zhang. * 2*one-sided Suissa-Shuster Z-pooled test. ** Q-test for homogeneity (H0) of risk ratios (treatment by subgroup interaction).

Subgroup Category	N	_Plac n	ebo	- <u>N</u>	E pool n	led	p-value *	Risk ratio	(exact (asymp	95% 95%			Placebo_ CI)	Risk diff.	(95% CI)	p-value **
Overall	53	7	13.2	52	6	11.5	0.8737	0.87	(0.29, (0.31,		0.86	(0.25	5, 2.85)	-0.02	(-0.15, 0.12)
Overall comparison of treatments is not significant on 5% level.																

Page

105

Only treatment emergent AEs are displayed (onset between first dose until treatment stop +7 days). Subgroups will only be analysed if at least 10 patients are in each subgroup category and at least 10 patients with event in at least one subgroup category (both treatments combined).

A ratio less than one or risk difference less than zero indicates less risk for E pooled.

MedDRA version: 25.0. N: number of patients. n: number of patients with an AE. Risk ratio exact CI estimated by Chan and Zhang, asymptotic CI by Wald. CIs for odds ratios are exact mid-p estimates. Risk diff. exact CI estimated by Chan and Zhang. * 2*one-sided Suissa-Shuster Z-pooled test. ** Q-test for homogeneity (H0) of risk ratios (treatment by subgroup interaction).

There is no data to be displayed.

Table 1.5.3 Frequencies and proportions of patients with adverse events with severe maximum intensity with >=5% occurrence in at least one treatment arm on SOC level overall and by subgroup up to week 26 - TS (TG1)

There is no data to be displayed.

Table 1.5.4	Frequencies and proportions of patients with adverse events leading to treatment discontinuation on SOC level
	up to week 26 - TS (TG1)
System organ	n class: Gastrointestinal disorders

Subgroup		_Plac	ebo		Е рос	led	
Category	N	n	oło	N	n	olo	
Overall	53	1	1.9	52	0	0	

s1\taerisk4d001.sas 200CT2023

Page 108

Subgroup		Plac	ebo]	E poc	led
Subgroup Category	N	n	010	N	'n	010
Overall	53	1	1.9	52	0	0

Table 1.5.4 Frequencies and proportions of patients with adverse events leading to treatment discontinuation on SOC level up to week 26 - TS (TG1) System organ class: Renal and urinary disorders

109

Appendix 1, Table 1.5.4

Page

Only treatment emergent AEs are displayed (onset between first dose until treatment stop +7 days). N is the number of patients, n the number of patients with at least one event MedDRA version: 25.0.

up to week 26 – TS (TG1) System organ class: Reproductive system and breast disorders	

Subgroup		Plac	ebo	E pooled				
Category	N	n	olo	N	n	0/0		
Overall	53	1	1.9	52	0	0		

110

Only treatment emergent AEs are displayed (onset between first dose until treatment stop +7 days). N is the number of patients, n the number of patients with at least one event MedDRA version: 25.0.

1.1.6 Adverse events on PT level

1.6

Table 1.6.1 Frequencies and proportions of patients with adverse events with >=10% occurrence in at least one treatment arm on PT level overall and by subgroup up to week 26 - TS (TG1)

System organ class: Metabolism and nutrition disorders Preferred term: Hypoglycaemia

Subgroup Category	N	_Place n		- <u>N</u>	E poo	led	p-value *	Risk ratio	(exact (asymp			ed vs Placebo (95% CI)	Risk	(95% CI)	p-value **
Overall	53	5	9.4	52	11	21.2	0.1152	2.24		9.54) 6.01)	2.58	(0.83, 8.76	5) 0.12	(-0.02, 0.26)	
Overall comparison of treatments is not significant on 5% level.															

Only treatment emergent AEs are displayed (onset between first dose until treatment stop +7 days).

Subgroups will only be analysed if at least 10 patients are in each subgroup category and at least 10 patients with event in at least one subgroup category (both treatments combined).

A ratio less than one or risk difference less than zero indicates less risk for E pooled.

MedDRA version: 25.0. N: number of patients. n: number of patients with an AE. Risk ratio exact CI estimated by Chan and Zhang, asymptotic CI by Wald. CIs for odds ratios are exact mid-p estimates. Risk diff. exact CI estimated by Chan and Zhang. * 2*one-sided Suissa-Shuster Z-pooled test. ** Q-test for homogeneity (H0) of risk ratios (treatment by subgroup interaction).

Table 1.6.1 Frequencies and proportions of patients with adverse events with >=10% occurrence in at least one treatment arm on PT level overall and by subgroup up to week 26 - TS (TG1) System organ class: Nervous system disorders

Preferred term: Headache

					_							ed vs Place	ebo_			
Subgroup Category	N	_Plac n	ebo %	N	E poo. n	led	p-value *	Risk ratio	(exact (asymp	95% CI) 95% CI)	Odds ratio	(95% CI)		Risk diff.	(95% CI)	p-value **
Overall	53	7	13.2	52	8	15.4	0.8366	1.16		3.29) 2.98)	1.19	(0.39, 3	.73)	0.02	(-0.12, 0.1	")
Overall comparison of treatments is not significant on 5% level.																

Only treatment emergent AEs are displayed (onset between first dose until treatment stop +7 days). Subgroups will only be analysed if at least 10 patients are in each subgroup category and at least 10 patients with event in at least one subgroup category (both treatments combined).

A ratio less than one or risk difference less than zero indicates less risk for E pooled.

MedDRA version: 25.0. N: number of patients. n: number of patients with an AE. Risk ratio exact CI estimated by Chan and Zhang, asymptotic CI by Wald. CIs for odds ratios are exact mid-p estimates. Risk diff. exact CI estimated by Chan and Zhang. * 2*one-sided Suissa-Shuster Z-pooled test. ** Q-test for homogeneity (H0) of risk ratios (treatment by subgroup interaction).

Boehringer Ingelheim BI Trial No.: x1218.ped01

Table 1.6.2 Frequencies and proportions of patients with serious adverse events with >=5% occurrence in at least one treatment arm on PT level overall and by subgroup up to week 26 - TS (TG1)

There is no data to be displayed.

Table 1.6.3 Frequencies and proportions of patients with adverse events with severe maximum intensity with >=5% occurrence in at least one treatment arm on PT level overall and by subgroup up to week 26 - TS (TG1)

There is no data to be displayed.

Table 1.6.4	Frequencies and	l proportions	of patients	with	adverse	events	leading	to treat	tment	discontinuation	on F	т 16	evel
	up to week 26 -	- TS (TG1)											
System organ	class: Gastroin	ntestinal disc	orders										
Preferred te	rm: Pancreatitis	acute											

n gʻ	
11 0	
0 0	
	0 0

Only treatment emergent AEs are displayed (onset between first dose until treatment stop +7 days). N is the number of patients, n the number of patients with at least one event MedDRA version: 25.0.

Table 1.6.4	Frequencies and	proportions of	patients	with	adverse	events	leading	to	treatment	discontinuation	on P	T level
	up to week 26 -	TS (TG1)										
System organ	class: Renal and	d urinary diso	ders									
Preferred te	rm: Polyuria											

Subgroup		Plac	ebo		E poo	led
Category	Ν	n	510	Ν	n	0
Overall	53	1	1.9	52	0	0

Only treatment emergent AEs are displayed (onset between first dose until treatment stop +7 days). N is the number of patients, n the number of patients with at least one event MedDRA version: 25.0.

Table 1.6.4	Frequencies and proportions of patients with adverse events leading to treatment discontinuation on PT level
	up to week 26 - TS (TG1)
System organ	n class: Reproductive system and breast disorders

Preferred term: Menstruation irregular

Subgroup		Plac	ebo]	Е рос	led	
Category	N	n	010	N	n	olo	
Overall	53	1	1.9	52	0	0	

Only treatment emergent AEs are displayed (onset between first dose until treatment stop +7 days). N is the number of patients, n the number of patients with at least one event MedDRA version: 25.0.

1.1.7 Other adverse Events

Subgroup Category	N	_Place n				.ed	p-value *	Risk ratio	E (exact 95% CI) (asymp 95% CI)		d vs Placebo_ (95% CI)	Risk diff.	(95% CI)	p-value **
Overall	53	2	3.8	52	6	11.5	0.1532	3.06	(0.68,33.98) (0.65,14.46)	3.33	(0.66,24.70)	0.08	(-0.03,0.20)	

Table 1.7.1	Frequencies and proportions of	patients with rep	ported non-severe	hypoglycaemia with	symptoms and plasma	glucose <54 mg/dl
	overall and by subgroup up to	week 26 - TS (TG1))			

A ratio less than one or risk difference less than zero indicates less risk for E pooled.

Only treatment emergent AEs are displayed (onset between first dose until treatment stop +7 days). Subgroups will only be analysed if at least 10 patients are in each subgroup category and at least 10 patients with event in at least one subgroup category (both treatments combined).

MedDRA version: 25.0. N: number of patients. n: number of patients with an AE. Risk ratio exact CI estimated by Chan and Zhang, asymptotic CI by Wald. CIs for odds ratios are exact mid-p estimates. Risk diff. exact CI estimated by Chan and Zhang. * 2*one-sided Suissa-Shuster Z-pooled test. ** Q-test for homogeneity (H0) of risk ratios (treatment by subgroup interaction).

Subgroup Category	N		bo			.ed	p-value *	Risk ratio	E (exact 95% CI) (asymp 95% CI)	pooled Odds ratio	d vs Placebo_ (95% CI)	Risk diff.	(95% CI)	p-value **
Overall	53	2	3.8	52	8	15.4	0.0507	4.08	(1.00,33.98) (0.91,18.30)	4.64	(1.00,32.98)	0.12	(0.00,0.25)	

Table 1.7.2	requencies and proportions of patients with reported non-severe hypoglycaemia with symptoms and plasma glucose <=70 mg/dl	L
	overall and by subgroup up to week 26 - TS (TG1)	

A ratio less than one or risk difference less than zero indicates less risk for E pooled.

Only treatment emergent AEs are displayed (onset between first dose until treatment stop +7 days). Subgroups will only be analysed if at least 10 patients are in each subgroup category and at least 10 patients with event in at least one subgroup category (both treatments combined).

MedDRA version: 25.0. N: number of patients. n: number of patients with an AE. Risk ratio exact CI estimated by Chan and Zhang, asymptotic CI by Wald. CIs for odds ratios are exact mid-p estimates. Risk diff. exact CI estimated by Chan and Zhang. * 2*one-sided Suissa-Shuster Z-pooled test. ** Q-test for homogeneity (H0) of risk ratios (treatment by subgroup interaction).

Table 1.7.3 Frequencies and proportions of patients with reported severe hypoglycaemia (requiring the assistance of another person) overall and by subgroup up to week 26 - TS (TG1)

There is no data to be displayed.

1.2 Efficacy Analysis - TG1

Boehringer Ingelheim BI Trial No.: x1218.ped01 1.2.1 Responder Analyses

Boehringer Ingelheim BI Trial No.: x1218.ped01

						-						d vs Placebo_			
Subgroup Category	N	_Place n	\$	N	E pool n	.ed	p-value *			95% CI) 95% CI)		(95% CI)	Risk diff.	(95% CI)	p-value **
Overall	53	5	9.4	52	11	21.2	0.1152	2.24	(0.85, (0.84,		2.58	(0.83, 8.76)	0.12	(-0.02,0.26)	
Sex Male Female	19 34	2 3	10.5 8.8	19 33	5 6	26.3 18.2									
Age <15 >=15 to <18	26 27	2 3	7.7 11.1	25 27	5 6	20.0 22.2									
Region US Non-US	33 20	2 3	6.1 15.0		5 6	13.9 37.5									
BMI [kg/m2] at baseline < median	27	3	11.1	26	7	26.9	0.1711	2.42	(0.71,1		2.95	(0.66,15.38)	0.16	(-0.06,0.38)	0.8531
>= median	26	2	7.7	26	4	15.4	0.5291	2.00	(0.70, (0.37,1 (0.40,	4.81)	2.18	(0.35,18.20)	0.08	(-0.12,0.28)	
BMI Z-Score <=2 (Underweight,	9	2	22.2	5	2	40.0									
normal or overweight) >2 to <=3 (Class 1 obesity)	17	1	5.9	21	5	23.8									
>3 (Class 2 or 3 obesity)	27	2	7.4	26	4	15.4									
HbAlc [%] at baseline <8.0	29	5	17.2	28	9	32.1	0.2491	1.86	(0.70,		2.27	(0.64, 8.51)	0.15	(-0.08,0.39)	NC.
8.0 to 9.0	12	0	0	12	1	8.3	0.5233	NC.	(0.71, NC. NC.	4.00/	inf	(0.11,inf)	0.08	(-0.19,0.38)	
>9.0	12	0	0	12	1	8.3	0.5233	NC.	NC. NC. NC.		inf	(0.11,inf)	0.08	(-0.19,0.38)	

Table 2.1.1 Responder analysis for HbAlc [%] <6.5% at week 26 overall and by subgroup - mITT (TG1) (NCF)

Subgroups will only be analysed if at least 10 patients are in each subgroup category and at least 10 patients with event in at least one subgroup category (both treatments combined).

A ratio less than one or risk difference less than zero indicates less risk for E pooled.

N: number of patients. n: number of patients with response. Risk ratio exact CI estimated by Chan and Zhang, asymptotic CI by Wald. CIs for odds ratios are exact mid-p estimates. Risk diff. exact CI estimated by Chan and Zhang. * 2*one-sided Suissa-Shuster Z-pooled test. ** Q-test for homogeneity of risk ratios (treatment by subgroup interaction). inf=infinity. NC.=Not calculated. Page

125

Table 2.1.1 Responder analysis for HbAlc [%] <6.5% at week 26 overall and by subgroup - mITT (TG1) (NCF)

											d vs Placebo_			
Subgroup Category	N	_Plac n	ebo %		E pool n	Led	p-value *		(exact 95% CI) (asymp 95% CI)		(95% CI)	Risk diff.	(95% CI)	p-value **
FPG [mg/dl] at baseline														
<126	13	3	23.1		6	31.6								
>=126	39	2	5.1	29	4	13.8								
eGFR (Zappitelli) at baseline														0.7170
<120	24	3	12.5	21	7	33.3	0.1121	2.67	(0.79,16.71) (0.79, 9.02)	3.50	(0.76,18.64)	0.21	(-0.04,0.46)	
120 to <150	23	2	8.7	19	3	15.8	0.6158	1.82	(0.32,17.76) (0.34, 9.77)	1.97	(0.26,17.93)	0.07	(-0.15,0.33)	
>=150	6	0	0	12	1	8.3	0.7821	NC.	NC. NC.	inf	(0.06,inf)	0.08	(-0.37,0.39)	
Backg. Antidiabetic Med. at baseline														
Metformin only	28	4	14.3	26	8	30.8								
Insulin only	2	0	0	3	1	33.3								
Metformin and Insulin	19	1	5.3	22	2	9.1								
None	4	0	0	1	0	0								
Time since diagnosis of T2DM														
<l td="" year<=""><td>18</td><td>1</td><td>5.6</td><td>17</td><td>2</td><td>11.8</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></l>	18	1	5.6	17	2	11.8								
1 year - 3 years	24 11	2	8.3	21	5	23.8								
>3 years	11	2	18.2	14	4	28.6								

Subgroups will only be analysed if at least 10 patients are in each subgroup category and at least 10 patients with event in at least one subgroup category (both treatments combined).

A ratio less than one or risk difference less than zero indicates less risk for E pooled.

N: number of patients. n: number of patients with response. Risk ratio exact CI estimated by Chan and Zhang, asymptotic CI by Wald. CIs for odds ratios are exact mid-p estimates. Risk diff. exact CI estimated by Chan and Zhang. * 2*one-sided Suissa-Shuster Z-pooled test. ** Q-test for homogeneity of risk ratios (treatment by subgroup interaction). inf=infinity. NC.=Not calculated.

Subgroup		Place	aho		E pool	od	p-value	Dick	lovact	95% CI)	Odds	d vs Placebo_	Risk		p-value
Category	N	n	*	N	n n	8 8	*					(95% CI)		(95% CI)	**
Overall	53	13	24.5	52	18	34.6	0.2871	1.41	(0.77, (0.77,		1.63	(0.69, 3.86)	0.10	(-0.08,0.28)	
Sex Male	19	4	21.1	19	7	36.8	0.3201	1.75	(0.60, (0.61,		2.19	(0.50,10.18)	0.16	(-0.14,0.44)	0.6157
Female	34	9	26.5	33	11	33.3	0.6628	1.26	(0.59, (0.60,	3.07)	1.39	(0.48, 4.08)	0.07	(-0.16,0.29)	
Age															0.8519
<15	26	7	26.9	25	9	36.0	0.5562	1.34	(0.54,		1.53	(0.45, 5.22)	0.09	(-0.17,0.35)	
>=15 to <18	27	6	22.2	27	9	33.3	0.5269	1.50	(0.59, (0.62, (0.62,	4.15)	1.75	(0.51, 6.18)	0.11	(-0.14,0.35)	
Region															0.9114
ŬS.	33	6	18.2	36	10	27.8	0.5353	1.53	(0.61, (0.62,		1.73	(0.54, 5.77)	0.10	(-0.11,0.30)	
Non-US	20	7	35.0	16	8	50.0	0.5864	1.43	(0.62, (0.63, (0.66,	3.80)	1.86	(0.47, 7.40)	0.15	(-0.18,0.46)	
BMI [kg/m2] at baseline															0.8629
< median	27	7	25.9	26	10	38.5	0.5423	1.48	(0.65, (0.67,		1.79	(0.54, 5.97)	0.13	(-0.13,0.37)	
>= median	26	6	23.1	26	8	30.8	0.5915	1.33	(0.52, (0.54,	3.63)	1.48	(0.42, 5.36)	0.08	(-0.17,0.32)	

Table 2.1.2 Responder analysis for HbAlc [%] <7% at week 26 overall and by subgroup - mITT (TG1) (NCF)

Subgroups will only be analysed if at least 10 patients are in each subgroup category and at least 10 patients with event in at least one subgroup category (both treatments combined).

A ratio less than one or risk difference less than zero indicates less risk for E pooled.

N: number of patients. n: number of patients with response. Risk ratio exact CI estimated by Chan and Zhang, asymptotic CI by Wald. CIs for odds ratios are exact mid-p estimates. Risk diff. exact CI estimated by Chan and Zhang. * 2*one-sided Suissa-Shuster Z-pooled test. ** Q-test for homogeneity of risk ratios (treatment by subgroup interaction). inf=infinity. NC.=Not calculated.

s1\tbinr6001.sas 200CT2023

Table 2.1.2 Responder analysis for HbAlc [%] <7% at week 26 overall and by subgroup - mITT (TG1) (NCF)

											d vs Placebo			
Subgroup Category	N	_Place n	ebo %	- <u>N</u>	E pool n	.ed %	p-value *		(exact 95% CI) (asymp 95% CI)		(95% CI)	Risk diff.	(95% CI)	p-value **
<pre>BMI Z-Score <=2 (Underweight, normal or overweight)</pre>	9	2	22.2	5	3	60.0	0.2083	2.70	(0.55,24.48)	5.25	(0.41,66.09)	0.38	(-0.18,0.80)	0.2861
>2 to <=3 (Class 1 obesity)	17	6	35.3	21	6	28.6	0.7035	0.81	(0.66,11.13) (0.26, 2.49)	0.73	(0.18, 3.06)	-0.07	(-0.37,0.25)	
>3 (Class 2 or 3 obesity)	27	5	18.5	26	9	34.6	0.2491	1.87	(0.32, 2.06) (0.71, 5.95) (0.72, 4.84)	2.33	(0.65, 8.84)	0.16	(-0.08,0.40)	
HbAlc [%] at baseline <8.0	29	11	37.9	28	15	53.6	0.2930	1.41	(0.78, 2.82) (0.79, 2.52)	1.89	(0.64, 5.54)	0.16	(-0.12,0.41)	0.3837
8.0 to 9.0	12	2	16.7	12	1	8.3	0.6750	0.50	(0.02, 5.08) (0.05, 4.81)	0.45	(0.01, 6.99)	-0.08	(-0.42,0.25)	
>9.0	12	0	0	12	2	16.7	0.2202	NC.	NC. NC.	inf	(0.48,inf)	0.17	(-0.11,0.49)	
<pre>FPG [mg/dl] at baseline <126 >=126</pre>	13 39	7 5	53.8 12.8	19 29	11 6	57.9 20.7	0.9235 0.4207		(0.56, 2.31) (0.57, 2.02) (0.50, 5.33)	1.18 1.77	(0.27, 5.09) (0.46, 6.96)		(-0.31,0.39) (-0.11,0.29)	0.5263
eGFR (Zappitelli) at									(0.55, 4.78)					0.9285
baseline <120	24	8	33.3	21	11	52.4	0.2431	1.57	(0.77, 3.54)	2.20	(0.64, 7.57)	0.19	(-0.11,0.47)	
120 to <150	23	4	17.4	19	5	26.3	0.6169	1.51	(0.78, 3.16) (0.39, 5.51) (0.47, 4.86)	1.70	(0.36, 8.21)	0.09	(-0.17,0.37)	
>=150	6	1	16.7	12	2	16.7	NC.	1.00	(0.10,27.02) (0.11, 8.95)	1.00	(0.06,35.11)	0.00	(-0.48,0.37)	

Subgroups will only be analysed if at least 10 patients are in each subgroup category and at least 10 patients with event in at least one subgroup category (both treatments combined).

A ratio less than one or risk difference less than zero indicates less risk for E pooled.

s1\tbinr6001.sas 200CT2023

N: number of patients. n: number of patients with response. Risk ratio exact CI estimated by Chan and Zhang, asymptotic CI by Wald. CIs for odds ratios are exact mid-p estimates. Risk diff. exact CI estimated by Chan and Zhang. * 2*one-sided Suissa-Shuster Z-pooled test. ** Q-test for homogeneity of risk ratios (treatment by subgroup interaction). inf=infinity. NC.=Not calculated.

Table 2.1.2 Responder analysis for HbAlc [%] <7% at week 26 overall and by subgroup - mITT (TG1) (NCF)

		_									d vs Placebo_			
Subgroup Category	N	_Plac n	ebo %	N	E poo n		p-value *		(exact 95% CI (asymp 95% CI		(95% CI)	Risk diff.	(95% CI)	p-value **
Backg. Antidiabetic Med. at baseline														
Metformin only	28	8	28.6	26	13	50.0								
Insulin only	2	0	0	3	1	33.3								
Metformin and Insulin	19	4	21.1	22	4	18.2								
None	4	1	25.0	1	0	0								
Time since diagnosis of T2DM														0.4067
<1 year	18	6	33.3	17	6	35.3	0.9998	1.06	(0.35, 3.22) (0.42, 2.65)	1.09	(0.26, 4.63)	0.02	(-0.30,0.34)	
1 year – 3 years	24	3	12.5	21	7	33.3	0.1121	2.67	(0.79,16.71) (0.79, 9.02)	3.50	(0.76,18.64)	0.21	(-0.04,0.46)	
>3 years	11	4	36.4	14	5	35.7	1.0000	0.98	(0.28, 3.27) (0.34, 2.81)	0.97	(0.18, 5.54)	-0.01	(-0.39,0.38)	

Subgroups will only be analysed if at least 10 patients are in each subgroup category and at least 10 patients with event in at least one subgroup category (both treatments combined).

Page

129

A ratio less than one or risk difference less than zero indicates less risk for E pooled.

N: number of patients. n: number of patients with response. Risk ratio exact CI estimated by Chan and Zhang, asymptotic CI by Wald. CIs for odds ratios are exact mid-p estimates. Risk diff. exact CI estimated by Chan and Zhang. * 2*one-sided Suissa-Shuster Z-pooled test. ** Q-test for homogeneity of risk ratios (treatment by subgroup interaction). inf=infinity. NC.=Not calculated.

											d vs Placebo_			
Subgroup Category	N	_Plac n	ebo %	N	E pool n	.ed %	p-value *		(exact 95% CI) (asymp 95% CI)		(95% CI)	Risk diff.	(95% CI)	p-valu **
Overall	53	6	11.3	52	5	9.6	0.8575	0.85	(0.25,2.92) (0.28,2.61)	0.83	(0.22,3.05)	-0.02	(-0.15,0.11)	
Sex Male Female	19 34	4 2	21.1 5.9	19 33	1 4	5.3 12.1								
Age <15 >=15 to <18	26 27	3 3	11.5 11.1	25 27	3 2	12.0 7.4								
Region US Non-US	33 20	4 2	12.1 10.0		4 1	11.1 6.3								
BMI [kg/m2] at baseline < median >= median	27 26	2 4	7.4 15.4		3 2	11.5 7.7								
BMI Z-Score <=2 (Underweight, normal or overweight)	9	0	0	5	0	0								
>2 to <=3 (Class 1 obesity) >3 (Class 2 or 3 obesity)	17 27	1 5	5.9 18.5	21 26	3 2	14.3 7.7								
HbAlc [%] at baseline <8.0 8.0 to 9.0 >9.0	29 12 12	2 1 3	6.9 8.3 25.0	28 12 12	1 3 1	3.6 25.0 8.3								
FPG [mg/dl] at baseline <126	13	1	7.7	19	0	0	0.3904	0.00	(0.00,9.81) NC.	0.00	(0.00,6.16)	-0.08	(-0.36,0.11)	NC.
>=126	39	5	12.8	29	5	17.2	0.6594	1.34	NC. (0.39,4.65) (0.43,4.22)	1.42	(0.34,5.79)	0.04	(-0.13,0.24)	

Table 2.1.3 Responder analysis of patients who initiate glycaemic rescue therapy up to 26 weeks, overall and by subgroup - mITT (TG1) (OR)

Subgroups will only be analysed if at least 10 patients are in each subgroup category and at least 10 patients with event in at least one subgroup category (both treatments combined).

A ratio less than one or risk difference less than zero indicates less risk for E pooled.

N: number of patients. n: number of patients with response. Risk ratio exact CI estimated by Chan and Zhang, asymptotic CI by Wald. CIs for odds ratios are exact mid-p estimates. Risk diff. exact CI estimated by Chan and Zhang. * 2*one-sided Suissa-Shuster Z-pooled test. ** Q-test for homogeneity of risk ratios (treatment by subgroup interaction). NC.=Not calculated.

s1\tbinr6001.sas 200CT2023

					_			 			d vs Placebo			
Subgroup Category	N	_Plac n	ebo %	<u>N</u>	E poo n	 چ	p-value *	(exact		Odds ratio	(95% CI)	Risk diff.	(95% CI)	p-value **
			-			-		 (,		(,		(,	
eGFR (Zappitelli) at														
baseline														
<120	24	5	20.8	21	1	4.8								
120 to <150	23	1	4.3	19	1	5.3								
>=150	6	0	0	12		25.0								
Backg. Antidiabetic Med. at baseline														
Metformin only	28	2	7.1	26	2	7.7								
Insulin only	28 2	2 0	0	3	1	33.3								
Metformin and Insulin	19	3	15.8			9.1								
None	4	1	25.0	1	0	0.1								
None	4	T	25.0	T	0	0								
Time since diagnosis of T2DM														
<1 year	18	3	16.7	17	1	5.9								
1 year - 3 years	24	2			2	9.5								
>3 years	11	1	9.1	14	2	14.3								

Table 2.1.3 Responder analysis of patients who initiate glycaemic rescue therapy up to 26 weeks, overall and by subgroup - mITT (TG1) (OR)

Subgroups will only be analysed if at least 10 patients are in each subgroup category and at least 10 patients with event in at least one subgroup category (both treatments combined).

A ratio less than one or risk difference less than zero indicates less risk for E pooled.

s1\tbinr6001.sas 200CT2023

N: number of patients. n: number of patients with response. Risk ratio exact CI estimated by Chan and Zhang, asymptotic CI by Wald. CIs for odds ratios are exact mid-p estimates. Risk diff. exact CI estimated by Chan and Zhang. * 2*one-sided Suissa-Shuster Z-pooled test. ** Q-test for homogeneity of risk ratios (treatment by subgroup interaction). NC.=Not calculated.

1.2.2 Analyses of continuous variables

Subgroup							e_from-				-					
Category				ie at—		—bas	eline_		2.1.1				n vs Plac		0.5.9	CT.
Visit Treatment	Ν	n	Mean	sit— SD		SE	—95∛ Lower	CI <u></u> Upper		SE		CI	p-value	Hedges′ g	—95% Lower	
Overall																
Baseline																
Placebo	53	52		1.23												
E pooled	52	51	7.95	1.25												
Week 4																
Placebo	53	50		1.56			-0.08									
E pooled	52	50	7.39	1.05	-0.57	0.08	-0.73	-0.42	-0.65	0.11	-0.86	-0.43	<0.0001	-1.19	-1.59	-0.80
Week 12																
Placebo	53	52		1.96			-0.03									
E pooled	52	48	7.24	1.50	-0.66	0.18	-1.03	-0.30	-0.99	0.26	-1.50	-0.48	0.0002	-0.77	-1.17	-0.38
Week 26																
Placebo	53	50		2.41			0.23									
E pooled	52	47	7.58	1.69	-0.32	0.23	-0.78	0.13	-1.00	0.32	-1.63	-0.37	0.0022	-0.63	-1.04	-0.23
Sex																
Test for homogeneity (UO) of sub	aroun	categori	og nor	wigit											
Week 4	IIU) OI BUD	group	categori	les per	VIBIC								0.5999			
Week 12													0.7556			
Week 26													0.3678			
Male													0.3070			
Baseline																
Placebo	19	19	8 1 2	1.42												
E pooled	19	19		1.26												
Week 4	19	10	7.52	1.20												
Placebo	19	18	8 24	1.80	0 07	0 13	-0.18	0 32								
E pooled	19	19	7.27	0.90			-0.90		-0.72	0 18	-1 08	-0 37	<0.0001			
Week 12	19	10	/.2/	0.90	0.05	0.13	0.50	0.10	0.72	0.10	1.00	0.57	<0.0001			
Placebo	19	19	8.17	2.25	0.06	0.30	-0.52	0.65								
E pooled	19	18	6.80						-1.10	0.42	-1.93	-0.26	0.0104			
Week 26	10	10	0.00	3.70	1.05	0.50	1.00	0.11	1.10	0.12	1.75	0.20	0.0104			
Placebo	19	18	8.64	2.34	0.57	0.37	-0.16	1.31								
E pooled	19	17							-1.39	0.53	-2.44	-0.33	0.0104			
2 200100		± ·	0.90		0.02	0.00	1.07	0.00	2.00	0.00	2.11	0.00	0.0101			

N: Number of patients in analysis set, n: Number of patients analysed at visit, ^: Interaction p-value. * Model includes Visit by Treatment by subgroup interaction, Age (2 cat.), Baseline HBA1C [%] by Visit interaction as fixed effect(s).

Covariate removed from model if also used as the subgroup. The model for overall analysis includes visit by treatment interaction

instead of visit by treatment by subgroup interaction.

The following covariance structure has been used to fit the mixed model: Unstructured

Note: All covariate effects are set equal to their mean values within subgroup for the calculation of adjusted means.

Hedges'g is based on adjusted means and respective pooled standard deviation and will only be presented in case of a significant treatment comparison.

A subgroup (all of the subgroup categories) will not be analysed (n:=0) if in at least one subgroup category N<10. The linagliptin treatment group was included in analyses but not displayed in this table.

Appendix 1, Table 2.2.1

133

Boehringer Ingelheim BI Trial No.: x1218.ped01

Subgroup							e_from-						_]			
Category Visit					Adj.	-base		CI—	- ام ۲			parison CI——	ı vs Plac		0.5%.0	
Treatment	Ν	n	Mean	sit—— SD		SE		Upper		SE			p-value		' —95% C Lower U	
Sex																
Female Baseline																
Placebo	34	33	0 04	1.13												
	34	33	8.04 7.97													
E pooled Week 4	2.2	32	1.97	1.27												
Placebo	34	32	0 1 2	1.44	0 0 0	0 10	-0.11	0 26								
E pooled	33	31		1.44					-0.60	0 14	_0 87	-0 33	<0.0001			
Week 12	55	JT	7.40	1.15	-0.55	0.10	-0.72	-0.55	-0.00	0.14	-0.07	-0.55	<0.0001			
Placebo	34	33	8 52	1.79	0 48	0 22	0.04	0 93								
E pooled	33	30		1.77				0.01	-0.93	0.32	-1.57	-0.29	0.0045			
Week 26	00	50			0.15	0.20	0.50	0.01	0.90	0.02	2.07	0.25	0.0010			
Placebo	34	32	8.84	2.48	0.74	0.28	0.18	1.29								
E pooled	33	30		1.92					-0.78	0.40	-1.58	0.01	0.0533			
1																
Age																
Test for homogeneity	(H0) of sub	group	categori	es per	visit											
Week 4													0.7240			
Week 12														•		
													0.7124			
Week 26													0.7124			
<15																
<15 Baseline																
<15 Baseline Placebo	26	25		1.40												
<15 Baseline Placebo E pooled	26 25	25 25		1.40 1.26												
<15 Baseline Placebo E pooled Week 4	25	25	7.98	1.26												
<15 Baseline Placebo E pooled Week 4 Placebo	25 26	25 24	7.98 8.22	1.26 1.74			-0.13		0.00	0.15	0.00	0.20	0.3333^			
<15 Baseline Placebo E pooled Week 4 Placebo E pooled	25	25	7.98 8.22	1.26					-0.69	0.15	-0.99	-0.38				
<15 Baseline Placebo E pooled Week 4 Placebo E pooled Week 12	25 26 25	25 24 25	7.98 8.22 7.38	1.26 1.74 1.02	-0.60	0.11	-0.81	-0.39	-0.69	0.15	-0.99	-0.38	0.3333^			
<15 Baseline Placebo E pooled Week 4 Placebo E pooled Week 12 Placebo	25 26 25 26	25 24 25 25	7.98 8.22 7.38 8.55	1.26 1.74 1.02 2.17	-0.60 0.44	0.11	-0.81	-0.39					<0.0001			
<15 Baseline Placebo E pooled Week 4 Placebo E pooled Week 12 Placebo E pooled	25 26 25	25 24 25	7.98 8.22 7.38 8.55	1.26 1.74 1.02	-0.60 0.44	0.11	-0.81	-0.39	-0.69				0.3333^			
<15 Baseline Placebo E pooled Week 4 Placebo E pooled Week 12 Placebo E pooled Week 26	25 26 25 26 25	25 24 25 25 25	7.98 8.22 7.38 8.55 7.33	1.26 1.74 1.02 2.17 1.82	-0.60 0.44 -0.66	0.11 0.26 0.26	-0.81 -0.07 -1.16	-0.39 0.95 -0.15					<0.0001			
<15 Baseline Placebo E pooled Week 4 Placebo E pooled Week 12 Placebo E pooled	25 26 25 26	25 24 25 25	7.98 8.22 7.38 8.55 7.33 9.01	1.26 1.74 1.02 2.17	-0.60 0.44 -0.66 0.90	0.11 0.26 0.26 0.32	-0.81 -0.07 -1.16 0.26	-0.39 0.95 -0.15 1.53		0.36	-1.81	-0.38	<0.0001			

N: Number of patients in analysis set, n: Number of patients analysed at visit, ^: Interaction p-value. * Model includes Visit by Treatment by subgroup interaction, Age (2 cat.), Baseline HBA1C [%] by Visit interaction as fixed effect(s). Covariate removed from model if also used as the subgroup. The model for overall analysis includes visit by treatment interaction instead of visit by treatment by subgroup interaction.

The following covariance structure has been used to fit the mixed model: Unstructured

Note: All covariate effects are set equal to their mean values within subgroup for the calculation of adjusted means.

Hedges'g is based on adjusted means and respective pooled standard deviation and will only be presented in case of a significant treatment comparison.

Subgroup							e from-									
Category						—bas			2.1.1				n vs Plac			OT.
Visit	37			.sit—— SD		an		CI—		0.11		CI		Hedges'		
Treatment	N	n	Mean	SD	lilean	SE	Lower	Upper	mean	SE	LOwer	opper	p-value	g	Lower	upper
Aqe																
>=15 to <18																
Baseline																
Placebo	27	27	8.03	1.08												
E pooled	27	26	7.92	1.26												
Week 4																
Placebo	27	26	8.12	1.41	0.06	0.11	-0.15	0.27								
E pooled	27	25	7.39	1.09	-0.55	0.11	-0.76	-0.34	-0.61	0.15	-0.91	-0.31	<0.0001			
Week 12																
Placebo	27	27	8.25	1.76	0.23	0.25	-0.26	0.72								
E pooled	27	23	7.13	1.10	-0.68	0.26	-1.19	-0.17	-0.91	0.36	-1.62	-0.20	0.0124			
Week 26																
Placebo	27	25	8.53	2.13	0.46	0.31	-0.16	1.09								
T	27	24	7 57	1.47	-0 23	0.32	-0.87	0.41	-0.69	0.45	-1.59	0 20	0.1261			
E pooled	27	24	1.51	±•1/	0.25						2.00	0.20	0.1201			
1	21	24	1.51	1.17	0.25						1.00	0.20	0.1201			
Region											1.05	0.20	0.1201			
1											2105	0.20	0.2736			
Region Test for homogeneity (1											1.05	0.20				
Region Test for homogeneity (1 Week 4											1.05	0.20	0.2736	•		
Region Test for homogeneity (Week 4 Week 12											1.05	0.20	0.2736 0.2594	•		
Region Test for homogeneity (Week 4 Week 12 Week 26											1.05	0.20	0.2736 0.2594	•		
Region Test for homogeneity (Week 4 Week 12 Week 26 US			categori									0.20	0.2736 0.2594	•		
Region Test for homogeneity (Week 4 Week 12 Week 26 US Baseline Placebo	H0) of sub	group	categori 8.08	.es per 1.16								0.20	0.2736 0.2594	•		
Region Test for homogeneity (Week 4 Week 12 Week 26 US Baseline	HO) of sub	group 33	categori 8.08	es per								0.20	0.2736 0.2594	•		
Region Test for homogeneity (Week 4 Week 12 Week 26 US Baseline Placebo E pooled	H0) of sub 33 36	group 33	categori 8.08 7.97	1.16 1.25	visit			0.22				0.20	0.2736 0.2594	•		
Region Test for homogeneity (1 Week 4 Week 12 Week 26 US Baseline Placebo E pooled Week 4 Placebo	HO) of sub	group 33 35	categori 8.08 7.97 8.15	.es per 1.16	visit 0.03	0.10	-0.16		-0.56				0.2736 0.2594	•		
Region Test for homogeneity (Week 4 Week 12 Week 26 US Baseline Placebo E pooled Week 4	H0) of sub 33 36 33	group 33 35 31	categori 8.08 7.97 8.15	1.16 1.25 1.43	visit 0.03	0.10	-0.16		-0.56				0.2736 0.2594 0.2497	•		
Region Test for homogeneity (Week 4 Week 12 Week 26 US Baseline Placebo E pooled Week 4 Placebo E pooled	H0) of sub 33 36 33	group 33 35 31	categori 8.08 7.97 8.15 7.45	1.16 1.25 1.43	visit 0.03 -0.53	0.10 0.09	-0.16	-0.35	-0.56				0.2736 0.2594 0.2497	•		
Region Test for homogeneity (Week 4 Week 12 Week 26 US Baseline Placebo E pooled Week 4 Placebo E pooled Week 12	H0) of sub 33 36 33 36	group 33 35 31 34	8.08 7.97 8.15 7.45 8.38	1.16 1.25 1.43 1.10	visit 0.03 -0.53 0.30	0.10 0.09 0.23	-0.16 -0.72 -0.15	-0.35 0.75	-0.56	0.13	-0.83	-0.30	0.2736 0.2594 0.2497	•		
Region Test for homogeneity (1 Week 4 Week 12 Week 26 US Baseline Placebo E pooled Week 4 Placebo E pooled Week 12 Placebo	H0) of sub 33 36 33 36 33	group 33 35 31 34 33	8.08 7.97 8.15 7.45 8.38	1.16 1.25 1.43 1.10 1.73	visit 0.03 -0.53 0.30	0.10 0.09 0.23	-0.16 -0.72 -0.15	-0.35 0.75		0.13	-0.83	-0.30	0.2736' 0.2594' 0.2497' <0.0001	•		
Region Test for homogeneity (1 Week 4 Week 12 Week 26 US Baseline Placebo E pooled Week 4 Placebo E pooled Week 12 Placebo E pooled	H0) of sub 33 36 33 36 33	group 33 35 31 34 33	8.08 7.97 8.15 7.45 8.38 7.41	1.16 1.25 1.43 1.10 1.73	visit 0.03 -0.53 0.30 -0.49	0.10 0.09 0.23 0.22	-0.16 -0.72 -0.15	-0.35 0.75 -0.05		0.13	-0.83	-0.30	0.2736' 0.2594' 0.2497' <0.0001	•		

N: Number of patients in analysis set, n: Number of patients analysed at visit, ^: Interaction p-value. * Model includes Visit by Treatment by subgroup interaction, Age (2 cat.), Baseline HBA1C [%] by Visit interaction as fixed effect(s). Covariate removed from model if also used as the subgroup. The model for overall analysis includes visit by treatment interaction instead of visit by treatment by subgroup interaction.

The following covariance structure has been used to fit the mixed model: Unstructured

Note: All covariate effects are set equal to their mean values within subgroup for the calculation of adjusted means.

Hedges'g is based on adjusted means and respective pooled standard deviation and will only be presented in case of a significant treatment comparison.

Subgroup						ge_from—				a		51			
Category				ie at—		seline		7.1.1				ı vs Plac		0.5.9	CT.
Visit	N			.sit— SD	- Adj. mean SE	—95% C			SE		CI			95% ⊺	
Treatment	N	n	Mean	SD	mean SE	Lower (pper	lilean	SE	rower	opper	p-value	g	Lower	uppe.
Region															
Non-US															
Baseline															
Placebo	20	19	8.05	1.38											
E pooled	16	16	7.91	1.30											
Week 4															
Placebo	20	19	8.20	1.80	0.15 0.1	3 -0.10	0.40								
E pooled	16	16	7.25	0.94	-0.66 0.1	4 -0.93 -	0.39	-0.81	0.19	-1.18	-0.45	<0.0001			
Week 12															
Placebo	20	19	8.42	2.35	0.38 0.3	0 -0.21	0.97								
E pooled	16	16	6.88	0.80	-1.03 0.3	2 -1.67 -	0.39	-1.41	0.44	-2.28	-0.54	0.0017			
Week 26															
Placebo	20	19		2.26		6 -0.19									
E pooled	16	16	6.91	1.09	-1.00 0.4	0 -1.78 -	0.22	-1.53	0.54	-2.59	-0.47	0.0051			
BMI [kg/m2] at baseline															
Test for homogeneity		group	categori	.es per	visit										
Test for homogeneity Week 4		group	categori	es per	visit							0.1470			
Test for homogeneity Week 4 Week 12		group	categori	es per	visit							0.4864	•		
Test for homogeneity Week 4 Week 12 Week 26		group	categori	es per	visit								•		
Test for homogeneity Week 4 Week 12 Week 26 < median		group	categori	.es per	visit							0.4864	•		
Test for homogeneity Week 4 Week 12 Week 26 < median Baseline	(H0) of sub		5	-	visit							0.4864	•		
Test for homogeneity Week 4 Week 12 Week 26 < median Baseline Placebo	(H0) of sub 27	26	8.25	1.30	visit							0.4864	•		
Test for homogeneity Week 4 Week 12 Week 26 < median Baseline Placebo E pooled	(H0) of sub		8.25	-	visit							0.4864	•		
Test for homogeneity Week 4 Week 12 Week 26 < median Baseline Placebo E pooled Week 4	(H0) of sub 27 26	26 26	8.25 8.11	1.30 1.29								0.4864	•		
Test for homogeneity Week 4 Week 12 Week 26 < median Baseline Placebo E pooled Week 4 Placebo	(H0) of sub 27 26 27	26 26 26	8.25 8.11 8.37	1.30 1.29 1.62	0.11 0.1	1 -0.10			0.15	1.00	0.50	0.4864 0.3109	•		
Test for homogeneity Week 4 Week 22 Week 26 < median Baseline Placebo E pooled Week 4 Placebo E pooled	(H0) of sub 27 26	26 26	8.25 8.11 8.37	1.30 1.29				-0.80	0.15	-1.09	-0.50	0.4864	•		
Test for homogeneity Week 4 Week 12 Week 26 < median Baseline Placebo E pooled Week 4 Placebo E pooled Week 12	(H0) of sub 27 26 27 26	26 26 26 26 26	8.25 8.11 8.37 7.42	1.30 1.29 1.62 0.98	0.11 0.1 -0.69 0.1	1 -0.90 -	0.48	-0.80	0.15	-1.09	-0.50	0.4864 0.3109	•		
Test for homogeneity Week 4 Week 12 Week 26 < median Baseline Placebo E pooled Week 4 Placebo E pooled Week 12 Placebo	(H0) of sub 27 26 27 26 27	26 26 26 26 26 26	8.25 8.11 8.37 7.42 8.48	1.30 1.29 1.62 0.98 2.03	0.11 0.1 -0.69 0.1 0.23 0.2	1 -0.90 - 5 -0.28	0.48					0.4864 0.3109 <0.0001	•		
Test for homogeneity Week 4 Week 12 Week 26 < median Baseline Placebo E pooled Week 4 Placebo E pooled Week 12 Placebo E pooled Week 26	(H0) of sub 27 26 27 26	26 26 26 26 26	8.25 8.11 8.37 7.42 8.48	1.30 1.29 1.62 0.98	0.11 0.1 -0.69 0.1	1 -0.90 - 5 -0.28	0.48					0.4864 0.3109	•		
Test for homogeneity Week 4 Week 12 Week 26 < median Baseline Placebo E pooled Week 4 Placebo E pooled Week 12 Placebo E pooled	(H0) of sub 27 26 27 26 27	26 26 26 26 26 26	8.25 8.11 8.37 7.42 8.48 7.17	1.30 1.29 1.62 0.98 2.03	0.11 0.1 -0.69 0.1 0.23 0.2 -0.94 0.2	1 -0.90 - 5 -0.28	0.48					0.4864 0.3109 <0.0001	•		

N: Number of patients in analysis set, n: Number of patients analysed at visit, ^: Interaction p-value. * Model includes Visit by Treatment by subgroup interaction, Age (2 cat.), Baseline HBA1C [%] by Visit interaction as fixed effect(s). Covariate removed from model if also used as the subgroup. The model for overall analysis includes visit by treatment interaction instead of visit by treatment by subgroup interaction.

The following covariance structure has been used to fit the mixed model: Unstructured

Note: All covariate effects are set equal to their mean values within subgroup for the calculation of adjusted means.

Hedges'g is based on adjusted means and respective pooled standard deviation and will only be presented in case of a significant treatment comparison.

A subgroup (all of the subgroup categories) will not be analysed (n:=0) if in at least one subgroup category N<10. The linagliptin treatment group was included in analyses but not displayed in this table.

s1\tmmrm4b001.sas 200CT2023

Subgroup							e_from				~		51			
Category Visit			—vi	le at— .sit——	Adj.			CI		45	<u> 95</u> %	CI		Hedges'		
Treatment	N	n	Mean	SD	mean	SE	Lower	Upper	mean	SE	Lower	upper	p-value	g	Lower	Uppei
BMI [kg/m2] at baseline																
>= median																
Baseline																
Placebo	26	26	7.89	1.15												
E pooled	26	25		1.22												
Week 4																
Placebo	26	24	7.95	1.50	0.03	0.11	-0.19	0.24								
E pooled	26	24		1.13					-0.48	0.15	-0.79	-0.18	0.0022			
Week 12																
Placebo	26	26	8.32	1.91	0.43	0.25	-0.07	0.94								
E pooled	26	22	7.31	1.98	-0.37	0.27	-0.90	0.15	-0.81	0.37	-1.54	-0.08	0.0305			
Week 26																
Placebo	26	24	8.79	2.75	0.86	0.32	0.23	1.48								
E pooled	26	22		2.03				0.86	-0.65	0.46	-1.55	0.26	0.1590			
BMI Z-Score																
Test for homogeneity (H0)	of sub	aroun	categori	es ner	visit											
Week 4	or bub	group	cutegori	eb per	VIDIC								0.0695	`		
Week 12													0.0917			
Week 26													0.8190			

N: Number of patients in analysis set, n: Number of patients analysed at visit, ^: Interaction p-value.

* Model includes Visit by Treatment by subgroup interaction, Age (2 cat.), Baseline HBAIC [%] by Visit interaction as fixed effect(s). Covariate removed from model if also used as the subgroup. The model for overall analysis includes visit by treatment interaction instead of visit by treatment by subgroup interaction.

The following covariance structure has been used to fit the mixed model: Unstructured

Note: All covariate effects are set equal to their mean values within subgroup for the calculation of adjusted means.

Hedges g is based on adjusted means and respective pooled standard deviation and will only be presented in case of a significant treatment comparison.

A subgroup (all of the subgroup categories) will not be analysed (n:=0) if in at least one subgroup category N<10. The linagliptin treatment group was included in analyses but not displayed in this table.

s1\tmmrm4b001.sas 200CT2023

Subgroup			TTo]				e from- eline—				Gam		n vs Plac	- h - t		
Category Visit				le at— .sit——		—pas		CI—	Adi			CI		Hedges'	95%	CT.
Treatment	Ν	n	Mean	SD	mean	SE	Lower		mean	SE			p-value		Lower	
BMI Z-Score																
<=2 (Underweight, normal																
or overweight)																
Baseline																
Placebo	9	9	8.51	1.47												
E pooled	5	5	7.52	1.74												
Week 4																
Placebo	9	9		1.73	-0.17	0.18	-0.53	0.18								
E pooled	5	5	7.02	1.37	-0.47	0.25	-0.96	0.01	-0.30	0.31	-0.91	0.30	0.3282			
Week 12																
Placebo	9	9		2.12			-1.28									
E pooled	5	5	7.22	1.07	-0.31	0.58	-1.46	0.85	0.13	0.73	-1.31	1.56	0.8628			
Week 26																
Placebo	9	9		2.14			-0.91									
E pooled	5	5	7.20	1.12	-0.32	0.73	-1.77	1.12	-0.48	0.91	-2.28	1.32	0.6009			
>2 to <=3 (Class 1 obesity)																
Baseline																
Placebo	17	16		1.04												
E pooled	21	21	8.09	1.01												
Week 4	10	1.0	0 00	1 40	0.00	0 14	0 01	0 50								
Placebo	17 21	16		1.42			-0.01		0 00	0 1 0	1 22	0 60	.0.0001			
E pooled Week 12	∠⊥	21	1.31	0.77	-0.72	0.12	-0.96	-0.49	-0.98	0.18	-1.33	-0.62	<0.0001			
Placebo	17	16	0 4 5	1.95	0 (1	0 22	-0.02	1 25								
E pooled	21	20		0.90					-1.65	0 13	_2 50	_0 80	0.0002			
Week 26	21	20	7.00	0.90	-1.03	0.20	-1.09	-0.4/	-1.00	0.43	-2.50	-0.00	0.0002			
Placebo	17	16	8 46	2.16	0 62	0 41	-0.18	1 4 3								
E pooled	21	21		1.46					-1.12	0 54	-2 18	-0 05	0.0395			

N: Number of patients in analysis set, n: Number of patients analysed at visit, ^: Interaction p-value.

* Model includes Visit by Treatment by subgroup interaction, Age (2 cat.), Baseline HBA1C [%] by Visit interaction as fixed effect(s). Covariate removed from model if also used as the subgroup. The model for overall analysis includes visit by treatment interaction instead of visit by treatment by subgroup interaction.

The following covariance structure has been used to fit the mixed model: Unstructured

Note: All covariate effects are set equal to their mean values within subgroup for the calculation of adjusted means.

Hedges'g is based on adjusted means and respective pooled standard deviation and will only be presented in case of a significant treatment comparison.

A subgroup (all of the subgroup categories) will not be analysed (n:=0) if in at least one subgroup category N<10. The linagliptin treatment group was included in analyses but not displayed in this table.

Boehringer Ingelheim BI Trial No.: x1218.ped01 Appendix 1, Table 2.2.1

Page

138

Table 2.2.1	HbAlc [%]	change from baseline MMRM	results over time up to w	week 26 overall and by subgroup	- mITT (TG1) (OC-AD)
		-			

Subgroup						Chang	e_from				-					
Category				ie at—									n vs Plac			-
Visit				.sit—		~ -		CI				CI			95% (
Treatment	N	n	Mean	SD	mean	SE	Lower	Upper	mean	SE	Lower	Upper	p-value	g	Lower (Jppe
BMI Z-Score																
>3 (Class 2 or 3 obesity)																
Baseline																
Placebo	27	27	8.06	1.26												
E pooled	26	25	7.92	1.36												
Week 4																
Placebo	27	25	8.16	1.65	0.04	0.11	-0.17	0.25								
E pooled	26	24	7.48	1.20	-0.46	0.11	-0.68	-0.24	-0.51	0.15	-0.81	-0.20	0.0013			
Week 12																
Placebo	27	27		1.98			-0.08									
E pooled	26	23	7.45	1.95	-0.41	0.26	-0.94	0.11	-0.82	0.36	-1.54	-0.11	0.0247			
Week 26																
Placebo	27	25		2.70			0.26									
E pooled	26	21	7.66	2.03	-0.18	0.34	-0.86	0.49	-1.07	0.47	-2.00	-0.15	0.0234			
HbA1c [%] at baseline																
	of gub	aroun	rategori	eg ner	wigit											
Test for homogeneity (H0) of	of sub	group (categori	les per	visit								<0 0001			
Test for homogeneity (H0) o Week 4	of sub	group (categori	es per	visit								<0.0001			
Test for homogeneity (H0) o Week 4 Week 12	of sub	group (categori	es per	visit								0.0004			
Test for homogeneity (H0) o Week 4 Week 12 Week 26	of sub	group (categori	es per	visit											
Test for homogeneity (H0) o Week 4 Week 12	of sub	group (categori	es per	visit								0.0004			
Test for homogeneity (H0) o Week 4 Week 12 Week 26 <8.0 Baseline		-	5	-	visit								0.0004			
Test for homogeneity (H0) o Week 4 Week 12 Week 26 <8.0 Baseline Placebo	29 28	group (28 28	7.15	0.48	visit								0.0004			
Test for homogeneity (H0) o Week 4 Week 12 Week 26 <8.0 Baseline	29	28	7.15	-	visit								0.0004			
Test for homogeneity (H0) of Week 4 Week 12 Week 26 <8.0 Baseline Placebo E pooled	29 28	28 28 28	7.15 7.01	0.48 0.51		0.10	-0.30	0.09					0.0004			
Test for homogeneity (H0) of Week 4 Week 12 Week 26 <8.0 Baseline Placebo E pooled Week 4 Placebo	29	28	7.15 7.01 7.02	0.48	-0.11				-0.17	0.14	-0.44	0.10	0.0004			
Test for homogeneity (H0) of Week 4 Week 12 Week 26 <8.0 Baseline Placebo E pooled Week 4	29 28 29	28 28 26	7.15 7.01 7.02	0.48 0.51 0.66	-0.11				-0.17	0.14	-0.44	0.10	0.0004 0.0080			
Test for homogeneity (H0) of Week 4 Week 12 Week 26 <8.0 Baseline Placebo E pooled Week 4 Placebo E pooled	29 28 29	28 28 26	7.15 7.01 7.02 6.73	0.48 0.51 0.66	-0.11 -0.28	0.10		-0.08	-0.17	0.14	-0.44	0.10	0.0004 0.0080			
Test for homogeneity (H0) of Week 4 Week 12 Week 26 <8.0 Baseline Placebo E pooled Week 4 Placebo E pooled Week 12	29 28 29 28	28 28 26 27	7.15 7.01 7.02 6.73 7.26	0.48 0.51 0.66 0.71	-0.11 -0.28 0.11	0.10	-0.47	-0.08	-0.17				0.0004 0.0080			
Test for homogeneity (H0) of Week 4 Week 12 Week 26 <8.0 Baseline Placebo E pooled Week 4 Placebo E pooled Week 12 Placebo	29 28 29 28 29	28 28 26 27 28	7.15 7.01 7.02 6.73 7.26	0.48 0.51 0.66 0.71 1.08	-0.11 -0.28 0.11	0.10	-0.47	-0.08					0.0004 0.0080 0.2162			
Test for homogeneity (H0) of Week 4 Week 12 Week 26 <8.0 Baseline Placebo E pooled Week 4 Placebo E pooled Week 12 Placebo E pooled	29 28 29 28 29	28 28 26 27 28	7.15 7.01 7.02 6.73 7.26 6.96	0.48 0.51 0.66 0.71 1.08	-0.11 -0.28 0.11 -0.02	0.10 0.23 0.24	-0.47	-0.08 0.57 0.44					0.0004 0.0080 0.2162			

N: Number of patients in analysis set, n: Number of patients analysed at visit, ^: Interaction p-value. * Model includes Visit by Treatment by subgroup interaction, Age (2 cat.), Baseline HBA1C [%] by Visit interaction as fixed effect(s). Covariate removed from model if also used as the subgroup. The model for overall analysis includes visit by treatment interaction instead of visit by treatment by subgroup interaction.

The following covariance structure has been used to fit the mixed model: Unstructured

Note: All covariate effects are set equal to their mean values within subgroup for the calculation of adjusted means.

Hedges'g is based on adjusted means and respective pooled standard deviation and will only be presented in case of a significant treatment comparison.

Subgroup			_				e from						_			
Category						—bas							n vs Plac			~ -
Visit Treatment	Ν	n	Mean	.sit SD		SE		CI <u> </u> Upper				CI <u> </u> Upper	p-value	Hedges′ g	95% Lower	
HbAlc [%] at baseline 8.0 to 9.0 Baseline																
Placebo	12	12	8.36	0.29												
E pooled	12	12	8.38	0.32												
Week 4																
Placebo	12	12	8.53	0.48	0.18	0.14	-0.11	0.46								
E pooled	12	12		0.42					-1.01	0.20	-1.41	-0.60	<0.0001	-2.01	-2.82	-1.20
Week 12				0.12	0.00	0.11		0.01	1.01	0.20		0.00		2.01	2.02	
Placebo	12	12	8 62	1.28	0 26	0 36	-0.45	0 97								
E pooled	12	11		0.61					-1.49	0 51	-2 49	-0 48	0.0040	-1 22	-2.04	-0 40
Week 26	12		1.05	0.01	1.25	0.50	1.91	0.51	1.15	0.51	2.17	0.10	0.0010	1.22	2.01	0.10
Placebo	12	11	8 80	1.61	0 47	0 46	-0.44	1 39								
E pooled	12	12		1.41					-1.02	0 65	-2 30	0 26	0.1169			
>9.0	12	12	7.05	1.11	0.55	0.45	1.11	0.55	1.02	0.05	2.50	0.20	0.1105			
Baseline																
Placebo	12	12	9 92	0.67												
E pooled	12	11		0.54												
Week 4	12	11	2.00	0.54												
Placebo	12	12	10.28	1 23	0 36	0 14	0.08	0 65								
E pooled	12	11		0.61					-1.40	0 21	_1 82		<0.0001	-2 79	-3.62	_1 07
Week 12	12	± ±	0.05	0.01	1.04	0.15	1.34	0.74	1.40	0.21	1.02	0.55	<0.0001	2.15	5.02	1.97
Placebo	12	12	10.83	1 97	0 91	0 36	0.20	1 61								
E pooled	12	10		1.09				-0.89	-2.55	0 52	_3 58	_1 52	<0.0001	-2 08	-2.93	_1 2/
Week 26	12	10	0.17	1.09	-1.04	0.30	-2.40	-0.09	-2.55	0.52	-3.30	-1.52	20.0001	-2.00	-2.95	-1.24
Placebo	12	12	11.14	1 0 2	1 22	0 45	0.33	2 1 2								
E pooled	12	9		1.33					-2.82	0 60	1 10	1 47	<0.0001	1 0 0	-2.69	0 05
-	12	9	0.57	1.33	-1.59	0.51	-2.39	-0.39	-2.02	0.00	-4.10	-1.4/	<0.0001	-1.02	-2.09	-0.95
FPG [mg/dl] at baseline Test for homogeneity (H	0) of sub	group	categori	es per	visit											
Week 4		-	-	-									0.0529			
Week 12													0.0359^			
Week 26													0.0433			

N: Number of patients in analysis set, n: Number of patients analysed at visit, ^: Interaction p-value. * Model includes Visit by Treatment by subgroup interaction, Age (2 cat.), Baseline HBA1C [%] by Visit interaction as fixed effect(s). Covariate removed from model if also used as the subgroup. The model for overall analysis includes visit by treatment interaction instead of visit by treatment by subgroup interaction.

The following covariance structure has been used to fit the mixed model: Unstructured

Note: All covariate effects are set equal to their mean values within subgroup for the calculation of adjusted means.

Hedges'g is based on adjusted means and respective pooled standard deviation and will only be presented in case of a significant treatment comparison.

Subgroup							e from									
Category						—bas							n vs Plac			~-
Visit Treatment	N	n	Mean	.sit—— SD		SE		CI— Upper		SE		CI— Upper	p-value	Hedges′ a	—95% Lower	
				-		-							1	5		
FPG [mg/dl] at baseline <126																
Baseline																
Placebo	13	12		1.33												
E pooled Week 4	19	19		0.70												
Placebo	13	11		1.78			-0.33									
E pooled Week 12	19	18	6.76	0.80	-0.34	0.13	-0.59	-0.09	-0.32	0.20	-0.73	0.08	0.1135			
Placebo	13	12		2.40			-0.76									
E pooled Week 26	19	18	6.91	2.11	-0.17	0.30	-0.76	0.42	-0.14	0.47	-1.08	0.80	0.7674			
Placebo	13	11	7.74	2.77	0.26	0.47	-0.66	1.18								
E pooled >=126	19	18	7.34	2.27	0.24	0.37	-0.49	0.96	-0.02	0.59	-1.20	1.15	0.9699			
Baseline																
Placebo	39	39	8 28	1.15												
E pooled	29	29		1.15												
Week 4																
Placebo	39	38		1.47			-0.07									
E pooled Week 12	29	29	7.79	0.99	-0.70	0.10	-0.90	-0.50	-0.80	0.13	-1.06	-0.54	<0.0001			
Placebo	39	39		1.74			0.04									
E pooled Week 26	29	27	7.50	0.98	-0.91	0.24	-1.38	-0.43	-1.35	0.32	-1.98	-0.73	<0.0001	-1.07	-1.56	-0.57
Placebo	39	38	9.12	2.25	0.85	0.25	0.35	1.35								
E pooled	29	27	7.79	1.22	-0.63	0.30	-1.22	-0.03	-1.48	0.39	-2.26	-0.70	0.0003	-0.94	-1.44	-0.45
eGFR (Zappitelli) at basel Test for homogeneity (HG		aroun	categori	eg ner	vicit											
Week 4	, or sub	9-0up	Callgori	CD PCI	* 1010								0.2813			
Week 12													0.7244			
Week 26													0.7244			

N: Number of patients in analysis set, n: Number of patients analysed at visit, ^: Interaction p-value. * Model includes Visit by Treatment by subgroup interaction, Age (2 cat.), Baseline HBA1C [%] by Visit interaction as fixed effect(s). Covariate removed from model if also used as the subgroup. The model for overall analysis includes visit by treatment interaction instead of visit by treatment by subgroup interaction.

The following covariance structure has been used to fit the mixed model: Unstructured

Note: All covariate effects are set equal to their mean values within subgroup for the calculation of adjusted means.

Hedges'g is based on adjusted means and respective pooled standard deviation and will only be presented in case of a significant treatment comparison.

Subgroup							e_from									
Category				ie at—		—bas	eline_		7.24				n vs Plac		0.5.9	CT.
Visit Treatment	Ν	~	VI Mean	SD	Adj.	SE		CI— Upper		0 F		CI		Hedges'		
	IN	n	Meall	50	mean	SE	LOWET	opper	mean	SE	LOWET	opper	p-value	g	LOWET	Upper
eGFR (Zappitelli) at baseline	:															
<120																
Baseline																
Placebo	24	23	7.71	1.32												
E pooled	21	21	7.44	1.13												
Week 4																
Placebo	24	22	7.75	1.73	0.01	0.12	-0.22	0.24								
E pooled	21	20	6.99	0.92	-0.45	0.12	-0.69	-0.21	-0.46	0.17	-0.79	-0.12	0.0074			
Week 12																
Placebo	24	23	7.89	2.10	0.18	0.27	-0.36	0.73								
E pooled	21	20	6.77	0.88	-0.65	0.29	-1.22	-0.08	-0.83	0.40	-1.62	-0.04	0.0385			
Week 26																
Placebo	24	21	8.03	2.23	0.32	0.34	-0.36	0.99								
E pooled	21	19	6.94	1.30	-0.42	0.36	-1.13	0.29	-0.73	0.50	-1.71	0.25	0.1414			
120 to <150																
Baseline																
Placebo	23	23		0.99												
E pooled	19	19	7.99	0.98												
Week 4																
Placebo	23	22		1.31	0.11	0.12	-0.12	0.33								
E pooled	19	19	7.39	0.87	-0.59	0.13	-0.84	-0.35	-0.70	0.17	-1.04	-0.36	<0.0001			
Week 12																
Placebo	23	23		1.87	0.47	0.27	-0.07	1.01								
E pooled	19	19	7.55	2.02	-0.44	0.30	-1.04	0.15	-0.91	0.41	-1.72	-0.11	0.0264			
Week 26																
Placebo	23	23	9.30	2.58	1.04	0.33	0.38	1.70								
E pooled	19	19	7.97	2.05	-0.03	0.37	-0.75	0.70	-1.07	0.50	-2.05	-0.09	0.0329			

N: Number of patients in analysis set, n: Number of patients analysed at visit, ^: Interaction p-value.

* Model includes Visit by Treatment by subgroup interaction, Age (2 cat.), Baseline HBA1C [%] by Visit interaction as fixed effect(s). Covariate removed from model if also used as the subgroup. The model for overall analysis includes visit by treatment interaction

instead of visit by treatment by subgroup interaction.

The following covariance structure has been used to fit the mixed model: Unstructured

Note: All covariate effects are set equal to their mean values within subgroup for the calculation of adjusted means.

Hedges'g is based on adjusted means and respective pooled standard deviation and will only be presented in case of a significant treatment comparison.

A subgroup (all of the subgroup categories) will not be analysed (n:=0) if in at least one subgroup category N<10. The linagliptin treatment group was included in analyses but not displayed in this table.

s1\tmmrm4b001.sas 200CT2023

	ue at— isit— SD	Adj.		95%	CI Upper	Adj. mean	SE	<u> 95</u> %	CI	ı vs Plac p-value	Hedges'	—95% CI— Lower Uppe
			SE				SE			p-value		
										-		
6 8.68	1.53											
LI 8.85	1.46											
6 8.88	1.58	0.20	0.22	-0.25	0.64							
LI 8.09	1.24	-0.76	0.17	-1.08	-0.43	-0.95	0.28	-1.50	-0.40	0.0008		
6 9.08	1.42	0.38	0.54	-0.68	1.44							
9 7.61	1.16	-1.08	0.41	-1.89	-0.26	-1.46	0.68	-2.79	-0.12	0.0329		
6 9.35	1.92	0.64	0.65	-0.65	1.94							
9 8.12	1.19	-0.70	0.52	-1.73	0.32	-1.35	0.83	-2.99	0.30	0.1084		
	11 8.85 6 8.88 11 8.09 6 9.08 9 7.61 6 9.35	11 8.85 1.46 6 8.88 1.58 11 8.09 1.24 6 9.08 1.42 9 7.61 1.16 6 9.35 1.92 9 8.12 1.19	11 8.85 1.46 6 8.88 1.58 0.20 11 8.09 1.24 -0.76 6 9.08 1.42 0.38 9 7.61 1.16 -1.08 6 9.35 1.92 0.64 9 8.12 1.19 -0.70	11 8.85 1.46 6 8.88 1.58 0.20 0.22 11 8.09 1.24 -0.76 0.17 6 9.08 1.42 0.38 0.54 9 7.61 1.16 -1.08 0.41 6 9.35 1.92 0.64 0.65 9 8.12 1.19 -0.70 0.52	11 8.85 1.46 6 8.88 1.58 0.20 0.22 -0.25 11 8.09 1.24 -0.76 0.17 -1.08 6 9.08 1.42 0.38 0.54 -0.68 9 7.61 1.16 -1.08 0.41 -1.89 6 9.35 1.92 0.64 0.65 -0.65	11 8.85 1.46 6 8.88 1.58 0.20 0.22 -0.25 0.64 11 8.09 1.24 -0.76 0.17 -1.08 -0.43 6 9.08 1.42 0.38 0.54 -0.68 1.44 9 7.61 1.16 -1.08 0.41 -1.89 -0.26 6 9.35 1.92 0.64 0.65 -0.65 1.94	11 8.85 1.46 6 8.88 1.58 0.20 0.22 -0.25 0.64 11 8.09 1.24 -0.76 0.17 -1.08 -0.43 -0.95 6 9.08 1.42 0.38 0.54 -0.68 1.44 9 7.61 1.16 -1.08 0.41 -1.89 -0.26 -1.46 6 9.35 1.92 0.64 0.65 1.94	11 8.85 1.46 6 8.88 1.58 0.20 0.22 -0.25 0.64 11 8.09 1.24 -0.76 0.17 -1.08 -0.43 -0.95 0.28 6 9.08 1.42 0.38 0.54 -0.68 1.44 9 7.61 1.16 -1.08 0.41 -1.89 -0.26 -1.46 0.68 6 9.35 1.92 0.64 0.65 -0.65 1.94	11 8.85 1.46 6 8.88 1.58 0.20 0.22 -0.25 0.64 11 8.09 1.24 -0.76 0.17 -1.08 -0.43 -0.95 0.28 -1.50 6 9.08 1.42 0.38 0.54 -0.68 1.44 9 7.61 1.16 -1.08 0.41 -1.89 -0.26 -1.46 0.68 -2.79 6 9.35 1.92 0.64 0.65 1.94	11 8.85 1.46 6 8.88 1.58 0.20 0.22 -0.25 0.64 11 8.09 1.24 -0.76 0.17 -1.08 -0.95 0.28 -1.50 -0.40 6 9.08 1.42 0.38 0.54 -0.68 1.44 -1.46 0.68 -2.79 -0.12 6 9.35 1.92 0.64 0.65 -0.65 1.94	11 8.85 1.46 6 8.88 1.58 0.20 0.22 -0.25 0.64 11 8.09 1.24 -0.76 0.17 -1.08 -0.95 0.28 -1.50 -0.40 0.0008 6 9.08 1.42 0.38 0.54 -0.68 1.44 0.68 -2.79 -0.12 0.0329 6 9.35 1.92 0.64 0.65 -0.65 1.94	11 8.85 1.46 6 8.88 1.58 0.20 0.22 -0.25 0.64 11 8.09 1.24 -0.76 0.17 -1.08 -0.95 0.28 -1.50 -0.40 0.0008 6 9.08 1.42 0.38 0.54 -0.68 1.44 -1.08 0.41 -1.89 -0.26 -1.46 0.68 -2.79 -0.12 0.0329 6 9.35 1.92 0.64 0.65 -0.65 1.94

N: Number of patients in analysis set, n: Number of patients analysed at visit, ^: Interaction p-value.

* Model includes Visit by Treatment by subgroup interaction, Age (2 cat.), Baseline HBA1C [%] by Visit interaction as fixed effect(s). Covariate removed from model if also used as the subgroup. The model for overall analysis includes visit by treatment interaction instead of visit by treatment by subgroup interaction.

The following covariance structure has been used to fit the mixed model: Unstructured

Note: All covariate effects are set equal to their mean values within subgroup for the calculation of adjusted means.

Hedges'g is based on adjusted means and respective pooled standard deviation and will only be presented in case of a significant treatment comparison.

A subgroup (all of the subgroup categories) will not be analysed (n:=0) if in at least one subgroup category N<10. The linagliptin treatment group was included in analyses but not displayed in this table.

Table 2.2.1 HbA1c [%]	change from baseline M	RM results over time up to week 26	5 overall and by subgroup - mITT	(TG1) (OC-AD)
-----------------------	------------------------	------------------------------------	----------------------------------	---------------

Subgroup						-Chang	ge_from-				_		- 1			
Category				ue at—		—bas	seline_	CT.	7 J.J.			parison	vs Plac		0.5.9	CT.
Visit				isit—		0D	<u> 95</u> %			0.11	<u> 95</u> %			Hedges'		
Treatment	N	n	Mean	SD	mean	SE	Lower	Upper	mean	SE	Lower	Upper p	-value	g	Lower	Upper
Backg. Antidiabetic Med. at																
baseline																
Metformin only Baseline																
Placebo	28	0														
E pooled	26	0														
Week 4																
Placebo	28	0														
E pooled	26	0														
Week 12																
Placebo	28	0														
E pooled	26	0														
Week 26																
Placebo	28	0														
E pooled	26	0														
Insulin only																
Baseline																
Placebo	2 3	0														
E pooled	3	0														
Week 4																
Placebo	2	0														
E pooled Week 12	3	0														
Placebo	2	0														
E pooled Week 26	3	0														
Placebo	2	0														
E pooled	2 3	0														

N: Number of patients in analysis set, n: Number of patients analysed at visit, ^: Interaction p-value.

* Model includes Visit by Treatment by subgroup interaction, Age (2 cat.), Baseline HBA1C [%] by Visit interaction as fixed effect(s). Covariate removed from model if also used as the subgroup. The model for overall analysis includes visit by treatment interaction instead of visit by treatment by subgroup interaction.

The following covariance structure has been used to fit the mixed model: Unstructured

Note: All covariate effects are set equal to their mean values within subgroup for the calculation of adjusted means.

Hedges'g is based on adjusted means and respective pooled standard deviation and will only be presented in case of a significant treatment comparison.

A subgroup (all of the subgroup categories) will not be analysed (n:=0) if in at least one subgroup category N<10. The linagliptin treatment group was included in analyses but not displayed in this table.

Subgroup						-Chang	ge_from-				_		- 7			
Category				ue at —		—ba	seline_		- 11				n vs Plac		0.5.0	a
Visit				isit—		~ -	95%	C1—	Adj.			CI	-	Hedges′		
Treatment	N	n	Mean	SD	mean	SE	Lower	Upper	mean	SE	Lower	Upper	p-value	g	Lower	Upper
Backg. Antidiabetic Med. at																
baseline																
Metformin and Insulin Baseline																
Placebo	19	0														
E pooled	22	0														
Week 4																
Placebo	19	0														
E pooled	22	0														
Week 12		-														
Placebo	19	0														
E pooled	22	0														
Week 26		-														
Placebo	19	0														
E pooled	22	Õ														
None		Ũ														
Baseline																
Placebo	4	0														
E pooled	1	õ														
Week 4	-	0														
Placebo	4	0														
E pooled	1	Ő														
Week 12	-	0														
Placebo	4	0														
E pooled	1	0														
Week 26	_	-														
Placebo	4	0														
E pooled	1	0														

N: Number of patients in analysis set, n: Number of patients analysed at visit, ^: Interaction p-value.

* Model includes Visit by Treatment by subgroup interaction, Age (2 cat.), Baseline HBA1C [%] by Visit interaction as fixed effect(s). Covariate removed from model if also used as the subgroup. The model for overall analysis includes visit by treatment interaction instead of visit by treatment by subgroup interaction.

The following covariance structure has been used to fit the mixed model: Unstructured

Note: All covariate effects are set equal to their mean values within subgroup for the calculation of adjusted means.

Hedges'g is based on adjusted means and respective pooled standard deviation and will only be presented in case of a significant treatment comparison.

A subgroup (all of the subgroup categories) will not be analysed (n:=0) if in at least one subgroup category N<10. The linagliptin treatment group was included in analyses but not displayed in this table.

Subgroup							ge_from-									
Category						—bas			- 11				n vs Plac		0.5.0	
Visit				.sit—		a-		CI				CI		Hedges'		
Treatment	N	n	Mean	SD	mean	SE	Lower	Upper	mean	SE	Lower	Upper	p-value	g	Lower	Upper
Time since diagnosis of	T2DM															
Test for homogeneity (Week 4		group	categori	.es per	visit								0.3933^			
Week 12													0.3210			
Week 26													0.3793			
<1 year													0.0750			
Baseline																
Placebo	18	18	8.28	1.56												
E pooled	17	17	7.61	1.22												
Week 4																
Placebo	18	17	8.44	1.89	0.05	0.13	-0.22	0.31								
E pooled	17	17	7.22	1.08	-0.40	0.13	-0.66	-0.13	-0.44	0.1	9 -0.82	-0.07	0.0194			
Week 12																
Placebo	18	18		2.38	0.39	0.30	-0.21	0.99								
E pooled	17	17	7.51	2.11	-0.12	0.31	0.73	0.50	-0.51	0.44	4 -1.37	0.35	0.2468			
Week 26																
Placebo	18	18		2.30			3 -0.15									
E pooled	17	15	7.62	2.14	0.03	0.40	0 -0.76	0.82	-0.57	0.5	5 -1.66	0.52	0.3032			
1 year – 3 years																
Baseline																
Placebo	24	24		1.13												
Epooled	21	21	8.06	1.20												
Week 4																
Placebo	24	23		1.50			2 -0.08		0 70	0 1		0.46	0 0001			
E pooled Week 12	21	20	1.46	1.02	-0.64	0.12	0.88	-0.40	-0.79	0.1	/ -1.13	-0.46	<0.0001			
Placebo	24	24	0 4 2	1.84	0.40	0.00	5 -0.06	0 07								
E pooled	24 21	24 20		$1.84 \\ 1.12$			-0.06 -1.48		1 20	0 21	0 0 1 /	0 60	0.0005			
Week 26	21	20	/.15	1.12	-0.92	0.20	o −⊥.40	-0.30	-1.30	0.30	5 -2.14	-0.62	0.0005			
Placebo	24	23	9 15	2.66	1 10	0 33	0.46	1 75								
E pooled	24 21	20		1.46					-1.45	0 4	8 _2 40	_0 50	0.0030			
P POOTEG	21	20	1.15	1.40	-0.55	0.55	, -1.04	0.54	.T.40	0.40	5 -2.40	-0.50	0.0030			

N: Number of patients in analysis set, n: Number of patients analysed at visit, ^: Interaction p-value. * Model includes Visit by Treatment by subgroup interaction, Age (2 cat.), Baseline HBA1C [%] by Visit interaction as fixed effect(s). Covariate removed from model if also used as the subgroup. The model for overall analysis includes visit by treatment interaction instead of visit by treatment by subgroup interaction.

The following covariance structure has been used to fit the mixed model: Unstructured

Note: All covariate effects are set equal to their mean values within subgroup for the calculation of adjusted means.

Hedges'g is based on adjusted means and respective pooled standard deviation and will only be presented in case of a significant treatment comparison.

A subgroup (all of the subgroup categories) will not be analysed (n:=0) if in at least one subgroup category N<10. The linagliptin treatment group was included in analyses but not displayed in this table.

Subgroup			TT-]				e from-				G			- 1	
Category Visit Treatment	N	n	—vi	e at— sit— SD				CI— Upper	Adj. mean	SE	<u> 95</u> %	CI	ı vs Plac p-value	Hedges'	CI
Time since diamonia of TODM															
Time since diagnosis of T2DM															
>3 years Baseline															
Placebo	11	10	7.88	0 77											
	14	13	8.22												
E pooled Week 4	14	13	8.22	1.3/											
	1 1	1.0	7 01	1 00	0.00	0 17	-0.41	0 00							
Placebo	11	10		1.08					0 60		1 00				
Epooled	14	13	7.49	1.11	-0.70	0.16	-1.00	-0.39	-0.63	0.23	-1.09	-0.17	0.0077		
Week 12															
Placebo	11	10		1.34			-0.89								
E pooled	14	11	6.97	0.96	-0.97	0.37	-1.69	-0.24	-0.87	0.55	-1.95	0.21	0.1117		
Week 26															
Placebo	11	9	7.53	1.63	-0.23	0.52	-1.25	0.79							
E pooled	14	12	7.29	1.50	-0.75	0.46	-1.65	0.15	-0.52	0.69	-1.88	0.84	0.4517		

N: Number of patients in analysis set, n: Number of patients analysed at visit, ^: Interaction p-value. * Model includes Visit by Treatment by subgroup interaction, Age (2 cat.), Baseline HBA1C [%] by Visit interaction as fixed effect(s).

Covariate removed from model if also used as the subgroup. The model for overall analysis includes visit by treatment interaction


instead of visit by treatment by subgroup interaction.

The following covariance structure has been used to fit the mixed model: Unstructured

Note: All covariate effects are set equal to their mean values within subgroup for the calculation of adjusted means.

Hedges g is based on adjusted means and respective pooled standard deviation and will only be presented in case of a significant treatment comparison.

A subgroup (all of the subgroup categories) will not be analysed (n:=0) if in at least one subgroup category N<10. The linagliptin treatment group was included in analyses but not displayed in this table.



Appendix 1, Figure 2.2.2

Boehringer Ingelheim BI Trial No.: x1218.ped01

s1\fcot1001.sas 200CT2023

Subgroup						Cha		rom Baseli Week 261	
Category Treatment	N	n	Baselin Mean SD		261	Mean	SD	95 Lower	CI Upper
1100000000				moun	55			201102	02202
Overall									
Placebo	53	52	158.62 53	.80 174.34	79.49	15.73	67.73	-3.13	34.58
E pooled	52	48	154.43 57	.78 136.91	55.03	-17.52	67.45	-37.11	2.06
Sex									
Male									
Placebo	19	19	155.28 56				55.44	-7.38	46.06
E pooled Female	19	18	151.47 50	.07 130.86	35.37	-20.61	32.02	-36.54	-4.69
Placebo	34	33	160.54 53	.11 174.19	00 03	13 65	74.64	-12.82	40.11
E pooled	33	30	156.20 62			-15.67		-46.37	15.04
Aqe									
<15									
Placebo	26	25	152.37 67			17.73	82.88	-16.48	51.94
E pooled	25	23	151.30 50	.08 123.95	28.25	-27.34	44.37	-46.53	-8.15
>=15 to <18						10.05		6 50	
Placebo E pooled	27 27	27 25	164.40 38 157.31 64				51.48 83.22	-6.50 -42.84	34.23 25.87
E poored	27	25	157.31 64	.9/ 140.02	69.93	-0.40	03.22	-42.04	25.07
Region US									
Placebo	33	32	151.47 41	.89 178.91	73.05	27.44	63.05	4.71	50.17
E pooled	36	34	147.50 53	.20 140.28	62.14	-7.22	66.79	-30.53	16.08
Non-US									
Placebo	20	20	170.06 68				72.29	-36.85	30.82
E pooled	16	14	171.25 66	.73 128.73	32.33	-42.53	64.59	-79.82	-5.23

N: Number of patients in analysis set, n: Number of patients analysed at visit, 'Absolute (unadjusted) values, 'Test for treatment difference at the visit, ^: Interaction p-value.

³ Model includes Baseline FPG [mg/dL] as linear covariate(s) and Age (2 cat.), Treatment, subgroup, Treatment by subgroup interaction as fixed effect(s). Covariate removed from model if also used as the subgroup. The overall model does not include subgroup or treatment by subgroup interaction.

Note: All covariate effects are set equal to their mean values within subgroup for the calculation of adjusted means.

Hedges'g is based on adjusted means and respective pooled standard deviation and will only be presented in case of a significant treatment comparison.

A subgroup (all of the subgroup categories) will not be analysed (n:=0) if in at least one subgroup category N<10. The linagliptin treatment group was included in analyses but not displayed in this table.

Subgroup		_at Wee					.son vs P				Hedges'	g
Category Treatment	Adjusted mean	l SE	95% Lower	CI Upper	Adjuste mean	d SE	Lower	_95% CI Upper	p-value ²	Hedges g		CI Upper
Overall												
Placebo E pooled	15.70 -19.48	8.21 8.56		31.93 -2.57	-35.18	11.86	-58.61	-11.74	0.0035	-0.59	-0.99	-0.20
Sex Male									0.6938^			
Placebo E pooled Female	21.33 -19.97	13.72 14.10	-5.79 -47.84	48.45 7.91	-41.30	19.69	-80.23	-2.37	0.0377			
Placebo E pooled	12.21 -19.28	10.41 10.94	-8.36 -40.90		-31.50	15.09	-61.33	-1.66	0.0387			
Age <15									0.4022^			
Placebo E pooled >=15 to <18	15.83 -29.75	11.84 12.35		39.23 -5.34	-45.57	17.10	-79.37	-11.77	0.0086			
Placebo E pooled	15.57 -10.07	11.40 11.84		38.10 13.33	-25.65	16.44	-58.14	6.85	0.1210			
Region US									0.9030^			
Placebo E pooled Non-US	25.30 -10.93	10.46 10.16	4.63 -31.02		-36.24	14.57	-65.03	-7.44	0.0140			
Placebo E pooled	-0.08 -39.40		-26.26 -70.65		-39.32	20.62	-80.08	1.44	0.0585			

N: Number of patients in analysis set, n: Number of patients analysed at visit, 'Absolute (unadjusted) values, 'Test for treatment

information of particular interaction p-value.
 Model includes Baseline FPG [mg/dL] as linear covariate(s) and Age (2 cat.), Treatment, subgroup, Treatment by subgroup interaction
 as fixed effect(s). Covariate removed from model if also used as the subgroup. The overall model does not include subgroup or treatment by subgroup interaction.

Note: All covariate effects are set equal to their mean values within subgroup for the calculation of adjusted means.

Hedges'g is based on adjusted means and respective pooled standard deviation and will only be presented in case of a significant treatment comparison.

A subgroup (all of the subgroup categories) will not be analysed (n:=0) if in at least one subgroup category N<10. The linagliptin treatment group was included in analyses but not displayed in this table.

ubgroup							Cha		rom Baseli Week 261	.ne
Category			Basel		Week				95%	-
Treatment	Ν	n	Mean	SD	Mean	SD	Mean	SD	Lower	Upper
MI [kq/m2] at baseline										
< median										
Placebo	27	26	165.78		175.61			70.37	-18.60	38.25
E pooled	26	26	163.41	56.29	127.94	31.14	-35.47	52.88	-56.83	-14.11
>= median										
Placebo	26	26	151.46		173.08			65.83	-4.97	48.21
E pooled	26	22	143.82	59.00	147.51	73.53	3.69	77.34	-30.60	37.99
MI Z-Score <=2 (Underweight, normal or overweight)										
Placebo	9	9	162.84	53.87	178.50	67.89	15.66	67.06	-35.89	67.20
E pooled	5	5	164.38	43.18	147.01	22.50	-17.37	33.89	-59.45	24.70
>2 to <=3 (Class 1 obesity)										
Placebo	17	16	161.85		176.26			66.26	-20.90	49.71
E pooled	21	21	167.36	61.89	137.83	68.07	-29.54	93.36	-72.03	12.96
>3 (Class 2 or 3 obesity)	0.7	0.7	155 00	F1 20	1 1 1 00	80.10	16 50	F1 00	11 66	44 50
Placebo E pooled	27 26	27 22	155.29 139.82		171.82 133.73			71.28 37.15	-11.66 -22.56	44.73 10.39
E pooled	20	22	139.02	55.20	133./3	4/.20	-0.09	37.15	-22.50	10.39
bA1c [%] at baseline <8.0										
Placebo	29	29	136.69	34.15	149.08	67.38	12.38	65.31	-12.46	37.23
E pooled	28	26	122.47	38.82	131.97		9.50	68.37	-18.12	37.11
8.0 to 9.0										
Placebo	12	11	167.60		194.55			55.48	-10.33	64.22
E pooled	12	12	170.21	46.59	130.53	29.84	-39.69	27.09	-56.90	-22.48
>9.0			· · · · / -							
Placebo	12	12	203.37		216.89			86.33	-41.34	68.37
E pooled	12	10	218.56	52.31	157.40	55.22	-61.16	/0.68	-111.72	-10.60

N: Number of patients in analysis set, n: Number of patients analysed at visit, 'Absolute (unadjusted) values, 'Test for treatment difference at the visit, ': Interaction p-value. ' Model includes Baseline FPG [mg/dL] as linear covariate(s) and Age (2 cat.), Treatment, subgroup, Treatment by subgroup interaction

as fixed effect(s). Covariate removed from model if also used as the subgroup. The overall model does not include subgroup or

treatment by subgroup interaction.

Note: All covariate effects are set equal to their mean values within subgroup for the calculation of adjusted means.

Hedges'g is based on adjusted means and respective pooled standard deviation and will only be presented in case of a significant treatment comparison.

A subgroup (all of the subgroup categories) will not be analysed (n:=0) if in at least one subgroup category N<10. The linagliptin treatment group was included in analyses but not displayed in this table.

Subgroup		_at Wee					.son vs P				Hedges'	
Category Treatment	Adjusted mean	SE	95%	CI Upper	Adjusted mean	d SE	Lower	_95% CI	p-value ²		95%	CI Upper
	lilean	55	HOWET	opper	lilean	55	HOWET	opper	p-varue	у	помет	opper
BMI [kg/m2] at baseline < median									0.2819^			
Placebo			-12.81									
E pooled	-36.50	11.61	-59.44	-13.56	-46.70	16.45	-79.22	-14.19	0.0052			
>= median	01 00											
Placebo	21.23 0.28			44.24	20.00	17 10	F4 02	12 02	0 0047			
E pooled	0.28	12.63	-24.70	25.25	-20.96	17.19	-54.93	13.02	0.2247			
BMI Z-Score <=2 (Underweight, normal									0.8765			
or overweight)												
Placebo			-25.74				100 65					
E pooled	-20.72	26.86	-73.83	32.38	-34.40	33.51	-100.65	31.86	0.3065			
>2 to <=3 (Class 1 obesity) Placebo	10 00	14 04	-17.32	11 77								
E pooled					-42.13	10 07	01 /1	2 05	0.0357			
>3 (Class 2 or 3 obesity)	-29.90	13.07	-55.75	-4.00	-42.15	19.07	-01.41	-2.00	0.0357			
Placebo	18.53	11.51	-4.23	41.28								
E pooled	-10.01				-28.53	17.32	-62.77	5.70	0.1017			
-												
HbAlc [%] at baseline <8.0									0.0680^			
Placebo	16.16		-5.45									
E pooled	5.84	11.54	-16.98	28.66	-10.32	15.93	-41.82	21.18	0.5181			
8.0 to 9.0												
Placebo	22.62		-12.49		65 04	04 51	110 51	16 50	0 0000			
E pooled >9.0	-42.42	10.97	-/5.9/	-8.8/	-65.04	24.51	-113.51	-10.58	0.0089			
Placebo	9.54	17 00	-24.08	43 15								
E pooled	-57.46				-67.00	25.20	-116.82	-17.17	0.0088			
<u>r</u>												

N: Number of patients in analysis set, n: Number of patients analysed at visit, 'Absolute (unadjusted) values, 'Test for treatment difference at the visit, ': Interaction p-value. ' Model includes Baseline FPG [mg/dL] as linear covariate(s) and Age (2 cat.), Treatment, subgroup, Treatment by subgroup interaction

as fixed effect(s). Covariate removed from model if also used as the subgroup. The overall model does not include subgroup or

treatment by subgroup interaction.

Note: All covariate effects are set equal to their mean values within subgroup for the calculation of adjusted means.

Hedges'g is based on adjusted means and respective pooled standard deviation and will only be presented in case of a significant treatment comparison.

A subgroup (all of the subgroup categories) will not be analysed (n:=0) if in at least one subgroup category N<10. The linagliptin treatment group was included in analyses but not displayed in this table.

Boehringer Ingelheim BI Trial No.: x1218.ped01

Subgroup Category Treatment	N	n	Baseline ¹ Mean SD	Week 261 Mean SD			com Baseli Neek 261 95% Lower	
FPG [mg/dl] at baseline <126								
Placebo	13	13	99.04 18.5	1 111.52 27.66	12.48	28.65	-4.84	29.79
E pooled	19	19	102.38 18.3		21.20		-14.13	56.52
>=126								
Placebo	39	39	178.48 46.4		16.81		-8.08	41.69
E pooled	29	29	188.53 48.4	2 145.64 40.59	-42.89	50.00	-61.91	-23.87
eGFR (Zappitelli) at baseline <120								
Placebo	24	24	141.55 53.7	5 139.60 50.04	-1.95	43.03	-20.12	16.22
E pooled	21	20	126.27 33.3	4 138.30 72.76	12.04	75.37	-23.24	47.31
120 to <150								
Placebo	23	22	168.59 37.8		29.34		-8.12	66.80
E pooled >=150	19	19	161.67 65.3	8 121.67 22.23	-39.99	62.03	-69.89	-10.10
Placebo	6	6	190.32 84.6	9 226.84 87.64	36.52	73.90	-41.04	114.08
E pooled	12	9	201.72 52.2		-35.76		-57.76	-13.76

N: Number of patients in analysis set, n: Number of patients analysed at visit, 'Absolute (unadjusted) values, 'Test for treatment

 Multiple of particles in analysis set, in fraction p-value.
 Model includes Baseline FPG [mg/dL] as linear covariate(s) and Age (2 cat.), Treatment, subgroup, Treatment by subgroup interaction as fixed effect(s). Covariate removed from model if also used as the subgroup. The overall model does not include subgroup or treatment by subgroup interaction.

Note: All covariate effects are set equal to their mean values within subgroup for the calculation of adjusted means.

Hedges g is based on adjusted means and respective pooled standard deviation and will only be presented in case of a significant treatment comparison.

A subgroup (all of the subgroup categories) will not be analysed (n:=0) if in at least one subgroup category N<10. The linagliptin treatment group was included in analyses but not displayed in this table.

Page
154

Subgroup Category	Chan	_at Wee	n Baseli: k 26³ 95%		Adjuste		son vs P	lacebo³ 95% CI		Hedges'	' ledges	g
Treatment	mean	SE	Lower		mean	SE	Lower		p-value ²	g		Upper
FPG [mg/dl] at baseline <126									0.0137^			
Placebo E pooled >=126	12.68 21.19	17.43 14.30	-21.77 -7.07		8.52	22.55	-36.05	53.08	0.7062			
Placebo E pooled	16.75 -42.88	10.00 11.57		36.52 -20.00	-59.63	15.30	-89.87	-29.38	0.0001	-0.96	-1.44	-0.47
eGFR (Zappitelli) at baseline <120									0.0044^			
Placebo E pooled 120 to <150	-1.18 5.10	11.65 12.82	-24.21 -20.26	21.86 30.45	6.27	17.34	-28.01	40.55	0.7180			
Placebo E pooled >=150	33.46 -39.06	12.19 13.10		57.56 -13.16	-72.52	17.90	-107.90	-37.14	<0.0001	-1.27	-1.89	-0.65
Placebo E pooled	32.03 -36.26	23.38 19.07	-14.20 -73.96		-68.29	30.25	-128.10	-8.48	0.0255	-1.19	-2.24	-0.15

N: Number of patients in analysis set, n: Number of patients analysed at visit, 'Absolute (unadjusted) values, 'Test for treatment

 Multiple of particles in analysis set, in fraction p-value.
 Model includes Baseline FPG [mg/dL] as linear covariate(s) and Age (2 cat.), Treatment, subgroup, Treatment by subgroup interaction as fixed effect(s). Covariate removed from model if also used as the subgroup. The overall model does not include subgroup or treatment by subgroup interaction.

Note: All covariate effects are set equal to their mean values within subgroup for the calculation of adjusted means.

Hedges g is based on adjusted means and respective pooled standard deviation and will only be presented in case of a significant treatment comparison.

A subgroup (all of the subgroup categories) will not be analysed (n:=0) if in at least one subgroup category N<10. The linagliptin treatment group was included in analyses but not displayed in this table.

Table 2.2.3	FPG [mg/dL]	change from baseline	e ANCOVA results at w	week 26 overall and by	subgroup - mITT (TG1)	(OC-AD-BOCF)
-------------	-------------	----------------------	-----------------------	------------------------	-----------------------	--------------

ubgroup						from Baseline t Week 261
Category			Baseline ¹	Week 261		95% CI
Treatment	Ν	n	Mean SD —	Mean SD	Mean SD	Lower Upper
ackg. Antidiabetic Med. at						
aseline						
Metformin only						
Placebo	28	0				
E pooled	26	0				
Insulin only						
Placebo	2	0				
E pooled	3	0				
Metformin and Insulin						
Placebo	19	0				
E pooled	22	0				
None						
Placebo	4	0				
E pooled	1	0				
ime since diagnosis of T2DM						
<1 year						
Placebo	18	17	164.15 67.27		-0.11 67.8	
E pooled	17	15	141.01 47.93	131.86 26.61	-9.15 46.1	12 -34.69 16.38
1 year – 3 years						
Placebo	24	24	166.76 48.55	194.69 86.64	27.93 68.8	
E pooled	21	20	159.95 64.47	141.80 76.47	-18.15 93.4	46 -61.89 25.60
>3 years						
Placebo	11	11	132.30 33.60	145.86 84.08	13.56 65.8	
E pooled	14	13	161.42 59.05	135.21 41.27	-26.21 36.5	54 -48.29 -4.13

N: Number of patients in analysis set, n: Number of patients analysed at visit, 'Absolute (unadjusted) values, 'Test for treatment difference at the visit, ': Interaction p-value. ³ Model includes Baseline FPG [mg/dL] as linear covariate(s) and Age (2 cat.), Treatment, subgroup, Treatment by subgroup interaction

as fixed effect(s). Covariate removed from model if also used as the subgroup. The overall model does not include subgroup or treatment by subgroup interaction.

Note: All covariate effects are set equal to their mean values within subgroup for the calculation of adjusted means. Hedges g is based on adjusted means and respective pooled standard deviation and will only be presented in case of a significant treatment comparison.

A subgroup (all of the subgroup categories) will not be analysed (n:=0) if in at least one subgroup category N<10. The linagliptin treatment group was included in analyses but not displayed in this table.

Subgroup Category Treatment	Char Adjustec mean	at Wee	n Baselin ek 263 95% Lower	CI	Adjuste mean		son vs P Lower	95% CI		Hedges' g	edges' 95% Lower	CI
Backg. Antidiabetic Med. at baseline Metformin only Placebo E pooled Insulin only Placebo E pooled Metformin and Insulin Placebo E pooled None Placebo E pooled E pooled												
Time since diagnosis of T2DM <1 year									0.5779^			
Pĺacebo E pooled 1 year – 3 years	6.43 -13.42	14.74 15.58	-22.71 -44.23		-19.86	21.09	-61.56	21.85	0.3482			
Placebo E pooled >3 years	29.32 -18.86	12.35 13.27	4.90 -45.10	53.74 7.38	-48.18	18.24	-84.25	-12.11	0.0092			
Placebo E pooled	0.54 -27.41	18.07 17.00			-27.95	24.94	-77.26	21.36	0.2644			

N: Number of patients in analysis set, n: Number of patients analysed at visit, 'Absolute (unadjusted) values, 'Test for treatment difference at the visit, ': Interaction p-value. ³ Model includes Baseline FPG [mg/dL] as linear covariate(s) and Age (2 cat.), Treatment, subgroup, Treatment by subgroup interaction

³ Model includes Baseline FPG [mg/dL] as linear covariate(s) and Age (2 cat.), Treatment, subgroup, Treatment by subgroup interaction as fixed effect(s). Covariate removed from model if also used as the subgroup. The overall model does not include subgroup or treatment by subgroup interaction.

Note: All covariate effects are set equal to their mean values within subgroup for the calculation of adjusted means.

Hedges'g is based on adjusted means and respective pooled standard deviation and will only be presented in case of a significant treatment comparison.

A subgroup (all of the subgroup categories) will not be analysed (n:=0) if in at least one subgroup category N<10. The linagliptin treatment group was included in analyses but not displayed in this table.

Subgroup					ange from-				~		- 7			
Category Visit			—Value at— ——visit——			CI—	7-1-1			arison d CI——	vs Plac		0.5%	at
Treatment	Ν	n	Mean SD		E Lower			SE			p-value	Hedges′ g	Lower	
Overall														
Baseline														
Placebo	53	52	98.87 29.62											
E pooled	52	52	98.66 24.35											
Week 4														
Placebo	53	50	97.99 29.50	0.05 0	.27 -0.48	0.58								
E pooled	52	49	96.41 23.84	-0.84 0	.27 -1.37	-0.30	-0.88	0.3	8 -1.64	-0.13	0.0216	-0.47	-0.86	-0.07
Week 12														
Placebo	53	52	99.14 29.52	0.27 0.	.46 -0.65	1.18								
E pooled	52	48	96.78 24.42	-1.14 0	.47 -2.06	-0.21	-1.40	0.6	6 -2.70	0 -0.10	0.0351	-0.43	-0.82	-0.03
Week 26														
Placebo	53	50	98.54 28.85		.69 -1.40									
E pooled	52	48	97.38 24.99	-0.79 0	.70 -2.17	0.59	-0.75	0.9	8 -2.68	3 1.19	0.4476			
- P00100														
1														
Sex														
Sex Test for homogeneity (H0) of sub	group	categories per	visit							0 5100^			
Sex Test for homogeneity (Week 4	H0) of sub	group	categories per	visit							0.7108			
Sex Test for homogeneity (Week 4 Week 12	H0) of sub	group	categories per	visit							0.7212			
Sex Test for homogeneity (Week 4 Week 12 Week 26	H0) of sub	group	categories per	visit										
Sex Test for homogeneity (Week 4 Week 12 Week 26 Male	H0) of sub	group	categories per	visit							0.7212			
Sex Test for homogeneity (Week 4 Week 12 Week 26 Male Baseline			5 - 1	visit							0.7212			
Sex Test for homogeneity (Week 4 Week 12 Week 26 Male Baseline Placebo	19	19	105.04 22.12	visit							0.7212			
Sex Test for homogeneity (Week 4 Week 12 Week 26 Male Baseline Placebo E pooled			5 - 1	visit							0.7212			
Sex Test for homogeneity (Week 4 Week 12 Week 26 Male Baseline Placebo E pooled Week 4	19 19	19 19 19	105.04 22.12 111.18 24.15		45 -0 52	1 25					0.7212			
Sex Test for homogeneity (Week 4 Week 12 Week 26 Male Baseline Placebo E pooled Week 4 Placebo	19 19 19	19 19 18	105.04 22.12 111.18 24.15 104.46 22.36	0.37 0	.45 -0.52 45 -1.61		-1 07	0.6	4 -2.34	6.19	0.7212^ 0.6671^			
Sex Test for homogeneity (Week 4 Week 12 Week 26 Male Baseline Placebo E pooled Week 4 Placebo E pooled	19 19	19 19 19	105.04 22.12 111.18 24.15	0.37 0	.45 -0.52 .45 -1.61		-1.07	0.6	4 -2.34	Ł 0.19	0.7212			
Sex Test for homogeneity (Week 4 Week 12 Week 26 Male Baseline Placebo E pooled Week 4 Placebo	19 19 19	19 19 18	105.04 22.12 111.18 24.15 104.46 22.36	0.37 0 -0.71 0		0.19	-1.07	0.6	4 -2.34	4 0.19	0.7212^ 0.6671^			
Sex Test for homogeneity (Week 4 Week 12 Week 26 Male Baseline Placebo E pooled Week 4 Placebo E pooled Week 12 Placebo	19 19 19 19	19 19 18 17	105.04 22.12 111.18 24.15 104.46 22.36 108.58 24.14	0.37 0 -0.71 0 1.08 0	.45 -1.61	0.19					0.7212^ 0.6671^			
Sex Test for homogeneity (Week 4 Week 12 Week 26 Male Baseline Placebo E pooled Week 4 Placebo E pooled Week 12	19 19 19 19	19 19 18 17 19	105.04 22.12 111.18 24.15 104.46 22.36 108.58 24.14 106.15 21.99	0.37 0 -0.71 0 1.08 0	.45 -1.61 .77 -0.44	0.19					0.7212^0.6671^			
Sex Test for homogeneity (Week 4 Week 12 Week 26 Male Baseline Placebo E pooled Week 4 Placebo E pooled Week 12 Placebo E pooled	19 19 19 19	19 19 18 17 19	105.04 22.12 111.18 24.15 104.46 22.36 108.58 24.14 106.15 21.99	0.37 0 -0.71 0 1.08 0 -0.63 0	.45 -1.61 .77 -0.44	0.19 2.59 0.90					0.7212^0.6671^			

N: Number of patients in analysis set, n: Number of patients analysed at visit, ^: Interaction p-value.

* Model includes Visit by Treatment by subgroup interaction, Age (2 cat.), Baseline body weight [kg] by Visit interaction as fixed effect(s). Covariate removed from model if also used as the subgroup. The model for overall analysis includes visit by treatment interaction instead of visit by treatment by subgroup interaction.

The following covariance structure has been used to fit the mixed model: Unstructured

Note: All covariate effects are set equal to their mean values within subgroup for the calculation of adjusted means.

Hedges'g is based on adjusted means and respective pooled standard deviation and will only be presented in case of a significant treatment comparison.

A subgroup (all of the subgroup categories) will not be analysed (n:=0) if in at least one subgroup category N<10. The linagliptin treatment group was included in analyses but not displayed in this table.

Subgroup					ge_from	-	-		
Category			—Value at—		seline			parison vs Placebo*-	
Visit Treatment	N	n	——visit—— Mean SD		—95% CI— Lower Upper			k CI—— Hedg C Upper p-value q	jes' —95% CI— Lower Upper
		11	Mean 3D			illeall	SE LOWEI	opper p-varue g	Tower obber
Sex									
Female									
Baseline									
Placebo	34	33	95.32 32.98						
E pooled	33	33	91.44 21.69						
Week 4									
Placebo	34	32	94.35 32.61	-0.14 0.3	4 -0.81 0.53				
E pooled	33	32	89.94 21.33	-0.92 0.3	4 -1.59 -0.24	-0.78	0.48 -1.72	2 0.17 0.1080	
Week 12									
Placebo	34	33	95.11 32.73	-0.21 0.5	8 -1.36 0.94				
E pooled	33	30	89.65 21.72	-1.43 0.5	9 -2.60 -0.26	-1.22	0.83 -2.86	5 0.42 0.1437	
Week 26									
Placebo	34	32	94.00 31.31		5 -2.74 0.60				
E pooled	33	31	89.95 21.87	-1.50 0.8	6 -3.19 0.20	-0.43	1.21 -2.81	L 1.95 0.7222	
Age									
Test for homogeneity (H0) of sub	group	categories per	visit					
Week 4								0.5749	
Week 12								0.6988	
Week 26									
								0.6186^	
<15								0.6186^	
<15 Baseline								0.6186^	
<15 Baseline Placebo	26	25	87.73 26.84					0.6186^	
<15 Baseline Placebo E pooled	26 25	25 25	87.73 26.84 99.91 24.40					0.6186^	
<15 Baseline Placebo E pooled Week 4	25	25	99.91 24.40					0.6186^	
<15 Baseline Placebo E pooled Week 4 Placebo	25 26	25 24	99.91 24.40 86.59 26.35		9 -0.57 0.97				
<15 Baseline Placebo E pooled Week 4 Placebo E pooled	25	25	99.91 24.40		9 -0.57 0.97 9 -1.23 0.33		0.56 -1.75	0.6186^	
<15 Baseline Placebo E pooled Week 4 Placebo E pooled Week 12	25 26 25	25 24 23	99.91 24.40 86.59 26.35 97.03 23.63	-0.45 0.3	9 -1.23 0.33	-0.65	0.56 -1.75		
<15 Baseline Placebo E pooled Week 4 Placebo E pooled Week 12 Placebo	25 26 25 26	25 24 23 25	99.91 24.40 86.59 26.35 97.03 23.63 88.05 27.46	-0.45 0.3	9 -1.23 0.33 7 -1.06 1.60	-0.65		5 0.45 0.2442	
<15 Baseline Placebo E pooled Week 4 Placebo E pooled Week 12 Placebo E pooled	25 26 25	25 24 23	99.91 24.40 86.59 26.35 97.03 23.63	-0.45 0.3	9 -1.23 0.33	-0.65			
<15 Baseline Placebo E pooled Week 4 Placebo E pooled Week 12 Placebo E pooled Week 26	25 26 25 26 25	25 24 23 25 25	99.91 24.40 86.59 26.35 97.03 23.63 88.05 27.46 99.02 25.19	-0.45 0.3 0.27 0.6 -0.84 0.6	9 -1.23 0.33 7 -1.06 1.60 7 -2.17 0.49	-0.65		5 0.45 0.2442	
<15 Baseline Placebo E pooled Week 4 Placebo E pooled Week 12 Placebo E pooled	25 26 25 26	25 24 23 25	99.91 24.40 86.59 26.35 97.03 23.63 88.05 27.46	-0.45 0.3 0.27 0.6 -0.84 0.6 0.36 1.0	9 -1.23 0.33 7 -1.06 1.60	-0.65	0.96 -3.00	5 0.45 0.2442	

N: Number of patients in analysis set, n: Number of patients analysed at visit, ^: Interaction p-value.

* Model includes Visit by Treatment by subgroup interaction, Age (2 cat.), Baseline body weight [kg] by Visit interaction as fixed effect(s). Covariate removed from model if also used as the subgroup. The model for overall analysis includes visit by treatment interaction instead of visit by treatment by subgroup interaction.

The following covariance structure has been used to fit the mixed model: Unstructured

Note: All covariate effects are set equal to their mean values within subgroup for the calculation of adjusted means.

Hedges'g is based on adjusted means and respective pooled standard deviation and will only be presented in case of a significant treatment comparison.

Subgroup					ge_from			
Category			—Value at—		seline	2.14		rison vs Placebo*
Visit	37		visit		—95% CI—		—95%	
Treatment	N	n	Mean SD	mean SE	Lower Upper	lilean	SE Lower	Upper p-value g Lower U
Aqe								
>=15 to <18								
Baseline								
Placebo	27	27	109.18 28.75					
E pooled	27	27	97.49 24.72					
Week 4								
Placebo	27	26	108.52 28.75	-0.11 0.3	7 -0.85 0.64			
E pooled	27	26	95.85 24.48	-1.19 0.3	8 -1.94 -0.45	-1.09	0.53 -2.15	-0.03 0.0435
Week 12								
Placebo	27	27	109.41 28.03	0.26 0.6	5 -1.02 1.54			
E pooled	27	23	94.35 23.87	-1.38 0.6	7 -2.70 -0.05	-1.63	0.94 -3.48	0.21 0.0828
Week 26								
Placebo	27	25	108.81 27.05	-0.45 0.9	7 -2.37 1.46			
E pooled	27	25	94.40 23.74	-1.66 0.9	9 -3.61 0.30	-1.21	1.39 -3.95	1.54 0.3870
Region								
Test for homogeneity	(H0) of sub	group	categories per	visit				
Week 4								0.2849
Week 12								0.3487
Week 26								0.3702
US								
Baseline								
Placebo	33	33	108.05 24.97					
E pooled	36	36	101.96 23.51					
Week 4								
Placebo	33	31	106.99 24.60		4 -0.77 0.56			
		33	99.50 23.68	-0.71 0.3	3 -1.35 -0.07	-0.60	0.47 -1.53	0.32 0.2010
E pooled	36	22						
Week 12								
Week 12 Placebo	33	33	108.11 24.43		8 -1.05 1.24			
Week 12 Placebo E pooled			108.11 24.43 100.44 24.35		8 -1.05 1.24 7 -2.00 0.25	-0.97	0.82 -2.58	0.64 0.2358
Week ¹ 2 Placebo E pooled Week 26	33 36	33 32	100.44 24.35	-0.88 0.5	7 -2.00 0.25	-0.97	0.82 -2.58	0.64 0.2358
Week 12 Placebo E pooled	33	33		-0.88 0.5				0.64 0.2358

N: Number of patients in analysis set, n: Number of patients analysed at visit, ^: Interaction p-value.

* Model includes Visit by Treatment by subgroup interaction, Age (2 cat.), Baseline body weight [kg] by Visit interaction as fixed effect(s). Covariate removed from model if also used as the subgroup. The model for overall analysis includes visit by treatment interaction instead of visit by treatment by subgroup interaction.

The following covariance structure has been used to fit the mixed model: Unstructured

Note: All covariate effects are set equal to their mean values within subgroup for the calculation of adjusted means.

Hedges'g is based on adjusted means and respective pooled standard deviation and will only be presented in case of a significant treatment comparison.

Subgroup			TT- Jacoba		hange from-				G			
Category Visit			—Value at— ——visit——		-baseline— —95%		⊼d-i			CI—	vs Placebo*	—95% CI—
Treatment	Ν	n	Mean SD		SE Lower			SE			p-value g	Lower Uppe
Region												
Non-US Baseline												
Placebo	20	19	82.92 30.91									
	20 16	19										
E pooled	16	10	91.22 25.34									
Week 4 Placebo	0.0	1.0	00 00 01 51	0 21 0		1 10						
	20	19	83.30 31.51		0.44 -0.56		1 10	0 65	0 74	0 1 0	0.0054	
E pooled Week 12	16	16	90.03 23.64	-1.16 (0.48 -2.10	-0.22	-1.46	0.65	-2.74	-0.18	0.0254	
Placebo	20	19	83.56 31.70	0.56 0	0.77 -0.96	2.08						
E pooled	16	16	89.46 23.61		0.83 -3.38		-2.29	1.14	-4.53	-0.05	0.0456	
Week 26												
Placebo	20	19	84.25 30.20	1.15 1	1.14 -1.11	3.40						
E pooled	16	16	90.34 24.25		1.24 -3.26		-1.96	1.69	-5.30	1.37	0.2462	
-												
BMI [kg/m2] at baseline												
- BMI [kg/m2] at baseline Test for homogeneity (H0)) of sub	group	categories per	visit								
BMI [kg/m2] at baseline Test for homogeneity (HC Week 4)) of sub	group	categories per	visit							0.4824	
- BMI [kg/m2] at baseline Test for homogeneity (H0 Week 4 Week 12)) of sub	group	categories per	visit							0.5533	
- BMI [kg/m2] at baseline Test for homogeneity (HC Week 4 Week 12 Week 26)) of sub	group	categories per	visit								
- BMI [kg/m2] at baseline Test for homogeneity (HC Week 4 Week 12 Week 26 < median)) of sub	group	categories per	visit							0.5533	
BMI [kg/m2] at baseline Test for homogeneity (H0 Week 4 Week 12 Week 26 < median Baseline		5 1	5 1	visit							0.5533	
BMI [kg/m2] at baseline Test for homogeneity (H0 Week 4 Week 12 Week 26 < median Baseline Placebo	27	26	78.20 16.43	visit							0.5533	
BMI [kg/m2] at baseline Test for homogeneity (H0 Week 4 Week 12 Week 26 < median Baseline Placebo E pooled		5 1	5 1	visit							0.5533	
BMI [kg/m2] at baseline Test for homogeneity (HG Week 4 Week 12 Week 26 < median Baseline Placebo E pooled Week 4	27 26	26 26	78.20 16.43 83.95 16.02								0.5533	
BMI [kg/m2] at baseline Test for homogeneity (HG Week 4 Week 12 Week 26 < median Baseline Placebo E pooled Week 4 Placebo	27 26 27	26 26 26	78.20 16.43 83.95 16.02 78.38 16.53	0.11 0	0.38 -0.64						0.5533^ 0.7710^	
BMI [kg/m2] at baseline Test for homogeneity (HG Week 4 Week 12 Week 26 < median Baseline Placebo E pooled Week 4 Placebo E pooled	27 26	26 26	78.20 16.43 83.95 16.02	0.11 0	0.38 -0.64 0.38 -1.26		-0.62	0.54	-1.68	0.44	0.5533	
BMI [kg/m2] at baseline Test for homogeneity (HG Week 4 Week 12 Week 26 < median Baseline Placebo E pooled Week 4 Placebo E pooled Week 12	27 26 27 26	26 26 26 26 26	78.20 16.43 83.95 16.02 78.38 16.53 83.42 15.90	0.11 (-0.51 (0.38 -1.26	0.24	-0.62	0.54	-1.68	0.44	0.5533^ 0.7710^	
BMI [kg/m2] at baseline Test for homogeneity (HG Week 4 Week 12 Week 26 < median Baseline Placebo E pooled Week 4 Placebo E pooled Week 12 Placebo	27 26 27 26 27	26 26 26 26 26 26	78.20 16.43 83.95 16.02 78.38 16.53 83.42 15.90 78.27 16.64	0.11 (-0.51 (-0.04 (0.38 -1.26 0.66 -1.35	0.24					0.5533^ 0.7710^	
BMI [kg/m2] at baseline Test for homogeneity (HG Week 4 Week 12 Week 26 < median Baseline Placebo E pooled Week 4 Placebo E pooled Week 12	27 26 27 26	26 26 26 26 26	78.20 16.43 83.95 16.02 78.38 16.53 83.42 15.90	0.11 (-0.51 (-0.04 (0.38 -1.26	0.24					0.5533 [°] 0.7710 [°]	
BMI [kg/m2] at baseline Test for homogeneity (HG Week 4 Week 12 Week 26 < median Baseline Placebo E pooled Week 4 Placebo E pooled Week 12 Placebo E pooled Week 12 Placebo E pooled	27 26 27 26 27	26 26 26 26 26 26	78.20 16.43 83.95 16.02 78.38 16.53 83.42 15.90 78.27 16.64	0.11 (-0.51 (-0.04 (-1.02 (0.38 -1.26 0.66 -1.35	0.24 1.27 0.28					0.5533^ 0.7710^	

N: Number of patients in analysis set, n: Number of patients analysed at visit, ^: Interaction p-value.

* Model includes Visit by Treatment by subgroup interaction, Age (2 cat.), Baseline body weight [kg] by Visit interaction as fixed effect(s). Covariate removed from model if also used as the subgroup. The model for overall analysis includes visit by treatment interaction instead of visit by treatment by subgroup interaction.

The following covariance structure has been used to fit the mixed model: Unstructured

Note: All covariate effects are set equal to their mean values within subgroup for the calculation of adjusted means.

Hedges'g is based on adjusted means and respective pooled standard deviation and will only be presented in case of a significant treatment comparison.

Subgroup					nange from				~			
Category Visit			—Value at— ——visit——	Adj.		CI	Adj.		—95 ^{\$}	CI		′ —95% CI—
Treatment	N	n	Mean SD	mean S	SE Lower	Upper	mean	SE	Lower	Upper	p-value g	Lower Uppe
BMI [kg/m2] at baseline												
>= median												
Baseline												
Placebo	26	26	119.53 25.15									
E pooled	26	26	113.36 22.43									
Week 4												
Placebo	26	24	119.23 25.53	-0.04 0	.39 -0.80	0.73						
E pooled	26	23	111.09 22.99	-1.20 0).39 -1.98	-0.42	-1.17	0.55	-2.26	-0.07	0.0365	
Week 12												
Placebo	26	26	120.01 24.40	0.55 0	0.66 -0.75	1.85						
E pooled	26	22	113.20 23.08	-1.23 0	.68 -2.58	0.12	-1.78	0.95	-3.66	0.10	0.0630	
Week 26												
Placebo	26	24	119.82 23.68	-0.68 0).99 -2.65	1.28						
E pooled	26	23	113.03 23.03	-1.09 1	.02 -3.10	0.91	-0.41	1.42	-3.22	2.40	0.7746	
BMI Z-Score												
Test for homogeneity ((H0) of sub	group	categories per ·	visit								
Week 4		- 1	5 1								0.8300^	
Week 12											0.8294	
Week 26											0.6440^	

N: Number of patients in analysis set, n: Number of patients analysed at visit, ^: Interaction p-value.

* Model includes Visit by Treatment by subgroup interaction, Age (2 cat.), Baseline body weight [kg] by Visit interaction as fixed effect(s). Covariate removed from model if also used as the subgroup. The model for overall analysis includes visit by treatment interaction instead of visit by treatment by subgroup interaction.

The following covariance structure has been used to fit the mixed model: Unstructured

Note: All covariate effects are set equal to their mean values within subgroup for the calculation of adjusted means.

Hedges g is based on adjusted means and respective pooled standard deviation and will only be presented in case of a significant treatment comparison.

A subgroup (all of the subgroup categories) will not be analysed (n:=0) if in at least one subgroup category N<10. The linagliptin treatment group was included in analyses but not displayed in this table.

Subgroup							e from-				a		- 1			
Category Visit				le at— sit——			eline— —95%	CI—	Adj.			CI—	vs Place	ebo*— Hedges'	<u> </u> 95%	CI—
Treatment	N	n	Mean	SD	mean	SE	Lower	Upper	mean	SE 1	Lower	Upper	p-value	g	Lower	Uppei
BMI Z-Score																
<=2 (Underweight, normal																
or overweight)																
Baseline																
Placebo	9	9		/ 13.39												
E pooled	5	5	63.52	2 15.40												
Week 4																
Placebo	9	9		9 13.20			-0.86									
E pooled	5	5	62.88	8 15.18	-0.5	9 0.87	-2.31	1.14	-1.01	1.09 .	-3.16	1.15	0.3567			
Week 12																
Placebo	9	9		2 12.97			-1.58									
E pooled	5	5	63.78	3 14.73	0.3	1 1.52	-2.70	3.32	-0.34	1.90 -	-4.09	3.41	0.8574			
Week 26																
Placebo	9 5	9		2 12.24			-1.68									
E pooled	5	5	61.98	3 14.96	-1.5	5 2.23	-5.97	2.86	-3.15	2.78 -	-8.66	2.35	0.2591			
>2 to <=3 (Class 1 obesity)																
Baseline				15 00												
Placebo	17	16		15.03												
E pooled	21	21	88.75	5 11.94												
Week 4	10	1.0	00.04	1 - 10	0 1	0 0 40	0.00	1 0 0								
Placebo	17	16		5 15.40			-0.86		0 50	0 65	1 07	0 60	0 0 0 1 7			
E pooled Week 12	21	21	88.21	11.68	-0.4	9 0.42	-1.33	0.35	-0.59	0.65	-1.8/	0.69	0.3617			
Placebo	17	16	02 22	16.13	0.0	C 0 0F	-1.62	1 74								
E pooled	21	20		9 11.88					-1.29	1 1 2	2 5 2	0 95	0.2582			
Week 26	21	20	07.05	, 11.00	-1.2	2 0.75	-2.70	0.25	-1.29	1.13	-3.52	0.95	0.2002			
Placebo	17	16	83 71	16.90	0 4	3 1 25	-2.04	2 90								
E pooled	21	21		5 12.70					-0.62	1 66	3 90	2 66	0.7082			

N: Number of patients in analysis set, n: Number of patients analysed at visit, ^: Interaction p-value.

* Model includes Visit by Treatment by subgroup interaction, Age (2 cat.), Baseline body weight [kg] by Visit interaction as fixed effect(s). Covariate removed from model if also used as the subgroup. The model for overall analysis includes visit by treatment interaction instead of visit by treatment by subgroup interaction.

The following covariance structure has been used to fit the mixed model: Unstructured

Note: All covariate effects are set equal to their mean values within subgroup for the calculation of adjusted means.

Hedges'g is based on adjusted means and respective pooled standard deviation and will only be presented in case of a significant treatment comparison.

A subgroup (all of the subgroup categories) will not be analysed (n:=0) if in at least one subgroup category N<10. The linagliptin treatment group was included in analyses but not displayed in this table.

MI Z-Score >3 (Class 2 or 3 obesity) Baseline Placebo	N	n		e at <u> </u> sit <u> </u> SD	Adj.			CI		0.7	<u> 95</u> %	CI		—95% CI—
Treatment MI Z-Score >3 (Class 2 or 3 obesity) Baseline Placebo		n				SE				0.0				
>3 (Class 2 or 3 obesity) Baseline Placebo								offor	mean	SE	Lower	Upper	p-value g	Lower Uppe
>3 (Class 2 or 3 obesity) Baseline Placebo														
Placebo														
	27	27	118.70	25 12										
i poorea	26	26	113.41											
Week 4	20	20	113.11	22.11										
	27	25	118.29	25.59	-0.10	0.38	-0.85	0.65						
	26	23	111.17					-0.42	-1.10	0.55	-2.19	-0.02	0.0468	
Week 12														
	27	27	118.94				-1.02							
	26	23	111.87	23.49	-1.36	0.69	-2.72	-0.01	-1.63	0.95	-3.51	0.24	0.0871	
Week 26														
	27	25		23.93			-2.79							
E pooled	26	22	113.95	23.15	-1.10	1.02	-3.13	0.92	-0.24	1.41	-3.03	2.56	0.8659	
bA1c [%] at baseline														
Test for homogeneity (H0) of	suba	roup c	ategori	es per v	visit									
Week 4	5 42 5	roup o	4009011	00 201	1010								0.5463	
Week 12													0.2914	
Week 26													0.4566	
<8.0														
Baseline														
	29	28	105.49											
	28	28	103.26	27.48										
Week 4														
	29	26	104.16				-0.77							
	28	25	99.69	27.48	-1.32	0.37	-2.05	-0.59	-1.27	0.52	-2.30	-0.25	0.0154	
Week 12 Placebo	29	28	100 00	20.27	0 54	0 60	0 00	1 70						
	29	28 27	106.02				-0.69	-0.58	_2 35	0 80	_1 00	-0 61	0.0084	
Week 26	20	41	101.20	20.04	-1.01	0.02	-3.05	-0.00	-2.55	0.00	-4.09	-0.01	0.0004	
	29	27	105.67	29 38	0 06	0 95	-1.82	1 94						
	28	27	102.09						-1.54	1.34	-4.20	1.12	0.2539	

N: Number of patients in analysis set, n: Number of patients analysed at visit, ^: Interaction p-value.

* Model includes Visit by Treatment by subgroup interaction, Age (2 cat.), Baseline body weight [kg] by Visit interaction as fixed effect(s). Covariate removed from model if also used as the subgroup. The model for overall analysis includes visit by treatment interaction instead of visit by treatment by subgroup interaction.

The following covariance structure has been used to fit the mixed model: Unstructured

Note: All covariate effects are set equal to their mean values within subgroup for the calculation of adjusted means.

Hedges'g is based on adjusted means and respective pooled standard deviation and will only be presented in case of a significant treatment comparison.

A subgroup (all of the subgroup categories) will not be analysed (n:=0) if in at least one subgroup category N<10. The linagliptin treatment group was included in analyses but not displayed in this table.

Appendix 1, Table 2.2.4

s1\tmmrm4b001.sas 200CT2023

Page

163

n		e at— sit— SD	Adj.		eline— —95% Lower	CI—			—95 [%]	CI	vs Place	bo*—— Hedges'	95%	CT
n				SE								Heages'		
	neun	55	mean	51	HOWCT				Lower	Unner	p-value	a -	Lower	
							licun	51	Hower	opper	p varae	9	HOWEI	opper
2 12	93.87	15.76												
	93.70	24.39	0.29	0.55	-0.79	1.37								
2 12	93.74	16.15	-0.14	0.55	-1.22	0.94	-0.43	0.77	-1.96	1.10	0.5780			
	93.98	24.54	0.58	0.95	-1.30	2.45								
2 11	94.90	18.34	0.16	0.96	-1.73	2.06	-0.41	1.35	-3.07	2.25	0.7587			
2 11	92.27	24.06	0.32	1.47	-2.58	3.22								
2 12	93.37	17.39	-0.62	1.44	-3.48	2.24	-0.94	2.06	-5.00	3.12	0.6481			
2 12	88.90	29.39												
2 12	88.92	29.95	0.00	0.55	-1.08	1.08								
							-0.45	0.77	-1.98	1.08	0.5596			
2 12	88.25	30.18	-0.66	0.95	-2.54	1.21								
							-0.18	1.37	-2.89	2.52	0.8940			
	00.92	17.20	0.05	0.00	2.00		0.10	2.07	2.05	2.02	0.0910			
2 12	88 24	29.37	-0 67	1 44	-3.52	2 18								
					5.52	4.04	1.61				0.4516			
	2 12 2 12 11 11 2 11 2 11 2 12 2 12 2 12 2 12 2 12 2 12 2 12 2 12 2 12 2 12 2 12 2 12 2 12 2 12 2 10	2 12 93.87 2 12 93.74 2 12 93.74 2 12 93.74 2 12 93.98 2 12 93.98 2 12 93.98 2 12 93.98 2 11 94.90 2 12 93.37 2 12 88.90 2 12 88.90 2 12 92.70 2 12 88.92 2 12 88.92 2 12 88.92 2 12 88.25 2 10 86.92	2 12 93.87 15.76 2 12 93.70 24.39 9 12 93.74 16.15 2 12 93.98 24.54 2 11 94.90 18.34 2 11 92.27 24.06 2 12 93.37 17.39 2 12 88.90 29.39 2 12 88.92 29.95 2 12 88.92 29.95 2 12 88.25 30.18 2 12 88.25 30.18	2 12 93.87 15.76 2 12 93.70 24.39 0.29 2 12 93.74 16.15 -0.14 2 12 93.98 24.54 0.58 2 12 93.98 24.54 0.58 2 11 92.27 24.06 0.32 2 12 93.37 17.39 -0.62 2 12 93.37 17.39 -0.62 2 12 88.90 29.39 2.04 2 12 88.92 29.95 0.00 2 12 88.92 29.95 0.00 2 12 88.92 29.95 -0.45 2 12 88.25 30.18 -0.66 2 10 86.92 17.25 -0.85	2 12 93.87 15.76 2 12 93.70 24.39 0.29 0.55 2 12 93.74 16.15 -0.14 0.55 2 12 93.98 24.54 0.58 0.95 2 12 93.98 24.54 0.58 0.96 2 11 92.27 24.06 0.32 1.47 2 12 93.37 17.39 -0.62 1.44 2 12 88.90 29.39 -0.62 1.44 2 12 88.90 29.39 -0.62 1.44 2 12 88.92 29.95 0.000 0.55 2 12 88.92 29.95 0.000 0.55 2 12 88.25 30.18 -0.45 0.55 2 12 88.25 30.18 -0.66 0.95 2 10 86.92 17.25 -0.85 0.99	$\begin{array}{cccccccccccccccccccccccccccccccccccc$								

N: Number of patients in analysis set, n: Number of patients analysed at visit, ^: Interaction p-value.

* Model includes Visit by Treatment by subgroup interaction, Age (2 cat.), Baseline body weight [kg] by Visit interaction as fixed effect(s). Covariate removed from model if also used as the subgroup. The model for overall analysis includes visit by treatment interaction instead of visit by treatment by subgroup interaction.

The following covariance structure has been used to fit the mixed model: Unstructured

Note: All covariate effects are set equal to their mean values within subgroup for the calculation of adjusted means.

Hedges'g is based on adjusted means and respective pooled standard deviation and will only be presented in case of a significant treatment comparison.

Subgroup							e_from-				~		_]			
Category				le at—		—bas			2.2.4				vs Place		0.5.8	at
Visit Treatment	N	n	Mean	.sit—— SD		SF		CI—— Upper		SE		CI—	p-value	Hedges'	—95∛ Lower	
				50	lilean	55	HOWEI	opper	lilean	55	HOWEL	opper	p-varue	9	HOWET	opper
FPG [mg/dl] at baseline																
<126																
Baseline																
Placebo	13	12		25.58												
E pooled	19	19	104.83	21.88												
Week 4																
Placebo	13	11	98.02	26.07	0.50	0.57	-0.62	1.63								
E pooled	19	17	100.59	20.29	-1.52	0.45	-2.42	-0.62	-2.02	0.73	-3.46	-0.58	0.0062			
Week 12																
Placebo	13	12	99.98	26.47	0.36	0.97	-1.57	2.28								
E pooled	19	18	102.33	22.96	-2.21	0.78	-3.75	-0.67	-2.56	1.25	-5.03	-0.10	0.0418			
Week 26																
Placebo	13	11	100.10	28.27	0.58	1.47	-2.33	3.50								
E pooled	19	18	104.01	24.22	-1.29	1.16	-3.59	1.00	-1.88	1.88	-5.58	1.83	0.3188			
>=126																
Baseline																
Placebo	39	39	99.03	31.35												
E pooled	29	29		25.77												
Week 4																
Placebo	39	38	98.37	31.03	-0.05	0.31	-0.66	0.57								
E pooled	29	2.8		26.21					-0.37	0.47	-1.30	0.57	0.4414			
Week 12		39	99.28	30.99	0.28	0.54	-0.79	1.34								
Week 12 Placebo	39															
Placebo	39 29				-0.46			0.80	-0.73	0.83	-2.38	0.91	0.3800			
Placebo E pooled	39 29	27		25.25	-0.46			0.80	-0.73	0.83	-2.38	0.91	0.3800			
Placebo			91.86			0.63			-0.73	0.83	-2.38	0.91	0.3800			

N: Number of patients in analysis set, n: Number of patients analysed at visit, ^: Interaction p-value.

* Model includes Visit by Treatment by subgroup interaction, Age (2 cat.), Baseline body weight [kg] by Visit interaction as fixed effect(s). Covariate removed from model if also used as the subgroup. The model for overall analysis includes visit by treatment interaction instead of visit by treatment by subgroup interaction.

The following covariance structure has been used to fit the mixed model: Unstructured

Note: All covariate effects are set equal to their mean values within subgroup for the calculation of adjusted means.

Hedges'g is based on adjusted means and respective pooled standard deviation and will only be presented in case of a significant treatment comparison.

A subgroup (all of the subgroup categories) will not be analysed (n:=0) if in at least one subgroup category N<10. The linagliptin treatment group was included in analyses but not displayed in this table.

Table 2.2.4 Body weight	g] change from baseline	MMRM results over time up to	week 26 overall and by subgroup	- mITT (TG1) (OC-AD)
-------------------------	-------------------------	------------------------------	---------------------------------	----------------------

Subgroup							e_from-									
Category			—Value a			—base							vs Plac			~-
Visit			visit				<u> </u> 95%					CI		Hedges'		
Treatment	N	n	Mean SI)	mean	SE	Lower	Upper	mean	SE	Lower	Upper	p-value	e g	Lower	Upper
eGFR (Zappitelli) at baselin	ie															
<120																
Baseline																
Placebo	24	23	107.13 26													
E pooled	21	21	105.10 28	.32												
Week 4																
Placebo	24	22	106.69 26	.72	0.26	0.40	-0.54	1.06								
E pooled	21	19	101.41 27	.90	-1.35	0.43	-2.20	-0.49	-1.61	0.59	-2.77	-0.44	0.0073			
Week 12																
Placebo	24	23	107.91 26	.46	0.79	0.69	-0.57	2.15								
E pooled	21	20	103.25 29	.08	-1.62	0.73	-3.06	-0.19	-2.42	1.00	-4.39	-0.44	0.0169			
Week 26																
Placebo	24	21	107.91 26	.11	0.62	1.06	-1.48	2.71								
E pooled	21	20	104.90 29						-1.42	1.52	-4.43	1.59	0.3534			
120 to <150																
Baseline																
Placebo	23	23	97.82 31	50												
E pooled	19	19	94.72 19													
Week 4	10	10	51.72 15	.01												
Placebo	23	22	96.31 31	28	_0 42	0 40	-1.22	0 38								
E pooled	19	18	93.47 20				-1.22		0.01	0 60	_1 18	1 20	0.9863			
Week 12	10	10	JJ.47 20	.13	-0.41	0.44	-1.29	0.47	0.01	0.00	-1.10	1.20	0.9005			
Placebo	23	23	97.33 31	26	0 10	0 60	-1.85	0 07								
	23 19	23 19	93.99 20				-2.23		-0.25	1 0 2	2 27	1 70	0.8107			
E pooled Week 26	19	19	93.99 ZU	.02	-0.74	0.76	-2.23	0.76	-0.25	1.02	-2.2/	1./0	0.010/			
Placebo	22	22	00 01 20	25	1 1 2	1 04	2 1 0	0 00								
	23	23	96.64 30				-3.19		0 04	1 66	2 02	2 00	0 0011			
E pooled	19	19	93.67 20	.51	-1.10	1.14	-3.36	1.16	0.04	1.55	-3.02	3.09	0.9811			

N: Number of patients in analysis set, n: Number of patients analysed at visit, ^: Interaction p-value.

* Model includes Visit by Treatment by subgroup interaction, Age (2 cat.), Baseline body weight [kg] by Visit interaction as fixed effect(s). Covariate removed from model if also used as the subgroup. The model for overall analysis includes visit by treatment

interaction instead of visit by treatment by subgroup interaction. The following covariance structure has been used to fit the mixed model: Unstructured

Note: All covariate effects are set equal to their mean values within subgroup for the calculation of adjusted means.

Hedges'g is based on adjusted means and respective pooled standard deviation and will only be presented in case of a significant treatment comparison.

A subgroup (all of the subgroup categories) will not be analysed (n:=0) if in at least one subgroup category N<10. The linagliptin treatment group was included in analyses but not displayed in this table.

Subgroup			Volu	e at—			e from- eline—				Comm	- ni a o n	wa Dlaa	lacebo*		
Category Visit Treatment	N	n		sit—			<u> 95</u> %	CI Upper		SE	<u> 95</u> %	CI		Hedges'	—95% Lower	
eGFR (Zappitelli) at baseline																
>=150																
Baseline																
Placebo	6	6	71.18	16.76												
E pooled	12	12	93.60	22.93												
Week 4																
Placebo	6	6	72.25	16.74	0.96	0.79	-0.59	2.52								
E pooled	12	12	92.88	22.58	-0.64	0.56	-1.74	0.45	-1.61	0.97	-3.52	0.31	0.0999			
Week 12																
Placebo	6	6	72.45	16.04	1.23	1.35	-1.45	3.91								
E pooled	12	9	88.29	17.75	-0.90	1.01	-2.90	1.10	-2.13	1.70	-5.49	1.22	0.2114			
Week 26																
Placebo	6	6	73.00	14.51	1.40	2.05	-2.65	5.45								
E pooled	12	9	88.51	19.16	-0.11	1.57	-3.21	2.99	-1.51	2.59	-6.63	3.61	0.5607			
Backg. Antidiabetic Med. at baseline Test for homogeneity (HO) o: Week 4 Week 12 Week 26	f sub <u>c</u>	group	categori	es per [.]	visit											

N: Number of patients in analysis set, n: Number of patients analysed at visit, ^: Interaction p-value.

* Model includes Visit by Treatment by subgroup interaction, Age (2 cat.), Baseline body weight [kg] by Visit interaction as fixed effect(s). Covariate removed from model if also used as the subgroup. The model for overall analysis includes visit by treatment interaction instead of visit by treatment by subgroup interaction.

The following covariance structure has been used to fit the mixed model: Unstructured

Note: All covariate effects are set equal to their mean values within subgroup for the calculation of adjusted means.

Hedges'g is based on adjusted means and respective pooled standard deviation and will only be presented in case of a significant treatment comparison.

A subgroup (all of the subgroup categories) will not be analysed (n:=0) if in at least one subgroup category N<10. The linagliptin treatment group was included in analyses but not displayed in this table.

Subgroup							ge_from					_]				
Category Visit				ue at—— isit——		—bas	seline	ר ה ב			arison CI——	vs Place		0.5%	at	
Treatment	N	n	Mean	SD	Adj. mean	SE	—95% CI— Lower Upper		SE			p-value	Hedges'		Upper	
	IN	11	Mean	50	lilean	5E	Tower obber	lilean	55	LOWET	opper	p-varue	y	TOWET	opper	
Backg. Antidiabetic Med. at																
baseline																
Metformin only																
Baseline																
Placebo	28	0														
E pooled	26	0														
Week 4																
Placebo	28	0														
E pooled	26	0														
Week 12																
Placebo	28	0														
E pooled	26	0														
Week 26																
Placebo	28	0														
E pooled	26	0														
Insulin only																
Baseline																
Placebo	2	0														
E pooled	3	0														
Week 4																
Placebo	2	0														
E pooled	3	0														
Week 12																
Placebo	2	0														
E pooled Week 26	3	0														
Placebo	2	0														
E pooled	∠ 3	0														
E POOTER	3	0														

N: Number of patients in analysis set, n: Number of patients analysed at visit, ^: Interaction p-value.

* Model includes Visit by Treatment by subgroup interaction, Age (2 cat.), Baseline body weight [kg] by Visit interaction as fixed effect(s). Covariate removed from model if also used as the subgroup. The model for overall analysis includes visit by treatment interaction instead of visit by treatment by subgroup interaction.

The following covariance structure has been used to fit the mixed model: Unstructured

Note: All covariate effects are set equal to their mean values within subgroup for the calculation of adjusted means.

Hedges'g is based on adjusted means and respective pooled standard deviation and will only be presented in case of a significant treatment comparison.

A subgroup (all of the subgroup categories) will not be analysed (n:=0) if in at least one subgroup category N<10. The linagliptin treatment group was included in analyses but not displayed in this table.

Subgroup							ge_from			_					
Category				ue at—		—bas	seline	2.14				vs Place		0.5.9	CT.
Visit				isit—			—95% CI—			<u> </u> 95%			Hedges'		
Treatment	N	n	Mean	SD	mean	SE	Lower Upper	mean	SE	Lower	Upper	p-value	g	Lower	upper
Backg. Antidiabetic Med. at															
baseline															
Metformin and Insulin															
Baseline															
Placebo	19	0													
E pooled	22	0													
Week 4															
Placebo	19	0													
E pooled	22	0													
Week 12															
Placebo	19	0													
E pooled	22	0													
Week 26															
Placebo	19	0													
E pooled	22	0													
None															
Baseline															
Placebo	4	0													
E pooled	1	0													
Week 4															
Placebo	4	0													
E pooled	1	0													
Week 12															
Placebo	4	0													
E pooled	1	0													
Week 26															
Placebo	4	0													
E pooled	1	0													

N: Number of patients in analysis set, n: Number of patients analysed at visit, ^: Interaction p-value.

* Model includes Visit by Treatment by subgroup interaction, Age (2 cat.), Baseline body weight [kg] by Visit interaction as fixed effect(s). Covariate removed from model if also used as the subgroup. The model for overall analysis includes visit by treatment interaction instead of visit by treatment by subgroup interaction.

The following covariance structure has been used to fit the mixed model: Unstructured

Note: All covariate effects are set equal to their mean values within subgroup for the calculation of adjusted means.

Hedges'g is based on adjusted means and respective pooled standard deviation and will only be presented in case of a significant treatment comparison.

A subgroup (all of the subgroup categories) will not be analysed (n:=0) if in at least one subgroup category N<10. The linagliptin treatment group was included in analyses but not displayed in this table.

Subgroup							e_from-									
Category						—bas							vs Place			~ =
Visit			——vi					CI				CI		Hedges'		
Treatment	N	n	Mean	SD	mean	SE	Lower	Upper	mean	SE I	lower	Upper	p-value	g	Lower	Uppe
Time since diagnosis of	торм															
Test for homogeneity		aroun	categori	es ner	visit											
Week 4	(110) 01 540	group	cacegori	ob per	VIDIC								0.9650^			
Week 12													0.8732			
Week 26													0.4845			
<1 year													0.1010			
Baseline																
Placebo	18	18	92.12	34.59												
E pooled	17	17	100.19													
Week 4		- /	200125	51.05												
Placebo	18	17	90.52	34.33	0.06	0.48	-0.88	1.00								
E pooled	17	16		32.26					-1.06	0.67 -	-2.38	0.26	0.1133			
Week 12																
Placebo	18	18	92.67	34.88	0.41	0.79	-1.15	1.98								
E pooled	17	17		31.60	-1.22	0.81	-2.82	0.38	-1.63	1.13 -	-3.86	0.60	0.1501			
Week 26																
Placebo	18	18	93.03	34.20	0.67	1.17	-1.65	2.99								
E pooled	17	16	99.71	33.53	-1.18	1.22	-3.59	1.22	-1.85	1.69 -	-5.19	1.48	0.2735			
1 year – 3 years																
Baseline																
Placebo	24	24	104.28	29.23												
E pooled	21	21	101.49	22.27												
Week 4																
Placebo	24	23	103.31				-0.96									
E pooled	21	19	97.73	20.15	-1.07	0.44	-1.93	-0.21	-0.92	0.60 -	-2.12	0.27	0.1286			
Week 12																
Placebo	24	24	104.31				-1.24									
E pooled	21	20	100.20	22.69	-0.94	0.73	-2.39	0.50	-1.05	1.00 -	-3.04	0.93	0.2967			
Week 26																
Placebo	24	23	103.70				-2.58									
E pooled	21	20	101.97	22.31	0.07	1.09	-2.08	2.22	0.63	1.50 -	-2.32	3.59	0.6726			

N: Number of patients in analysis set, n: Number of patients analysed at visit, ^: Interaction p-value. * Model includes Visit by Treatment by subgroup interaction, Age (2 cat.), Baseline body weight [kg] by Visit interaction as fixed effect(s). Covariate removed from model if also used as the subgroup. The model for overall analysis includes visit by treatment interaction instead of visit by treatment by subgroup interaction.

The following covariance structure has been used to fit the mixed model: Unstructured

Note: All covariate effects are set equal to their mean values within subgroup for the calculation of adjusted means.

Hedges'g is based on adjusted means and respective pooled standard deviation and will only be presented in case of a significant treatment comparison.

A subgroup (all of the subgroup categories) will not be analysed (n:=0) if in at least one subgroup category N<10. The linagliptin treatment group was included in analyses but not displayed in this table.

Subgroup Category			—Value	at			e from- eline—				Comp	arigon	vs Plac	eho*		
Visit Treatment	N	n	vis		Adj. mean		<u> 95</u> %		Adj. mean	SE	—95 ^{\$}	CI		Hedges'	—95% Lower	
				52	moun	22	20//01	02201		50	20101	SPPCI	P .urue	5	20#01	Spber
Time since diagnosis of T2DM																
>3 years																
Baseline																
Placebo	11	10	98.01	18.96												
E pooled	14	14	92.55	17.83												
Week 4																
Placebo	11	10	98.45	19.52	0.44	0.61	-0.77	1.65								
E pooled	14	14	92.11	17.53	-0.35	0.54	-1.42	0.73	-0.79	0.82	-2.41	0.84	0.3402			
Week 12																
Placebo	11	10	98.37	19.81	0.36	1.05	-1.72	2.43								
E pooled	14	11	87.13	9.58	-1.52	0.95	-3.39	0.35	-1.88	1.41	-4.68	0.91	0.1856			
Week 26																
Placebo	11	9	96.34	19.46	-0.20	1.60	-3.35	2.96								
E pooled	14	12	86.64	10.17	-1.85	1.41	-4.63	0.94	-1.65	2.13	-5.85	2.56	0.4400			

N: Number of patients in analysis set, n: Number of patients analysed at visit, ^: Interaction p-value.

* Model includes Visit by Treatment by subgroup interaction, Age (2 cat.), Baseline body weight [kg] by Visit interaction as fixed effect(s). Covariate removed from model if also used as the subgroup. The model for overall analysis includes visit by treatment interaction instead of visit by treatment by subgroup interaction.

The following covariance structure has been used to fit the mixed model: Unstructured

Note: All covariate effects are set equal to their mean values within subgroup for the calculation of adjusted means.

Hedges g is based on adjusted means and respective pooled standard deviation and will only be presented in case of a significant treatment comparison.

A subgroup (all of the subgroup categories) will not be analysed (n:=0) if in at least one subgroup category N<10. The linagliptin treatment group was included in analyses but not displayed in this table.